

【Name of Document】 APPLICATION FOR PATENT

【Identification Number】 C1-A0320Y1

【Filing Date】 March 12, 2004

【Addressee】 Esq. Commissioner of the Patent Office

【Inventor】

【Address】 c/o CHUGAI SEIYAKU KABUSHIKI KAISHA,
153-2, Nagai, Niihari-mura, Niihari-gun,
Ibaraki

【Name】 TSUNODA, Hiroyuki

【Inventor】

【Address】 c/o CHUGAI SEIYAKU KABUSHIKI KAISHA,
153-2, Nagai, Niihari-mura, Niihari-gun,
Ibaraki

【Name】 NAKANO, Kiyotaka

【Inventor】

【Address】 c/o CHUGAI SEIYAKU KABUSHIKI KAISHA,
153-2, Nagai, Niihari-mura, Niihari-gun,
Ibaraki

【Name】 ORITA, Tetsuro

【Inventor】

【Address】 c/o CHUGAI SEIYAKU KABUSHIKI KAISHA,
135, Komakado 1-chome, Gotenba-shi,
Shizuoka

【Name】 TSUCHIYA, Masayuki

【Inventor】

【Address】 c/o CHUGAI SEIYAKU KABUSHIKI KAISHA,
153-2, Nagai, Niihari-mura, Niihari-gun,
IBARAKI

【Name】 HIRATA, Yuichi

【Applicant】

【Identification Number】 000003311

【Name or Appellation】 CHUGAI SEIYAKU KABUSHIKI KAISHA

【Attorney】

【Identification Number】 100102978

【Patent Attorney】

【Name or Appellation】 Hatsushi Shimizu

【Nominated Attorney】

【Identification Number】 100108774

【Patent Attorney】

【Name or Appellation】 Kazunori Hashimoto

【Priority】

【Application Number】 JP2003-415746

【Filing Date】 December 12, 2003

【Payment】

【Registration Number】 041092

【Amount】 21000 yen

【List of Attached Documents】

【Name of Document】 Claims 1

【Name of Document】 Specification 1

【Name of Document】 Drawings 1

【Name of Document】 Abstract 1

【General Power of Attorney Number】 0216136

[Document Name] Claims

[Claim 1]

An antibody comprising a single-chain polypeptide having binding activity against TPO receptor (Mpl), wherein said antibody comprises two heavy chain variable regions and two light chain variable regions.

[Claim 2]

The antibody of claim 1, wherein the two heavy chain variable regions and the two light chain variable regions are arranged in the order of heavy chain variable region, light chain variable region, heavy chain variable region, and light chain variable region from the N terminus of the single-chain polypeptide.

[Claim 3]

The antibody of claim 1 or 2, wherein the two heavy chain variable regions and the two light chain variable regions are linked by linkers.

[Claim 4]

The antibody of claim 3, wherein the linkers comprise 15 amino acids.

[Claim 5]

A chimeric antibody that binds to Mpl.

[Claim 6]

The antibody of claim 5, which is a humanized antibody.

[Claim 7]

The antibody of claim 5 or 6, which is a minibody.

[Claim 8]

An antibody that binds to soluble Mpl.

[Claim 9]

An antibody that binds to human Mpl and monkey Mpl.

[Claim 10]

An antibody having agonistic activity against human Mpl and monkey Mpl.

[Claim 11]

An antibody whose binding activity to soluble Mpl is $KD = 10^{-6}$ M or lower.

[Claim 12]

An antibody whose binding activity to soluble Mpl is $KD = 10^{-7}$ M or lower.

[Claim 13]

An antibody whose binding activity to soluble Mpl is $KD = 10^{-8}$ M or lower.

[Claim 14]

An antibody whose TPO agonistic activity is $EC50 = 100$ nM or lower.

[Claim 15]

An antibody whose TPO agonistic activity is $EC_{50} = 30$ nM or lower.

[Claim 16]

An antibody whose TPO agonistic activity is $EC_{50} = 10$ nM or lower.

5 [Claim 17]

An antibody which comprises a heavy chain variable region, wherein said heavy chain variable regions comprises CDR1, CDR2 and CDR3 consisting of an amino acid sequence of any one of:

[1] SEQ ID NOs: 3, 4, and 5

10 [2] SEQ ID NOs: 6, 7, and 8

[3] SEQ ID NOs: 9, 10, and 11

[4] SEQ ID NOs: 12, 13, and 14

[5] SEQ ID NOs: 15, 16, and 17

[6] SEQ ID NOs: 18, 19, and 20

15 [7] SEQ ID NOs: 21, 22, and 23

[8] SEQ ID NOs: 24, 25, and 26

[9] SEQ ID NOs: 27, 28, and 29

[10] SEQ ID NOs: 30, 31, and 32

[11] SEQ ID NOs: 33, 34, and 35

20 [12] SEQ ID NOs: 36, 37, and 38

[13] SEQ ID NOs: 39, 40, and 41

[14] SEQ ID NOs: 42, 43, and 44

[15] SEQ ID NOs: 45, 46, and 47

[16] SEQ ID NOs: 48, 49, and 50

25 [17] SEQ ID NOs: 51, 52, and 53

[18] SEQ ID NOs: 54, 55, and 56

[19] SEQ ID NOs: 57, 58, and 59

[20] SEQ ID NOs: 231, 233, and 235

[21] SEQ ID NOs: 266, 268, and 270

30 [22] SEQ ID NOs: 280, 282, and 284.

[Claim 18]

An antibody which comprises a light chain variable region, wherein said light chain variable region comprises CDR1, CDR2 and CDR3 consisting of an amino acid sequence of any one of:

35 [1] SEQ ID NOs: 60, 61, and 62

[2] SEQ ID NOs: 63, 64, and 65

[3] SEQ ID NOs: 66, 67, and 68

[4] SEQ ID NOs: 69, 70, and 71

[5] SEQ ID NOs: 72, 73, and 74

[6] SEQ ID NOs: 75, 76, and 77

5 [7] SEQ ID NOs: 78, 79, and 80

[8] SEQ ID NOs: 81, 82, and 83

[9] SEQ ID NOs: 84, 85, and 86

[10] SEQ ID NOs: 87, 88, and 89

[11] SEQ ID NOs: 90, 91, and 92

10 [12] SEQ ID NOs: 93, 94, and 95

[13] SEQ ID NOs: 96, 97, and 98

[14] SEQ ID NOs: 99, 100, and 101

[15] SEQ ID NOs: 102, 103, and 104

[16] SEQ ID NOs: 105, 106, and 107

15 [17] SEQ ID NOs: 108, 109, and 110

[18] SEQ ID NOs: 111, 112, and 113

[19] SEQ ID NOs: 114, 115, and 116

[20] SEQ ID NOs: 240, 242, and 244

[21] SEQ ID NOs: 273, 275, and 277.

20 [Claim 19]

An antibody that comprises a heavy chain variable region and a light chain variable region of any one of:

[1] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 3, 4, and 5, and a light chain variable region that
25 comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 60, 61, and 62;

[2] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 6, 7, and 8, and a light chain variable region that
30 comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 63, 64, and 65;

[3] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 9, 10, and 11, and a light chain variable region that
comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 66, 67, and 68;

35 [4] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 12, 13, and 14, and a light chain variable region that

comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 69, 70, and 71;

5 [5] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 15, 16, and 17, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 72, 73, and 74;

10 [6] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 18, 19, and 20, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 75, 76, and 77;

[7] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 21, 22, and 23, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 78, 79, and 80;

15 [8] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 24, 25, and 26, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 81, 82, and 83;

20 [9] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 27, 28, and 29, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 84, 85, and 86;

25 [10] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 30, 31, and 32, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 87, 88, and 89;

30 [11] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 33, 34, and 35, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 90, 91, and 92;

[12] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 36, 37, and 38, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 93, 94, and 95;

35 [13] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 39, 40, and 41, and a light chain variable

region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 96, 97, and 98;

[14] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 42, 43, and 44, and a light chain variable
5 region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 99, 100, and 101;

[15] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 45, 46, and 47, and a light chain variable
10 region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 102, 103, and 104;

[16] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 48, 49, and 50, and a light chain variable
region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 105, 106, and 107;

[17] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 51, 52, and 53, and a light chain variable
15 region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 108, 109, and 110,

[18] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 54, 55, and 56, and a light chain variable
20 region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 111, 112, and 113;

[19] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 57, 58, and 59, and a light chain variable
25 region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 114, 115, and 116;

[20] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 231, 233, and 235, and a light chain
30 variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 240, 242, and 244;

[21] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 266, 268, and 270, and a light chain
variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 273, 275, and 277;

[22] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 280, 282, and 284, and a light chain
35

variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 273, 275, and 277.

[Claim 20]

An antibody that comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 118.

[Claim 21]

An antibody that comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 120.

[Claim 22]

An antibody that comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 118 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 120.

[Claim 23]

An antibody comprising the amino acid sequence of SEQ ID NO: 122 or 264.

[Claim 24]

An antibody that comprises a heavy chain variable region, wherein said heavy chain variable region comprises FR1, FR2, FR3, and FR4 consisting of amino acid sequences of any one of:

[1] SEQ ID NOs: 230, 232, 234, and 236

[2] SEQ ID NOs: 265, 267, 269, and 271

[3] SEQ ID NOs: 279, 281, 283, and 285.

[Claim 25]

An antibody comprising a light chain variable region, wherein said light chain variable region comprises FR1, FR2, FR3, and FR4 consisting of amino acid sequences of any one of:

[1] SEQ ID NOs: 239, 241, 243, and 245

[2] SEQ ID NOs: 272, 274, 276, and 278.

[Claim 26]

An antibody that comprises a heavy chain variable region and a light chain variable region of any one of:

[1] a heavy chain variable region which comprises FR1, FR2, FR3, and FR4 having the amino acid sequences consisting of SEQ ID NOs: 230, 232, 234, and 236, and a light chain variable region which comprises FR1, FR2, FR3, and FR4 having the amino acid sequences consisting of SEQ ID NOs: 239, 241, 243, and 245;

[2] a heavy chain variable region which comprises FR1, FR2, FR3, and FR4 having the amino acid sequences consisting of SEQ ID NOs: 265, 267, 269, and 271, and a light chain variable region which comprises FR1, FR2, FR3, and FR4 having the amino acid sequences

consisting of SEQ ID NOs: 272, 274, 276, and 278;

[3] a heavy chain variable region which comprises FR1, FR2, FR3, and FR4 having the amino acid sequences consisting of SEQ ID NOs: 279, 281, 283, and 285, and a light chain variable region which comprises FR1, FR2, FR3, and FR4 having the amino acid sequences consisting of SEQ ID NOs: 272, 274, 276, and 278.

[Claim 27]

An antibody that comprises a heavy chain variable region, wherein said heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 229, 256, or 262.

[Claim 28]

An antibody that comprises a light chain variable region, wherein said light chain variable region comprises the amino acid sequence of SEQ ID NO: 238 or 258.

[Claim 29]

An antibody that comprises a heavy chain variable region and a light chain variable region of any one of:

[1] a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 229, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 238;

[2] a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 256, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 258;

[3] a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 262, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 258.

[Claim 30]

An antibody that comprises the amino acid sequence of SEQ ID NO: 2, 254, or 260.

[Claim 31]

An antibody having an activity equivalent to that of an antibody of any one of claims 17 to 30, wherein said antibody comprises the amino acid sequence set forth in any one of claims 17 to 30, in which one or more amino acids have been substituted, deleted, added and/or inserted.

[Claim 32]

An antibody that recognizes an epitope recognized by an antibody of any one of claims 17 to 31.

[Claim 33]

An antibody that recognizes the region of amino acids 26 to 274 of human Mpl.

[Claim 34]

An antibody of any one of claims 1 to 33, which has TPO agonistic activity.

[Claim 35]

A polynucleotide encoding an antibody of any one of claims 1 to 34.

[Claim 36]

A polynucleotide hybridizing to the polynucleotide of claim 35 under stringent conditions, wherein said polynucleotide encodes an antibody having activity equivalent to that of an antibody of any one of claims 1 to 34.

[Claim 37]

5 A vector comprising the polynucleotide of claim 35 or 36.

[Claim 38]

A host cell that carries the polynucleotide of claim 35 or 36, or the vector of claim 37.

[Claim 39]

A pharmaceutical composition comprising an antibody of any one of claims 1 to 34.

[Document Name] Specification

[Title of the Invention] ANTI-MPL ANTIBODIES

[Technical Field]

5 [0001]

The present invention relates to anti-Mpl antibodies.

[Background of the Invention]

[0002]

10 Thrombopoietin (TPO) is a factor that enhances the differentiation and maturation of megakaryocytes (platelet precursor cells) from hemopoietic stem cells into platelets. TPO also functions as a cytokine with an important role in the regulation of platelet number. TPO is converted into its active form through the cleavage of a TPO precursor comprising 353 amino acids.

[0003]

15 Mpl is a TPO receptor, and human Mpl molecules are known to exist in two forms comprising 572 and 635 amino acids. The human Mpl gene sequence has already been analyzed (see Non-patent Document 1 and GenBank accession No. NM_005373).

[0004]

20 Most cytokine receptors dimerize upon ligand binding, and transduce signals into cells. It has been reported that TPO similarly binds to its own specific receptor MPL, which leads to dimerization of the receptor, thereby transducing signals into cells and exerting physiological effects (see Non-patent Document 2).

[0005]

25 Antibodies exhibiting agonistic activity have been reported among those antibodies that bind to receptors having the above features.

For example, an antibody against the erythropoietin (EPO) receptor has been reported to substitute for erythropoietin function. The monovalent form (Fab) of the antibody is capable of binding to the EPO receptor but is unable to transduce signals. Thus, dimerization of the erythropoietin receptor *via* bivalent binding is assumed to be essential for signal transduction
30 (see Non-patent Document 3).

[0006]

Antibodies that bind to Mpl and exhibit TPO agonistic activity have also been reported (see Non-patent Documents 4 and 5). This suggests that receptor dimerization is induced upon binding of a bivalent antibody with regards to MPL as well.

35 [0007]

Meanwhile, a single-chain antibody (scFv) has been reported to exhibit TPO agonistic

activity (see Patent Document 1). However, it has been revealed that, the underlying mechanism of scFv exhibiting TPO agonistic activity is that a part of scFv dimerizes (diabody) and this diabody becomes the actual active unit (see Patent Documents 2 to 4).

[0008]

- 5 [Patent Document 1] US Patent No. 6342220
[Patent Document 2] WO 01/79494
[Patent Document 3] WO 02/33072
[Patent Document 4] WO 02/33073
[Non-patent Document 1] Palacios *et al.*, 1985, Cell, 41, 727-734
10 [Non-patent Document 2] Souyri *et al.*, 1990, Cell, Vol.63, 1137-1147
[Non-patent Document 3] Elliott, S. *et al.*, 1996, J. Biol. Chem., 271(40), 24691-24697
[Non-patent Document 4] Abe *et al.*, 1998, Immunol. Lett., 61, 73-78
[Non-patent Document 5] Bijia Deng *et al.*, 1998, Blood, 92, 1981-1988

[Disclosure of the Invention]

15 [Problems to be Solved by the Invention]

[0009]

The present invention was achieved in view of the above circumstances. An objective of the present invention is to provide novel anti-Mpl antibodies having TPO agonistic activity.

[Means for Solving the Problems]

20 [0010]

The present inventors performed exhaustive research to solve the above objective. The present inventors prepared and purified anti-human Mpl antibody VB22B, and established a single-chain antibody expression system using genetic engineering techniques. Specifically, the variable region of anti-human Mpl antibody was first cloned, and a diabody expression vector pCXND3-VB22B db for the anti-human Mpl antibody was prepared. This pCXND3-VB22B db vector was then used to generate an expression vector pCXND3-VB22B sc(Fv)₂ for anti-human Mpl antibody sc(Fv)₂. Anti-human Mpl sc(Fv)₂ was expressed in CHO-DG44 cells using the expression vector pCXND3-VB22B sc(Fv)₂, and then purified from the culture supernatant. In control experiments, VB22B diabody was transiently expressed in COS7 cells using the above pCXND3-VB22B db vector, and then purified from the culture supernatant.

[0011]

In addition, VB22B diabody and VB22B sc(Fv)₂ were evaluated for their TPO-like agonistic activities. The results showed that VB22B diabody and VB22B sc(Fv)₂ exhibit higher agonistic activities compared to VB22B IgG, and thus activities equivalent to or higher than that of the natural ligand, human TPO.

[0012]

Furthermore, the present inventors succeeded in preparing three types of humanized VB22B sc(Fv)₂. The TPO-like agonistic activity was also proven to be unaltered by humanization.

[0013]

5 More specifically, the present invention relates to:

(1) an antibody comprising a single-chain polypeptide having binding activity against TPO receptor (Mpl), wherein said antibody comprises two heavy chain variable regions and two light chain variable regions;

10 (2) the antibody of (1), wherein the two heavy chain variable regions and the two light chain variable regions are arranged in the order of heavy chain variable region, light chain variable region, heavy chain variable region, and light chain variable region from the N terminus of the single-chain polypeptide;

(3) the antibody of (1) or (2), wherein the two heavy chain variable regions and the two light chain variable regions are linked by linkers;

15 (4) the antibody of (3), wherein the linkers comprise 15 amino acids;

(5) a chimeric antibody that binds to Mpl;

(6) the antibody of (5), which is a humanized antibody;

(7) the antibody of (5) or (6), which is a minibody;

(8) an antibody that binds to soluble Mpl;

20 (9) an antibody that binds to human Mpl and monkey Mpl;

(10) an antibody having agonistic activity against human Mpl and monkey Mpl;

(11) an antibody whose binding activity to soluble Mpl is $KD = 10^{-6}$ M or lower;

(12) an antibody whose binding activity to soluble Mpl is $KD = 10^{-7}$ M or lower;

(13) an antibody whose binding activity to soluble Mpl is $KD = 10^{-8}$ M or lower;

25 (14) an antibody whose TPO agonistic activity is $EC50 = 100$ nM or lower;

(15) an antibody whose TPO agonistic activity is $EC50 = 30$ nM or lower;

(16) an antibody whose TPO agonistic activity is $EC50 = 10$ nM or lower;

30 (17) an antibody which comprises a heavy chain variable region, wherein said heavy chain variable regions comprises CDR1, CDR2 and CDR3 consisting of an amino acid sequence of any one of:

[1] SEQ ID NOs: 3, 4, and 5

[2] SEQ ID NOs: 6, 7, and 8

[3] SEQ ID NOs: 9, 10, and 11

[4] SEQ ID NOs: 12, 13, and 14

35 [5] SEQ ID NOs: 15, 16, and 17

[6] SEQ ID NOs: 18, 19, and 20

[7] SEQ ID NOs: 21, 22, and 23

[8] SEQ ID NOs: 24, 25, and 26

[9] SEQ ID NOs: 27, 28, and 29

[10] SEQ ID NOs: 30, 31, and 32

5 [11] SEQ ID NOs: 33, 34, and 35

[12] SEQ ID NOs: 36, 37, and 38

[13] SEQ ID NOs: 39, 40, and 41

[14] SEQ ID NOs: 42, 43, and 44

[15] SEQ ID NOs: 45, 46, and 47

10 [16] SEQ ID NOs: 48, 49, and 50

[17] SEQ ID NOs: 51, 52, and 53

[18] SEQ ID NOs: 54, 55, and 56

[19] SEQ ID NOs: 57, 58, and 59

[20] SEQ ID NOs: 231, 233, and 235

15 [21] SEQ ID NOs: 266, 268, and 270

[22] SEQ ID NOs: 280, 282, and 284;

(18) an antibody which comprises a light chain variable region, wherein said light chain variable region comprises CDR1, CDR2 and CDR3 consisting of an amino acid sequence of any one of:

20 [1] SEQ ID NOs: 60, 61, and 62

[2] SEQ ID NOs: 63, 64, and 65

[3] SEQ ID NOs: 66, 67, and 68

[4] SEQ ID NOs: 69, 70, and 71

[5] SEQ ID NOs: 72, 73, and 74

25 [6] SEQ ID NOs: 75, 76, and 77

[7] SEQ ID NOs: 78, 79, and 80

[8] SEQ ID NOs: 81, 82, and 83

[9] SEQ ID NOs: 84, 85, and 86

[10] SEQ ID NOs: 87, 88, and 89

30 [11] SEQ ID NOs: 90, 91, and 92

[12] SEQ ID NOs: 93, 94, and 95

[13] SEQ ID NOs: 96, 97, and 98

[14] SEQ ID NOs: 99, 100, and 101

[15] SEQ ID NOs: 102, 103, and 104

35 [16] SEQ ID NOs: 105, 106, and 107

[17] SEQ ID NOs: 108, 109, and 110

[18] SEQ ID NOs: 111, 112, and 113

[19] SEQ ID NOs: 114, 115, and 116

[20] SEQ ID NOs: 240, 242, and 244

[21] SEQ ID NOs: 273, 275, and 277;

5 (19) an antibody that comprises a heavy chain variable region and a light chain variable region of any one of:

[1] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 3, 4, and 5, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting
10 of SEQ ID NOs: 60, 61, and 62;

[2] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 6, 7, and 8, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting
of SEQ ID NOs: 63, 64, and 65;

15 [3] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 9, 10, and 11, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting
of SEQ ID NOs: 66, 67, and 68;

[4] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising
20 the amino acid sequences consisting of SEQ ID NOs: 12, 13, and 14, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting
of SEQ ID NOs: 69, 70, and 71;

[5] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising
the amino acid sequences consisting of SEQ ID NOs: 15, 16, and 17, and a light chain variable
25 region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting
of SEQ ID NOs: 72, 73, and 74;

[6] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising
the amino acid sequences consisting of SEQ ID NOs: 18, 19, and 20, and a light chain variable
region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting
30 of SEQ ID NOs: 75, 76, and 77;

[7] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising
the amino acid sequences consisting of SEQ ID NOs: 21, 22, and 23, and a light chain variable
region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting
of SEQ ID NOs: 78, 79, and 80;

35 [8] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising
the amino acid sequences consisting of SEQ ID NOs: 24, 25, and 26, and a light chain variable

region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 81, 82, and 83;

5 [9] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 27, 28, and 29, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 84, 85, and 86;

10 [10] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 30, 31, and 32, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 87, 88, and 89;

[11] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 33, 34, and 35, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 90, 91, and 92;

15 [12] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 36, 37, and 38, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 93, 94, and 95;

20 [13] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 39, 40, and 41, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 96, 97, and 98;

25 [14] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 42, 43, and 44, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 99, 100, and 101;

30 [15] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 45, 46, and 47, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 102, 103, and 104;

[16] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 48, 49, and 50, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 105, 106, and 107;

35 [17] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 51, 52, and 53, and a light chain variable

region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 108, 109, and 110;

5 [18] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 54, 55, and 56, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 111, 112, and 113;

10 [19] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 57, 58, and 59, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 114, 115, and 116;

[20] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 231, 233, and 235, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 240, 242, and 244;

15 [21] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 266, 268, and 270, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 273, 275, and 277;

20 [22] a heavy chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 280, 282, and 284, and a light chain variable region that comprises CDR1, CDR2, and CDR3 comprising the amino acid sequences consisting of SEQ ID NOs: 273, 275, and 277;

(20) an antibody that comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 118;

25 (21) an antibody that comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO: 120;

(22) an antibody that comprises a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 118 and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 120;

30 (23) an antibody comprising the amino acid sequence of SEQ ID NO: 122 or 264;

(24) an antibody that comprises a heavy chain variable region, wherein said heavy chain variable region comprises FR1, FR2, FR3, and FR4 consisting of amino acid sequences of any one of:

[1] SEQ ID NOs: 230, 232, 234, and 236

35 [2] SEQ ID NOs: 265, 267, 269, and 271

[3] SEQ ID NOs: 279, 281, 283, and 285.

(25) an antibody comprising a light chain variable region, wherein said light chain variable region comprises FR1, FR2, FR3, and FR4 consisting of amino acid sequences of any one of:

[1] SEQ ID NOs: 239, 241, 243, and 245

5 [2] SEQ ID NOs: 272, 274, 276, and 278;

(26) an antibody that comprises a heavy chain variable region and a light chain variable region of any one of:

10 [1] a heavy chain variable region which comprises FR1, FR2, FR3, and FR4 having the amino acid sequences consisting of SEQ ID NOs: 230, 232, 234, and 236, and a light chain variable region which comprises FR1, FR2, FR3, and FR4 having the amino acid sequences consisting of SEQ ID NOs: 239, 241, 243, and 245;

15 [2] a heavy chain variable region which comprises FR1, FR2, FR3, and FR4 having the amino acid sequences consisting of SEQ ID NOs: 265, 267, 269, and 271, and a light chain variable region which comprises FR1, FR2, FR3, and FR4 having the amino acid sequences consisting of SEQ ID NOs: 272, 274, 276, and 278;

[3] a heavy chain variable region which comprises FR1, FR2, FR3, and FR4 having the amino acid sequences consisting of SEQ ID NOs: 279, 281, 283, and 285, and a light chain variable region which comprises FR1, FR2, FR3, and FR4 having the amino acid sequences consisting of SEQ ID NOs: 272, 274, 276, and 278;

20 (27) an antibody that comprises a heavy chain variable region, wherein said heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 229, 256, or 262;

(28) an antibody that comprises a light chain variable region, wherein said light chain variable region comprises the amino acid sequence of SEQ ID NO: 238 or 258;

25 (29) an antibody that comprises a heavy chain variable region and a light chain variable region of any one of:

[1] a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 229, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 238;

[2] a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 256, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 258;

30 [3] a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 262, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 258;

(30) an antibody that comprises the amino acid sequence of SEQ ID NO: 2, 254, or 260;

35 (31) an antibody having an activity equivalent to that of an antibody of any one of (17) to (30), wherein said antibody comprises the amino acid sequence set forth in any one of (17) to (30), in which one or more amino acids have been substituted, deleted, added and/or inserted;

(32) an antibody that recognizes an epitope recognized by an antibody of any one of

(17) to (31);

(33) an antibody that recognizes the region of amino acids 26 to 274 of human Mpl;

(34) an antibody of any one of (1) to (33), which has TPO agonistic activity;

(35) a polynucleotide encoding an antibody of any one of (1) to (34);

5 (36) a polynucleotide hybridizing to the polynucleotide of (35) under stringent conditions, wherein said polynucleotide encodes an antibody having activity equivalent to that of an antibody of any one of (1) to (34);

(37) a vector comprising the polynucleotide of (35) or (36);

(38) a host cell that carries the polynucleotide of (35) or (36), or the vector of (37); and

10 (39) a pharmaceutical composition comprising an antibody of any one of (1) to (34).

[Effects of the Invention]

[0014]

Recombinant human TPOs have been tested as therapeutic agents for chemotherapy-induced thrombocytopenia in various clinical trials. In these trials, a major
15 problem that was reported was the production of anti-TPO antibody in TPO-treated patients (Junzhi Li, *et al.*, Blood (2001) 98: 3241-324; Saroj Vandhan-Raj, *et al.*, Ann. Intern. Med. (2000) 132: 364-368). Specifically, production of neutralizing antibodies that inhibit endogenous TPO activity, and the resulting onset of thrombocytopenia, were reported. Administration of agonistic minibodies (low molecular weight antibodies) against anti-TPO
20 receptor of the present invention does not induce the production of antibodies against endogenous TPO. Furthermore, since antibody miniaturization results in increased specific activity and short half-life in blood, the effective concentration in blood can be easily regulated, presenting a further clinical advantage. Accordingly, the present antibodies are expected to be therapeutic agents for thrombocytopenia which are more effective than naturally-occurring TPO
25 or its agonistic antibodies. Furthermore, since minibodies are not glycosylated, expression systems for expressing the recombinant proteins are not limited, and minibodies can be produced in any expression system such as cell lines from mammals, yeast, insect cells, and *E. coli*. Since binding specificity against mutant TPO receptor is different from that of TPO, minibodies are expected to bind specific mutants and show agonistic activity against mutated TPO receptor
30 detected in the CAMT patients, who genetically have mutated TPO receptor and develop thrombocytopenia.

[Best Mode for Carrying Out the Invention]

[0015]

The present invention provides antibodies that bind to the TPO receptor (Mpl).

35 [0016]

The antibodies of the present invention comprise all types of antibodies, including

antibodies with modified amino acid sequences, such as minibodies, humanized antibodies, and chimeric antibodies; antibodies that have been modified by binding with other molecules (for example, polymers such as polyethylene glycol); and antibodies whose sugar chains have been modified.

5 [0017]

Mpl of the present invention may be a mutant receptor. A mutant receptor of the present invention is usually a receptor that exists at a frequency lower than 50%, preferably lower than 20%, more preferably lower than 10%, and even more preferably lower than 1%. The frequency is generally calculated using randomly selected subjects. However, the
10 frequency may vary depending on the country, area, sex, and such. Therefore, the frequency may also be calculated, for example, within a defined country or area, such as Japan, the United States, and Europe, or calculated for one sex. When there are two or more mutations in a receptor, the frequency may be calculated for multiple mutation sites or for any one of the mutation sites. Mutant receptors are preferably evaluated by a frequency as described above.
15 However, mutant receptors can also be evaluated, for example, by their signal transducing ability and such. Specifically, for example, when two different receptors are present, the one with stronger transducing signals upon natural ligand-binding maybe be used as a non-mutant type receptor, and the one with weaker transducing signals as a mutant receptor.

[0018]

20 In one embodiment, the mutant receptors of the present invention comprise receptors that are associated with disease onset. The phrase "mutant receptors associated with disease onset" means that the loss of reactivity to a natural ligand becomes part of the reason that triggers disease onset. In the present invention, the mutant receptor may be a contributing factor, but not necessarily the sole factor triggering disease onset. Many reports have been
25 previously published that describe the association of mutant receptors with disease onset. In addition to those that have been reported, associations of mutant receptors and disease onset can also be identified by statistical analysis methods (for example, correlation analyses). Correlation analyses, also called "case control studies", are well known to those skilled in the art (for example, Nishimura, Y., 1991, "Statistical analysis of polymorphisms", Saishin Igaku,
30 46:909-923; Oka, A. *et al.*, Hum. Mol. Genetics (1990) 8: 2165-2170; Ota, M. *et al.*, Am. J. Hum. Genet. (1999) 64: 1406-1410; Ozawa, A. *et al.*, Tissue Antigens (1999) 53: 263-268). For example, the correlation between a mutant receptor and a disease can be studied by computing the frequency of the mutant receptor in patients and healthy subjects, and testing whether the patient population has a higher mutant receptor frequency. Typically, differences in frequency
35 are evaluated using the χ -test. χ is obtained by the equation $\chi^2 = \sum (\text{observed value} - \text{expected value})^2 / \text{expected value}$. A p value is obtained from the χ^2 value determined. Based on this p

value, it can be determined whether there is a correlation between the mutant receptor and the disease. For example, when $p < 0.05$, the mutant receptor is considered to correlate with the disease. Mutant thrombopoietin (TPO) receptors have already been reported (Matthias Ballmaier *et al.*, BLOOD (2001) 97 (1): 139; and others).

5 [0019]

It is preferable that the antibodies of the present invention have agonistic activity against Mpl.

In a preferred embodiment, the antibodies of the present invention comprise, for example, minibodies.

10 The minibodies comprise antibody fragments lacking portions of the whole antibody (for example, whole IgG). The minibodies are not particularly limited as long as they have binding activity to their antigens. The minibodies of the present invention have markedly higher activities compared to their corresponding whole antibodies. There are no particular limitations on the antibody fragments of the present invention as long as they are portions of the
15 whole antibody, and preferably contain heavy chain variable regions (VH) and/or light chain variable regions (VL). The amino acid sequences of VH or VL may contain substitutions, deletions, additions and/or insertions. Furthermore, the antibody fragment may also lack portions of VH or/and VL, as long as it has binding ability to its antigen. In addition, the variable regions may be chimerized or humanized. Such antibody fragments include, for
20 example, Fab, Fab', F(ab')₂, and Fv. An example of a minibody includes Fab, Fab', F(ab')₂, Fv, scFv (single-chain Fv), diabody, and sc(Fv)₂ (single-chain (Fv)₂).

[0020]

Herein, an "Fv" fragment is the smallest antibody fragment and contains a complete antigen recognition site and a binding site. The "Fv" fragment is a dimer (VH-VL dimer) in
25 which a single VH and a single VL are strongly linked by a non-covalent bond. The three complementarity-determining regions (CDRs) of each of the variable regions interact with each other to form an antigen-binding site on the surface of the VH-VL dimer. Six CDRs confer the antigen-binding site of an antibody. However, a single variable region (or a half of Fv containing only three CDRs specific to an antigen) alone is also capable of recognizing and
30 binding an antigen although its affinity is lower than the affinity of the entire binding site.

[0021]

scFv contains the VH and VL regions of an antibody, and these regions exist on a single polypeptide chain. Generally, an Fv polypeptide further contains a polypeptide linker between VH and VL, and therefore an scFv can form a structure required for antigen binding. See,
35 Pluckthun "The Pharmacology of Monoclonal Antibodies" Vol. 113 (Rosenburg and Moore eds. (Springer Verlag, New York, pp.269-315, 1994) for the review of scFv. In the present invention,

linkers are not especially limited as long as they do not inhibit expression of antibody variable regions linked at both ends of the linkers.

[0022]

The term “diabody” refers to a bivalent antibody fragment constructed by gene fusion
 5 (Holliger P *et al.*, Proc. Natl. Acad. Sci. USA (1993) 90: 6444-6448; EP 404,097; WO 93/11161
 and others). Diabodies are dimers comprising two polypeptide chains, where each polypeptide
 chain comprises a VL and a VH connected with a linker short enough to prevent interaction of
 these two domains, for example, a linker of about five residues. The VL and VH encoded on
 10 the same polypeptide chain will form a dimer because the linker between them is too short to
 form a single-chain variable region fragment. As a result, the polypeptide chains form a dimer,
 and thus the diabody has two antigen binding sites.

[0023]

sc(Fv)₂ is a single-chain minibody produced by linking two units of VH and two units of
 VL with linkers and such (Hudson *et al.*, J Immunol. Methods (1999) 231:177-189). sc(Fv)₂
 15 exhibits a particularly high agonistic activity compared to the whole antibody and other
 minibodies. sc(Fv)₂ can be produced, for example, by linking two scFv molecules.

In a preferable antibody, the two VH units and two VL units are arranged in the order of
 VH, VL, VH, and VL ([VH]-linker-[VL]-linker-[VH]-linker-[VL]) beginning from the N
 terminus of a single-chain polypeptide.

20 [0024]

The order of the two VH units and two VL units is not limited to the above arrangement,
 and they may be arranged in any order. Examples of the arrangements are listed below.

[VL]-linker-[VH]-linker-[VH]-linker-[VL]

[VH]-linker-[VL]-linker-[VL]-linker-[VH]

25 [VH]-linker-[VH]-linker-[VL]-linker-[VL]

[VL]-linker-[VL]-linker-[VH]-linker-[VH]

[VL]-linker-[VH]-linker-[VL]-linker-[VH]

[0025]

The linkers to be used for linking the variable regions of an antibody comprise arbitrary
 30 peptide linkers that can be introduced by genetic engineering, synthetic linkers, and linkers
 disclosed in, for example, Holliger, P. *et al.*, Protein Engineering (1996) 9 (3): 299-305.
 Peptide linkers are preferred in the present invention. There are no limitations as to the length
 of the peptide linkers. The length can be selected accordingly by those skilled in the art
 depending on the purpose, and is typically 1-100 amino acids, preferably 3-50 amino acids, more
 35 preferably 5-30 amino acids, and even more preferably 12-18 amino acids (for example, 15
 amino acids).

[0026]

For example, such peptide linkers include:

Ser

Gly Ser

5 Gly Gly Ser

Ser Gly Gly

Gly Gly Gly Ser

Ser Gly Gly Gly

Gly Gly Gly Gly Ser

10 Ser Gly Gly Gly Gly

Gly Gly Gly Gly Gly Ser

Ser Gly Gly Gly Gly Gly

Gly Gly Gly Gly Gly Gly Ser

Ser Gly Gly Gly Gly Gly Gly

15 (Gly Gly Gly Gly Ser)_n

(Ser Gly Gly Gly Gly)_n

where n is an integer of 1 or larger. The lengths and sequences of peptide linkers can be selected accordingly by those skilled in the art depending on the purpose.

In an embodiment of the present invention, a particularly preferable sc(Fv)₂ includes, for example, the sc(Fv)₂ below.

[0027]

[VH]-peptide linker (15 amino acids)-[VL]-peptide linker (15 amino acids)-[VH]-peptide linker (15 amino acids)-[VL]

[0028]

25 Synthetic linkers (chemical crosslinking agents) include crosslinking agents routinely used to crosslink peptides, for example, N-hydroxy succinimide (NHS), disuccinimidyl suberate (DSS), bis(sulfosuccinimidyl) suberate (BS³), dithiobis(succinimidyl propionate) (DSP), dithiobis(sulfosuccinimidyl propionate) (DTSSP), ethylene glycol bis(succinimidyl succinate) (EGS), ethylene glycol bis(sulfosuccinimidyl succinate) (sulfo-EGS), disuccinimidyl tartrate (DST), disulfosuccinimidyl tartrate (sulfo-DST), bis[2-(succinimidoxycarbonyloxy)ethyl] sulfone (BSOCOES), and bis[2-(sulfosuccinimidoxycarbonyloxy)ethyl] sulfone (sulfo-BSOCOES). These crosslinking agents are commercially available.

[0029]

In general, three linkers are required to link four antibody variable regions together. The linkers to be used may be of the same type or different types. In the present invention, a preferable minibody is a diabody, even more preferably, an sc(Fv)₂. Such a minibody can be

prepared by treating an antibody with an enzyme, for example, papain or pepsin, to generate antibody fragments, or by constructing DNAs encoding those antibody fragments and introducing them into expression vectors, followed by expression in an appropriate host cell (see, for example, Co, M. S. *et al.*, *J. Immunol.* (1994) 152: 2968-2976; Better, M. and Horwitz, A. H., *Methods Enzymol.* (1989) 178: 476-496; Pluckthun, A. and Skerra, A., *Methods Enzymol.* (1989) 178: 497-515; Lamoyi, E., *Methods Enzymol.* (1986) 121: 652-663; Rousseaux, J. *et al.*, *Methods Enzymol.* (1986) 121: 663-669; Bird, R. E. and Walker, B. W., *Trends Biotechnol.* (1991) 9: 132-137).

[0030]

An antibody having exceedingly high agonistic activity can be prepared by reducing the molecular weight of a full-length antibody, particularly by converting it into an sc(Fv)₂.

In a preferred embodiment, the antibodies of the present invention comprise modified antibodies, such as chimeric antibodies and humanized antibodies that bind to Mpl. These modified antibodies can be produced by known methods.

[0031]

Chimeric antibodies are antibodies prepared by combining sequences derived from different animal species, and include for example, antibodies comprising the heavy chain and light chain variable regions of a murine antibody, and the heavy chain and light chain constant regions of a human antibody. Chimeric antibodies can be prepared by known methods. For example, a DNA encoding the V region of an antibody is linked to a DNA encoding the C region of a human antibody, and the construct is inserted into an expression vector and introduced into a host to produce chimeric antibodies.

[0032]

Humanized antibodies are also referred to as “reshaped human antibodies”. Such a humanized antibody is obtained by transferring the complementarity-determining region (CDR) of an antibody derived from a non-human mammal, for example mouse, to the complementarity-determining region of a human antibody, and the general gene recombination procedure for this is also known (see European Patent Application No. 125023 and WO 96/02576).

[0033]

Specifically, a DNA sequence designed to link a murine antibody CDR to the framework region (FR) of a human antibody can be synthesized by PCR, using primers prepared from several oligonucleotides containing overlapping portions of both CDR and FR terminal regions (see methods described in WO 98/13388).

[0034]

The human antibody framework region to be linked by CDR is selected in order to form

a favorable antigen-binding site in the complementarity-determining region. Amino acids of the framework region in the antibody variable region may be substituted, as necessary, for the complementarity-determining region of the reshaped human antibody to form a suitable antigen-binding site (Sato, K. *et al.*, Cancer Res. (1993) 53: 851-856).

5 [0035]

The constant region of a human antibody is used as the constant region of a chimeric antibody or humanized antibody. For example, C γ 1, C γ 2, C γ 3, and C γ 4 can be used as the H chain, and C κ and C λ can be used as the L chain. The human antibody constant region may be modified to improve the antibody or the stability of the antibody production.

10 [0036]

Generally, chimeric antibodies comprise the variable region of an antibody from a non-human mammal and the constant region derived from a human antibody. On the other hand, humanized antibodies comprise the complementarity-determining region of an antibody from a non-human mammal, and the framework region and constant region derived from a

15 human antibody.

[0037]

In addition, after a chimeric antibody or a humanized antibody is prepared, amino acids in the variable region (for example, FR) and the constant region may be replaced with other amino acids, and such.

20 The origin of the variable regions in chimeric antibodies or that of the CDRs in humanized antibodies is not particularly limited, and may be derived from any type of animal. For example, sequences of murine antibodies, rat antibodies, rabbit antibodies, camel antibodies may be used.

[0038]

25 In general, it is difficult to chimerize or humanize an antibody without losing the agonistic activity of the original antibody. Nevertheless, the present invention succeeded in preparing humanized antibodies having agonistic activity equivalent to that of the original murine antibody.

[0039]

30 A preferred humanized antibody of the present invention is an antibody comprising a heavy chain variable region that comprises the amino acid sequence of SEQ ID NO: 229 (humanized heavy chain sequence: hVB22B p-z VH), SEQ ID NO: 256 (humanized heavy chain sequence: hVB22B g-e VH), or SEQ ID NO: 262 (humanized heavy chain sequence: hVB22B e VH); or an antibody comprising a light chain variable region that comprises the amino acid

35 sequence of SEQ ID NO: 238 (humanized light chain hVB22B p-z VL), or SEQ ID NO: 258 (humanized light chain hVB22B g-e VL or hVB22B e VL). In particular, a preferred antibody

is an antibody comprising a heavy chain variable region and a light chain variable region of any one of (1) to (3) indicated below:

(1) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 229, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 238;

5 (2) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 256, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 258;

(3) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 262, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 258.

[0040]

10 Such antibodies include, for example, antibodies comprising the amino acid sequence of SEQ ID NO: 2, 254, or 260 (humanized sc(Fv)₂ sequence (hVB22B p-z sc(Fv)₂, hVB22B g-e sc(Fv)₂, or hVB22B e sc(Fv)₂).

[0041]

15 The nucleotide sequence of hVB22B p-z VH is shown in SEQ ID NO: 228; the nucleotide sequence of hVB22B g-e VH is shown in SEQ ID NO: 255; the nucleotide sequence of hVB22B e VH is shown in SEQ ID NO: 261; the nucleotide sequence of hVB22B p-z VL is shown in SEQ ID NO: 237; the nucleotide sequences of hVB22B g-e VL and hVB22B e VL are shown in SEQ ID NO: 257.

[0042]

20 In the amino acid sequence of SEQ ID NO: 229 (humanized heavy chain sequence: hVB22B p-z VH), SEQ ID NO: 256 (humanized heavy chain sequence: hVB22B g-e VH), or SEQ ID NO: 262 (humanized heavy chain sequence: hVB22B e VH), amino acids 31-35 correspond to CDR1; amino acids 50-66 correspond to CDR2; amino acids 99-107 correspond to CDR3; amino acids 1-30 correspond to FR1; amino acids 36-49 correspond to FR2; amino acids 67-98 correspond to FR3; and amino acids 108-118 correspond to FR4.

30 [0043]

In the amino acid sequence of SEQ ID NO: 238 (humanized light chain sequence: hVB22B p-z VL) or SEQ ID NO: 258 (humanized light chain sequence: hVB22B g-e VL or hVB22B e VL), amino acids 24-39 correspond to CDR1; amino acids 55-61 correspond to CDR2; amino acids 94-102 correspond to CDR3;

amino acids 1-23 correspond to FR1;
amino acids 40-54 correspond to FR2;
amino acids 62-93 correspond to FR3; and
amino acids 103-112 correspond to FR4.

5 [0044]

In the present invention, SEQ ID NOs of the CDRs and FRs in the hVB22B p-z VH sequence are shown below:

hVB22B p-z VH: FR1/SEQ ID NO: 230

hVB22B p-z VH: CDR1/SEQ ID NO: 231

10 hVB22B p-z VH: FR2/SEQ ID NO: 232

hVB22B p-z VH: CDR2/SEQ ID NO: 233

hVB22B p-z VH: FR3/SEQ ID NO: 234

hVB22B p-z VH: CDR3/SEQ ID NO: 235

hVB22B p-z VH: FR4/SEQ ID NO: 236.

15 [0045]

In the present invention, SEQ ID NOs of the CDRs and FRs in the hVB22B p-z VL sequence are shown below:

hVB22B p-z VL: FR1/SEQ ID NO: 239

hVB22B p-z VL: CDR1/SEQ ID NO: 240

20 hVB22B p-z VL: FR2/SEQ ID NO: 241

hVB22B p-z VL: CDR2/SEQ ID NO: 242

hVB22B p-z VL: FR3/SEQ ID NO: 243

hVB22B p-z VL: CDR3/SEQ ID NO: 244

hVB22B p-z VL: FR4/SEQ ID NO: 245.

25 [0046]

In the present invention, SEQ ID NOs of the CDRs and FRs in the hVB22B g-e VH sequence are shown below:

hVB22B g-e VH: FR1/SEQ ID NO: 265

hVB22B g-e VH: CDR1/SEQ ID NO: 266

30 hVB22B g-e VH: FR2/SEQ ID NO: 267

hVB22B g-e VH: CDR2/SEQ ID NO: 268

hVB22B g-e VH: FR3/SEQ ID NO: 269

hVB22B g-e VH: CDR3/SEQ ID NO: 270

hVB22B g-e VH: FR4/SEQ ID NO: 271.

35 [0047]

In the present invention, SEQ ID NOs of the CDRs and FRs in the hVB22B g-e VL

sequence are shown below:

hVB22B g-e VL: FR1/SEQ ID NO: 272

hVB22B g-e VL: CDR1/SEQ ID NO: 273

hVB22B g-e VL: FR2/SEQ ID NO: 274

5 hVB22B g-e VL: CDR2/SEQ ID NO: 275

hVB22B g-e VL: FR3/SEQ ID NO: 276

hVB22B g-e VL: CDR3/SEQ ID NO: 277

hVB22B g-e VL: FR4/SEQ ID NO: 278.

[0048]

10 In the present invention, SEQ ID NOs of the CDRs and FRs in the hVB22B e VH sequence are shown below:

hVB22B e VH: FR1/SEQ ID NO: 279

hVB22B e VH: CDR1/SEQ ID NO: 280

hVB22B e VH: FR2/SEQ ID NO: 281

15 hVB22B e VH: CDR2/SEQ ID NO: 282

hVB22B e VH: FR3/SEQ ID NO: 283

hVB22B e VH: CDR3/SEQ ID NO: 284

hVB22B e VH: FR4/SEQ ID NO: 285.

[0049]

20 In the present invention, SEQ ID NOs of the CDRs and FRs in the hVB22B e VL sequence are shown below:

hVB22B e VL: FR1/SEQ ID NO: 272

hVB22B e VL: CDR1/SEQ ID NO: 273

hVB22B e VL: FR2/SEQ ID NO: 274

25 hVB22B e VL: CDR2/SEQ ID NO: 275

hVB22B e VL: FR3/SEQ ID NO: 276

hVB22B e VL: CDR3/SEQ ID NO: 277

hVB22B e VL: FR4/SEQ ID NO: 278.

[0050]

30 SEQ ID NOs of the CDRs and FRs in the hVB22B p-z VH sequence and hVB22B p-z VL sequence are shown in Figure 18.

[0051]

In other embodiments, preferred humanized antibodies of the present invention include: humanized antibodies comprising a heavy chain variable region which has FR1, 2, 3, and 4

35 comprising amino acid sequences of any one of (1) to (3) indicated below:

(1) SEQ ID NOs: 230, 232, 234, and 236,

(2) SEQ ID NOs: 265, 267, 269, and 271,

(3) SEQ ID NOs: 279, 281, 283, and 285;

humanized antibodies comprising a light chain variable region which has FR1, 2, 3, and 4 comprising amino acid sequences of (1) or (2) listed below:

5 (1) SEQ ID NOs: 239, 241, 243, and 245,

(2) SEQ ID NOs: 272, 274, 276, and 278;

humanized antibodies comprising a heavy chain variable region which has CDR1, 2 and 3 comprising amino acid sequences of any one of (1) to (3) listed below:

(1) SEQ ID NOs: 231, 233, and 235,

10 (2) SEQ ID NOs: 266, 268, and 270,

(3) SEQ ID NOs: 280, 282, and 284; and

humanized antibodies comprising a light chain variable region which has CDR1, 2 and 3 comprising amino acid sequences of (1) or (2) listed below:

(1) SEQ ID NOs: 240, 242, and 244,

15 (2) SEQ ID NOs: 273, 275, and 277.

[0052]

In yet another preferred embodiments, preferred humanized antibodies of the present invention include:

humanized antibodies comprising heavy chain and light chain variable regions of any one of (1) to (3) indicated below.

20 (1) a heavy chain variable region which comprises FR1, 2, 3, and 4 comprising the amino acid sequences of SEQ ID NOs: 230, 232, 234, and 236, respectively, and a light chain variable region which comprises FR1, 2, 3, and 4 comprising the amino acid sequences of SEQ ID NOs: 239, 241, 243, and 245, respectively;

25 (2) a heavy chain variable region which comprises FR1, 2, 3, and 4 comprising the amino acid sequences of SEQ ID NOs: 265, 267, 269, and 271, respectively, and a light chain variable region which comprises FR1, 2, 3, and 4 comprising the amino acid sequences of SEQ ID NOs: 272, 274, 276, and 278, respectively;

30 (3) a heavy chain variable region which comprises FR1, 2, 3 and 4 comprising the amino acid sequences of SEQ ID NOs: 279, 281, 283, and 285, respectively, and a light chain variable region which comprises FR1, 2, 3, and 4 comprising the amino acid sequences of SEQ ID NOs: 272, 274, 276, and 278, respectively; and

humanized antibodies comprising heavy chain and light chain variable regions of any one of (1) to (3) indicated below:

35 (1) a heavy chain variable region which comprises CDR1, 2, and 3 comprising the amino acid sequences of SEQ ID NOs: 231, 233, and 235, respectively, and a light chain variable region

which comprises CDR1, 2, and 3 comprising the amino acid sequences of SEQ ID NOs: 240, 242, and 244, respectively;

(2) a heavy chain variable region which comprises CDR1, 2, and 3 comprising the amino acid sequences of SEQ ID NOs: 266, 268, and 270, respectively, and a light chain variable region
5 which comprises CDR1, 2, and 3 comprising the amino acid sequences of SEQ ID NOs: 273, 275, and 277, respectively;

(3) a heavy chain variable region which comprises CDR1, 2, and 3 comprising the amino acid sequences of SEQ ID NOs: 280, 282, and 284, respectively, and a light chain variable region
10 which comprises CDR1, 2, and 3 comprising the amino acid sequences of SEQ ID NOs: 273, 275, and 277, respectively.

[0053]

Chimeric antibodies and humanized antibodies exhibit lower antigenicity in the human body, and thus are expected to be useful when administered to humans for therapeutic purposes.

In one embodiment, the preferred antibodies of the present invention include antibodies
15 that bind to soluble Mpl. The term "soluble Mpl" herein refers to Mpl molecules excluding those expressed on the cell membrane. A specific example of a soluble Mpl is an Mpl lacking the entire or a portion of the transmembrane domain. The transmembrane domain of human Mpl corresponds to amino acids 492 to 513 in SEQ ID NO: 123.

[0054]

20 An antibody that binds to soluble recombinant Mpl can be used in detailed epitope analysis and kinetic analysis of receptor-ligand binding, as well as for assessing the blood concentration and dynamic behavior of the antibody in *in vivo* tests.

In one embodiment, the preferred antibodies of the present invention include antibodies
25 having binding activity against both human and monkey Mpl. Antibodies having agonistic activity to both human and monkey Mpl are expected to be highly useful since the dynamic behavior and *in vivo* effects of the antibody, which are generally difficult to determine in human body, can be examined with monkeys.

[0055]

30 The present invention also provides antibodies having agonistic activity to human Mpl and monkey Mpl. Such antibodies may also have binding activity or agonistic activity against Mpl from animals other than humans and monkeys (for example, mice).

[0056]

In addition, the antibodies of the present invention include antibodies with TPO
35 agonistic activity (agonistic activity against Mpl) of $EC_{50} = 100$ nM or lower, preferably $EC_{50} = 30$ nM or lower, more preferably $EC_{50} = 10$ nM or lower.

[0057]

The agonistic activity can be determined by methods known to those skilled in the art, for example, by the method described below.

The sequences for human Mpl (Palacios *et al.*, Cell (1985) 41:727-734; GenBank Accession NO. NM_005373), cynomolgus monkey Mpl (SEQ ID NO: 157), and mouse Mpl (GenBank
5 Accession NO. NM_010823) are already known.

[0058]

In addition, the present invention includes antibodies whose binding activities to soluble Mpl are $KD = 10^{-6}$ M or lower, preferably $KD = 10^{-7}$ M or lower, and more preferably $KD = 10^{-8}$ M or lower.

10 [0059]

In the present invention, whether the binding activity of an antibody to soluble recombinant Mpl is $KD = 10^{-6}$ M or lower can be determined by methods known to those skilled in the art. For example, the activity can be determined using surface plasmon resonance with Biacore. Specifically, soluble MPL-Fc protein is immobilized onto sensor chips. Reaction
15 rate constant can be determined by assessing the interaction between the antibody and the soluble Mpl-Fc protein. The binding activity can be evaluated by ELISA (enzyme-linked immunosorbent assays), EIA (enzyme immunoassays), RIA (radio immunoassays), or fluorescent antibody techniques. For example, in enzyme immunoassays, a sample containing a test antibody, such as purified antibody or culture supernatant of cells producing the test antibody,
20 is added to a plate coated with an antigen to which the test antibody can bind. After incubating the plate with a secondary antibody labeled with an enzyme such as alkaline phosphatase, the plate is washed and an enzyme substrate such as p-nitrophenyl phosphate is added. The antigen-binding activity can then be evaluated by determining the absorbance.

[0060]

25 There is no specific limitation as to the upper limit of the binding activity; for example, the upper limit may be set within a technically feasible range by those skilled in the art. However, the technically feasible range may expand with the advancement of technology.

[0061]

In an embodiment, the preferred antibodies of the present invention include antibodies
30 recognizing epitopes that are recognized by any one of the antibodies indicated in (I) to (XII) below. The antibody of any one of (I) to (XII) is preferably a minibody.

[0062]

(I)

Antibody comprising a VH that has CDR1, 2, and 3 comprising the amino acid
35 sequences according to SEQ ID NOs in any one of (1) to (22) indicated below (name of each antibody and the H chain CDR contained in the antibody are indicated inside the parentheses):

- (1) SEQ ID NOs: 3, 4, and 5 (VA7: H chain CDR1, 2, and 3),
- (2) SEQ ID NOs: 6, 7, and 8 (VA130: H chain CDR1, 2, and 3),
- (3) SEQ ID NOs: 9, 10, and 11 (VA259: H chain CDR1, 2, and 3),
- (4) SEQ ID NOs: 12, 13, and 14 (VB17B: H chain CDR1, 2, and 3),
- 5 (5) SEQ ID NOs: 15, 16, and 17 (VB12B: H chain CDR1, 2, and 3),
- (6) SEQ ID NOs: 18, 19, and 20 (VB140: H chain CDR1, 2, and 3),
- (7) SEQ ID NOs: 21, 22, and 23 (VB33: H chain CDR1, 2, and 3),
- (8) SEQ ID NOs: 24, 25, and 26 (VB45B: H chain CDR1, 2, and 3),
- (9) SEQ ID NOs: 27, 28, and 29 (VB8B: H chain CDR1, 2, and 3),
- 10 (10) SEQ ID NOs: 30, 31, and 32 (VB115: H chain CDR1, 2, and 3),
- (11) SEQ ID NOs: 33, 34, and 35 (VB14B: H chain CDR1, 2, and 3),
- (12) SEQ ID NOs: 36, 37, and 38 (VB22B: H chain CDR1, 2, and 3),
- (13) SEQ ID NOs: 39, 40, and 41 (VB16: H chain CDR1, 2, and 3),
- (14) SEQ ID NOs: 42, 43, and 44 (VB157: H chain CDR1, 2, and 3),
- 15 (15) SEQ ID NOs: 45, 46, and 47 (VB4B: H chain CDR1, 2, and 3),
- (16) SEQ ID NOs: 48, 49, and 50 (VB51: H chain CDR1, 2, and 3),
- (17) SEQ ID NOs: 51, 52, and 53 (AB317: H chain CDR1, 2, and 3),
- (18) SEQ ID NOs: 54, 55, and 56 (AB324: H chain CDR1, 2, and 3),
- (19) SEQ ID NOs: 57, 58, and 59 (TA136: H chain CDR1, 2, and 3),
- 20 (20) SEQ ID NOs: 231, 233, and 235 (hVB22B p-z: H chain CDR1, 2, and 3),
- (21) SEQ ID NOs: 266, 268, and 270 (hVB22B g-e: H chain CDR1, 2, and 3),
- (22) SEQ ID NOs: 280, 282, and 284 (hVB22B e: H chain CDR1, 2, and 3).

[0063]

(II)

- 25 Antibody comprising a VL which has CDR1, 2, and 3 comprising the amino acid sequences according to SEQ ID NOs in any one of (1) to (21) indicated below (name of each antibody and the L chain CDR in the antibody are indicated inside the parentheses):

- (1) SEQ ID NOs: 60, 61, and 62 (VA7: L chain CDR1, 2, and 3),
- (2) SEQ ID NOs: 63, 64, and 65 (VA130: L chain CDR1, 2, and 3),
- 30 (3) SEQ ID NOs: 66, 67, and 68 (VA259: L chain CDR1, 2, and 3),
- (4) SEQ ID NOs: 69, 70, and 71 (VB17B: L chain CDR1, 2, and 3),
- (5) SEQ ID NOs: 72, 73, and 74 (VB12B: L chain CDR1, 2, and 3),
- (6) SEQ ID NOs: 75, 76, and 77 (VB140: L chain CDR1, 2, and 3)
- (7) SEQ ID NOs: 78, 79, and 80 (VB33: L chain CDR1, 2, and 3),
- 35 (8) SEQ ID NOs: 81, 82, and 83 (VB45B: L chain CDR1, 2, and 3),
- (9) SEQ ID NOs: 84, 85, and 86 (VB8B: L chain CDR1, 2, and 3),

- (10) SEQ ID NOs: 87, 88, and 89 (VB115: L chain CDR1, 2, and 3),
(11) SEQ ID NOs: 90, 91, and 92 (VB14B: L chain CDR1, 2, and 3),
(12) SEQ ID NOs: 93, 94, and 95 (VB22B: L chain CDR1, 2, and 3),
(13) SEQ ID NOs: 96, 97, and 98 (VB16: L chain CDR1, 2, and 3),
5 (14) SEQ ID NOs: 99, 100, and 101 (VB157: L chain CDR1, 2, and 3),
(15) SEQ ID NOs: 102, 103, and 104 (VB4B: L chain CDR1, 2, and 3),
(16) SEQ ID NOs: 105, 106, and 107 (VB51: L chain CDR1, 2, and 3),
(17) SEQ ID NOs: 108, 109, and 110 (AB317: L chain CDR1, 2, and 3),
(18) SEQ ID NOs: 111, 112, and 113 (AB324: L chain CDR1, 2, and 3),
10 (19) SEQ ID NOs: 114, 115, and 116 (TA136: L chain CDR1, 2, and 3),
(20) SEQ ID NOs: 240, 242, and 244 (hVB22B p-z: L chain CDR1, 2, and 3),
(21) SEQ ID NOs: 273, 275, and 277 (hVB22B g-e or hVB22B e: L chain CDR1, 2, and 3).

[0064]

(III)

15 Antibody comprising a VH that comprises an amino acid sequence of the SEQ ID NO in any one of (1) to (22):

- (1) SEQ ID NO: 124 (VA7: VH),
(2) SEQ ID NO: 126 (VA130: VH),
(3) SEQ ID NO: 128 (VA259: VH),
20 (4) SEQ ID NO: 130 (VB17B: VH),
(5) SEQ ID NO: 132 (VB12B: VH),
(6) SEQ ID NO: 134 (VB140: VH),
(7) SEQ ID NO: 136 (VB33: VH),
(8) SEQ ID NO: 138 (VB45B: VH),
25 (9) SEQ ID NO: 140 (VB8B: VH),
(10) SEQ ID NO: 142 (VB115: VH),
(11) SEQ ID NO: 144 (VB14B: VH),
(12) SEQ ID NO: 118 (VB22B: VH),
(13) SEQ ID NO: 146 (VB16: VH),
30 (14) SEQ ID NO: 148 (VB157: VH),
(15) SEQ ID NO: 150 (VB4B: VH),
(16) SEQ ID NO: 152 (VB51: VH),
(17) SEQ ID NO: 155 (AB317: VH),
(18) SEQ ID NO: 159 (AB324: VH),
35 (19) SEQ ID NO: 162 (TA136: VH),
(20) SEQ ID NO: 229 (hVB22B p-z: VH),

(21) SEQ ID NO: 256 (hVB22B g-e: VH),

(22) SEQ ID NO: 262 (hVB22B e: VH).

[0065]

(IV)

5 Antibody comprising a VL that comprises an amino acid sequence of the SEQ ID NO in any one of (1) to (21):

(1) SEQ ID NO: 125 (VA7: VL),

(2) SEQ ID NO: 127 (VA130: VL),

(3) SEQ ID NO: 129 (VA259: VL),

10 (4) SEQ ID NO: 131 (VB17B: VL),

(5) SEQ ID NO: 133 (VB12B: VL),

(6) SEQ ID NO: 135 (VB140: VL),

(7) SEQ ID NO: 137 (VB33: VL),

(8) SEQ ID NO: 139 (VB45B: VL),

15 (9) SEQ ID NO: 141 (VB8B: VL),

(10) SEQ ID NO: 143 (VB115: VL),

(11) SEQ ID NO: 145 (VB14B: VL),

(12) SEQ ID NO: 120 (VB22B: VL),

(13) SEQ ID NO: 147 (VB16: VL),

20 (14) SEQ ID NO: 149 (VB157: VL),

(15) SEQ ID NO: 151 (VB4B: VL),

(16) SEQ ID NO: 153 (VB51: VL),

(17) SEQ ID NO: 157 (AB317: VL),

(18) SEQ ID NO: 161 (AB324: VL),

25 (19) SEQ ID NO: 163 (TA136: VL),

(20) SEQ ID NO: 238 (hVB22B p-z: VL),

(21) SEQ ID NO: 258 (hVB22B g-e: VL or hVB22B e: VL).

[0066]

(V)

30 Antibody comprising a VH and VL according to any one of (1) to (22):

(1) SEQ ID NOS: 3, 4, and 5 (VA7: H chain CDR1, 2, and 3); SEQ ID NOS: 60, 61, and 62 (VA7: L chain CDR1, 2, and 3),

(2) SEQ ID NOS: 6, 7, and 8 (VA130: H chain CDR1, 2, and 3), SEQ ID NOS: 63, 64, and 65 (VA130: L chain CDR1, 2, and 3),

35 (3) SEQ ID NOS: 9, 10, and 11 (VA259: H chain CDR1, 2, and 3); SEQ ID NOS: 66, 67, and 68 (VA259: L chain CDR1, 2, and 3),

- (4) SEQ ID NOs: 12, 13, and 14 (VB17B: H chain CDR1, 2, and 3); SEQ ID NOs: 69, 70, and 71 (VB17B: L chain CDR1, 2, and 3),
- (5) SEQ ID NOs: 15, 16, and 17 (VB12B: H chain CDR1, 2, and 3); SEQ ID NOs: 72, 73, and 74 (VB12B: L chain CDR1, 2, and 3),
- 5 (6) SEQ ID NOs: 18, 19, and 20 (VB140: H chain CDR1, 2, and 3); SEQ ID NOs: 75, 76, and 77 (VB140: L chain CDR1, 2, and 3),
- (7) SEQ ID NOs: 21, 22, and 23 (VB33: H chain CDR1, 2, and 3); SEQ ID NOs: 78, 79, and 80 (VB33: L chain CDR1, 2, and 3),
- (8) SEQ ID NOs: 24, 25, and 26 (VB45B: H chain CDR1, 2, and 3); SEQ ID NOs: 81, 82, and 10 83 (VB45B: L chain CDR1, 2, and 3),
- (9) SEQ ID NOs: 27, 28, and 29 (VB8B: H chain CDR1, 2, and 3); SEQ ID NOs: 84, 85, and 86 (VB8B: L chain CDR1, 2, and 3),
- (10) SEQ ID NOs: 30, 31, and 32 (VB115: H chain CDR1, 2, and 3); SEQ ID NOs: 87, 88, and 89 (VB115: L chain CDR1, 2, and 3),
- 15 (11) SEQ ID NOs: 33, 34, and 35 (VB14B: H chain CDR1, 2, and 3); SEQ ID NOs: 90, 91, and 92 (VB14B: L chain CDR1, 2, and 3),
- (12) SEQ ID NOs: 36, 37, and 38 (VB22B: H chain CDR1, 2, and 3); SEQ ID NOs: 93, 94, and 95 (VB22B: L chain CDR1, 2, and 3),
- (13) SEQ ID NOs: 39, 40, and 41 (VB16: H chain CDR1, 2, and 3); SEQ ID NOs: 96, 97, and 98 20 (VB16: L chain CDR1, 2, and 3),
- (14) SEQ ID NOs: 42, 43, and 44 (VB157: H chain CDR1, 2, and 3); SEQ ID NOs: 99, 100, and 101 (VB157: L chain CDR1, 2, and 3),
- (15) SEQ ID NOs: 45, 46, and 47 (VB4B: H chain CDR1, 2, and 3); SEQ ID NOs: 102, 103, and 104 (VB4B: L chain CDR1, 2, and 3),
- 25 (16) SEQ ID NOs: 48, 49, and 50 (VB51: H chain CDR1, 2, and 3); SEQ ID NOs: 105, 106, and 107 (VB51: L chain CDR1, 2, and 3),
- (17) SEQ ID NOs: 51, 52, and 53 (AB317: H chain CDR1, 2, and 3); SEQ ID NOs: 108, 109, and 110 (AB317: L chain CDR1, 2, and 3),
- (18) SEQ ID NOs: 54, 55, and 56 (AB324: H chain CDR1, 2, and 3); SEQ ID NOs: 111, 112, 30 and 113 (AB324: L chain CDR1, 2, and 3),
- (19) SEQ ID NOs: 57, 58, and 59 (TA136: H chain CDR1, 2, and 3); SEQ ID NOs: 114, 115, and 116 (TA136: L chain CDR1, 2, and 3),
- (20) SEQ ID NOs: 231, 233, and 235 (hVB22B p-z: H chain CDR1, 2, and 3); SEQ ID NOs: 240, 242, and 244 (hVB22B p-z: L chain CDR1, 2, and 3),
- 35 (21) SEQ ID NOs: 266, 268, and 270 (hVB22B g-e: H chain CDR1, 2, and 3); SEQ ID NOs: 273, 275, and 277 (hVB22B g-e: L chain CDR1, 2, and 3),

(22) SEQ ID NOs: 280, 282, and 284 (hVB22B e: H chain CDR1, 2, and 3); SEQ ID NOs: 273, 275, and 277 (hVB22B e: L chain CDR1, 2, and 3).

[0067]

(VI)

5 Antibody comprising a VH and a VL that comprise the amino acid sequences according to SEQ ID NOs in any one of (1) to (22) indicated below:

- (1) SEQ ID NO: 124 (VA7: VH), SEQ ID NO: 125 (VA7: VL),
 (2) SEQ ID NO: 126 (VA130: VH), SEQ ID NO: 127 (VA130: VL),
 (3) SEQ ID NO: 128 (VA259: VH), SEQ ID NO: 129 (VA259: VL),
 10 (4) SEQ ID NO: 130 (VB17B: VH), SEQ ID NO: 131 (VB17B: VL),
 (5) SEQ ID NO: 132 (VB12B: VH), SEQ ID NO: 133 (VB12B: VL),
 (6) SEQ ID NO: 134 (VB140: VH), SEQ ID NO: 135 (VB140: VL),
 (7) SEQ ID NO: 136 (VB33: VH), SEQ ID NO: 137 (VB33: VL),
 (8) SEQ ID NO: 138 (VB45B: VH), SEQ ID NO: 139 (VB45B: VL),
 15 (9) SEQ ID NO: 140 (VB8B: VH), SEQ ID NO: 141 (VB8B: VL),
 (10) SEQ ID NO: 142 (VB115: VH), SEQ ID NO: 143 (VB115: VL),
 (11) SEQ ID NO: 144 (VB14B: VH), SEQ ID NO: 145 (VB14B: VL),
 (12) SEQ ID NO: 118 (VB22B: VH), SEQ ID NO: 120 (VB22B: VL),
 (13) SEQ ID NO: 146 (VB16: VH), SEQ ID NO: 147 (VB16: VL),
 20 (14) SEQ ID NO: 148 (VB157: VH), SEQ ID NO: 149 (VB157: VL),
 (15) SEQ ID NO: 150 (VB4B: VH), SEQ ID NO: 151 (VB4B: VL),
 (16) SEQ ID NO: 152 (VB51: VH), SEQ ID NO: 153 (VB51: VL),
 (17) SEQ ID NO: 155 (AB317: VH), SEQ ID NO: 157 (AB317: VL),
 (18) SEQ ID NO: 159 (AB324: VH), SEQ ID NO: 161 (AB324: VL),
 25 (19) SEQ ID NO: 162 (TA136: VH), SEQ ID NO: 163 (TA136: VL),
 (20) SEQ ID NO: 229 (hVB22B p-z: VH), SEQ ID NO: 238 (hVB22B p-z: VL),
 (21) SEQ ID NO: 256 (hVB22B g-e: VH), SEQ ID NO: 258 (hVB22B g-e: VL),
 (22) SEQ ID NO: 262 (hVB22B e: VH), SEQ ID NO: 258 (hVB22B e: VL).

[0068]

30 (VII)

Antibody comprising the amino acid sequence of SEQ ID NO: 122 (VB22B: scFv).

[0069]

(VIII)

35 Humanized antibody comprising an amino acid sequence according to any one of SEQ ID NO: 2 (hVB22B p-z: sc(Fv)₂), SEQ ID NO: 254 (hVB22B g-e: sc(Fv)₂), and SEQ ID NO: 260 (hVB22B e: sc(Fv)₂).

[0070]

(IX)

Antibody comprising a VH which has FR1, 2, 3, and 4 comprising amino acid sequences according to SEQ ID NOs in any one of (1) to (3) indicated below:

- 5 (1) SEQ ID NOs: 230, 232, 234, and 236 (hVB22B p-z: H chain FR1, 2, 3, and 4),
(2) SEQ ID NOs: 265, 267, 269, and 271 (hVB22B g-e: H chain FR1, 2, 3, and 4),
(3) SEQ ID NOs: 279, 281, 283, and 285 (hVB22B e: H chain FR1, 2, 3, and 4).

[0071]

(X)

10 Antibody comprising a VL which has FR1, 2, 3 and 4 comprising amino acid sequences according to SEQ ID NOs in any one of (1) or (2) indicated below:

- (1) SEQ ID NOs: 239, 241, 243, and 245 (hVB22B p-z: L chain FR1, 2, 3, and 4),
(2) SEQ ID NOs: 272, 274, 276, and 278 (hVB22B g-e or hVB22B e: L chain FR1, 2, 3, and 4).

[0072]

15 (XI)

Antibody comprising VH and VL according to any one of (1) to (3) indicated below:

- (1) VH having FR1, 2, 3, and 4 comprising the amino acid sequences of SEQ ID NOs: 230, 232, 234, and 236, respectively, and VL having FR1, 2, 3, and 4 comprising the amino acid sequences of SEQ ID NOs: 239, 241, 243, and 245, respectively;
20 (2) VH having FR1, 2, 3, and 4 comprising the amino acid sequences of SEQ ID NOs: 265, 267, 269, and 271, respectively, and VL having FR1, 2, 3, and 4 comprising the amino acid sequences of SEQ ID NOs: 272, 274, 276, and 278, respectively;
(3) VH having FR1, 2, 3, and 4 comprising the amino acid sequences of SEQ ID NOs: 279, 281, 283, and 285, respectively, and VL having FR1, 2, 3, and 4 comprising the amino acid sequences
25 of SEQ ID NOs: 272, 274, 276, and 278, respectively.

[0073]

(XII)

Antibody comprising the amino acid sequence of SEQ ID NO: 264 (VB22B: sc(Fv)₂).

[0074]

30 An antibody comprising an amino acid sequence of any one of (I) to (XII) indicated above, in which one or more amino acids have been substituted, deleted, added, and/or inserted, wherein the antibody has activity equivalent to that of the antibody of any one of (I) to (XII).

[0075]

35 Herein, the phrase "functionally equivalent" means that an antibody of interest has a biological or biochemical activity comparable to that of an antibody of the present invention. Such activities include, for example, binding activities and agonistic activities.

[0076]

Methods for preparing polypeptides functionally equivalent to a certain polypeptide are well known to those skilled in the art, and include methods of introducing mutations into polypeptides. For example, those skilled in the art can prepare an antibody functionally
5 equivalent to the antibodies of the present invention by introducing appropriate mutations into the antibody using site-directed mutagenesis (Hashimoto-Gotoh, T. *et al.* *Gene* (1995) 152: 271-275; Zoller, MJ, and Smith, M. *Methods Enzymol.* (1983) 100: 468-500; Kramer, W. *et al.*, *Nucleic Acids Res.* (1984) 12: 9441-9456; Kramer, W. and Fritz HJ, *Methods Enzymol.* (1987) 154: 350-367; Kunkel, TA, *Proc. Natl. Acad. Sci. USA.* (1985) 82: 488-492; Kunkel, *Methods*
10 *Enzymol.* (1988) 85: 2763-2766), or such. Amino acid mutations may occur naturally. Thus, the present invention also comprises antibodies functionally equivalent to the antibodies of the present invention and comprising the amino acid sequences of these antibodies, in which one or more amino acids is mutated. Generally, the number of amino acids that are mutated is 50 amino acids or less, preferably 30 or less, more preferably 10 or less (for example, five amino
15 acids or less).

[0077]

An amino acid is preferably substituted for a different amino acid(s) that allows the properties of the amino acid side-chain to be conserved. Examples of amino acid side chain
20 properties are: hydrophobic amino acids (A, I, L, M, F, P, W, Y, and V), hydrophilic amino acids (R, D, N, C, E, Q, G, H, K, S, and T), amino acids comprising the following side chains: aliphatic side chains (G, A, V, L, I, and P); hydroxyl-containing side chains (S, T, and Y); sulfur-containing side chains (C and M); carboxylic acid- and amide-containing side chains (D, N, E, and Q); basic side chains (R, K, and H); aromatic ring-containing side chains (H, F, Y, and W) (amino acids are represented by one-letter codes in parentheses).

[0078]

A polypeptide comprising a modified amino acid sequence, in which one or more amino acid residues is deleted, added, and/or replaced with other amino acids, is known to retain its original biological activity (Mark, D. F. *et al.*, *Proc. Natl. Acad. Sci. USA* (1984) 81: 5662-5666; Zoller, M. J. & Smith, M. *Nucleic Acids Research* (1982) 10: 6487-6500; Wang, A. *et al.*,
30 *Science* 224: 1431-1433; Dalbadie-McFarland, G. *et al.*, *Proc. Natl. Acad. Sci. USA* (1982) 79: 6409-6413).

[0079]

Fusion proteins containing antibodies that comprise the amino acid sequence of an antibody of the present invention, in which two or more amino acid residues have been added,
35 are included in the present invention. The fusion protein results from a fusion between one of the above antibodies and a second peptide or protein, and is included in the present invention.

The fusion protein can be prepared by ligating a polynucleotide encoding an antibody of the present invention and a polynucleotide encoding a second peptide or polypeptide in frame, inserting this into an expression vector, and expressing the fusion construct in a host. Some techniques known to those skilled in the art are available for this purpose. The partner peptide or polypeptide to be fused with an antibody of the present invention may be a known peptide, for example, FLAG (Hopp, T. P. *et al.*, *BioTechnology* (1988) 6: 1204-1210), 6x His consisting of six His (histidine) residues, 10x His, influenza hemagglutinin (HA), human c-myc fragment, VSV-GP fragment, p18HIV fragment, T7-tag, HSV-tag, E-tag, SV40 T antigen fragment, Ick tag, α -tubulin fragment, B-tag, Protein C fragment. Other partner polypeptides to be fused with the antibodies of the present invention include, for example, GST (glutathione-S-transferase), HA (influenza hemagglutinin), immunoglobulin constant region, β -galactosidase, and MBP (maltose-binding protein). A polynucleotide encoding one of these commercially available peptides or polypeptides can be fused with a polynucleotide encoding an antibody of the present invention. The fusion polypeptide can be prepared by expressing the fusion construct.

[0080]

As described below, the antibodies of the present invention may differ in amino acid sequence, molecular weight, isoelectric point, presence/absence of sugar chains, and conformation depending on the cell or host producing the antibody, or purification method. However, a resulting antibody is included in the present invention, as long as it is functionally equivalent to an antibody of the present invention. For example, when an antibody of the present invention is expressed in prokaryotic cells, for example *E. coli*, a methionine residue is added to the N terminus of the original antibody amino acid sequence. Such antibodies are included in the present invention.

[0081]

An antibody that recognizes an epitope recognized by the antibody according to any one of (I) to (XII) indicated above is expected to have a high agonistic activity. Such antibodies can be prepared by methods known to those skilled in the art. The antibody can be prepared by, for example, determining the epitope recognized by the antibody according to any one of (I) to (XII) by conventional methods, and using a polypeptide comprising one of the epitope amino acid sequences as an immunogen. Alternatively, the antibody can be prepared by determining the epitopes of conventionally prepared antibodies and selecting an antibody that recognizes the epitope recognized by an antibody of any one of (I) to (XII).

[0082]

In the present invention, a particularly preferred antibody is an antibody that recognizes the epitope recognized by the antibody comprising the amino acid sequence of SEQ ID NO: 2. The antibody comprising the amino acid sequence of SEQ ID NO: 2 is predicted to recognize the

region from Glu 26 to Leu 274, preferably the region from Ala 189 to Gly 245, more preferably the region from Gln 213 to Ala 231 of human Mpl. Thus, antibodies recognizing the region of amino acids 26 to 274, or amino acids 189 to 245, or amino acids 213 to 231 of human Mpl are also included in the present invention.

5 [0083]

Antibodies recognizing regions of amino acids 26 to 274, amino acids 189 to 245, or amino acids 213 to 231 of the human Mpl amino acid sequence (SEQ ID NO: 123) can be obtained by methods known to those skilled in the art. Such antibodies can be prepared by, for example, using a peptide comprising amino acids 26 to 274, amino acids 189 to 245, or amino
10 acids 213 to 231 of the human Mpl amino acid sequence (SEQ ID NO: 123) as an immunogen. Alternatively, such antibodies can be prepared by determining the epitope of a conventionally prepared antibody and selecting an antibody that recognizes the same epitope recognized by an antibody of the present invention.

[0084]

15 The present invention provides antibodies described above in (I) to (XII). In an embodiment of the present invention, a preferred antibody is the one shown in (V), a more preferred antibody is the one shown in (VI), and a still more preferred is the one shown in (VIII).

[0085]

20 The present invention also provides vectors comprising polynucleotides encoding the antibodies of the present invention, or polynucleotides which hybridize under stringent conditions to the polynucleotides of the present invention and encode antibodies having activities equivalent to those of the antibodies of the present invention. The polynucleotides of the present invention are polymers comprising multiple bases or base pairs of deoxyribonucleic acids (DNA) or ribonucleic acids (RNA), and are not particularly limited, as long as they encode
25 the antibodies of the present invention. They may also contain non-natural nucleotides. The polynucleotides of the present invention can be used to express antibodies using genetic engineering techniques. The polynucleotides of this invention can also be used as probes in the screening of antibodies functionally equivalent to the antibodies of the present invention. Specifically, DNAs that hybridize under stringent conditions to a polynucleotide encoding an
30 antibody of the present invention, and encode antibodies having activity equivalent to those of the antibodies of the present invention can be obtained by techniques such as hybridization and gene amplification (for example, PCR), using a polynucleotide of the present invention or a portion thereof as a probe. Such DNAs are also included in the polynucleotides of the present invention. Hybridization techniques are well known to those skilled in the art (Sambrook, *J et al.*, Molecular Cloning 2nd ed., 9.47-9.58, Cold Spring Harbor Lab. press, 1989). Such
35 hybridization conditions include, for example, conditions of low stringency. Examples of

conditions of low stringency include post-hybridization washing in 0.1x SSC and 0.1% SDS at 42°C, and preferably in 0.1x SSC and 0.1% SDS at 50°C. More preferable hybridization conditions include those of high stringency. Highly stringent conditions include, for example, washing in 5x SSC and 0.1% SDS at 65°C. In these conditions, the higher the temperature, the higher the expectation of efficiently obtaining polynucleotides with a high homology. However, several factors, such as temperature and salt concentration, can influence hybridization stringency, and those skilled in the art can suitably select these factors to accomplish similar stringencies.

[0086]

Antibodies that are encoded by polynucleotides obtained by the hybridization and gene amplification techniques, and are functionally equivalent to the antibodies of the present invention generally exhibit high homology to the antibodies of the this invention at the amino acid level. The antibodies of the present invention include antibodies that are functionally equivalent to the antibodies of the present invention, and exhibit high amino acid sequence homology to the antibodies of this invention. The term "high homology" generally means identity at the amino acid level of at least 50% or higher, preferably 75% or higher, more preferably 85% or higher, still more preferably 95% or higher. Polypeptide homology can be determined by the algorithm described in the report: Wilbur, W. J. and Lipman, D. J. Proc. Natl. Acad. Sci. USA (1983) 80: 726-730.

[0087]

When *E. coli* is used as a host, there is no particular limitation as to the type of vector of the present invention, as long as the vector contains an "ori" responsible for its replication in *E. coli* and a marker gene. The "ori" ensures the amplification and mass production of the vector in *E. coli* (for example, JM109, DH5 α , HB101, and XL1Blue). The marker gene is used to select the *E. coli* transformants (for example, a drug resistance gene selected by an appropriate drug such as ampicillin, tetracycline, kanamycin, and chloramphenicol). The vectors include, for example, M13 vectors, pUC vectors, pBR322, pBluescript, and pCR-Script. In addition to the above vectors, for example, pGEM-T, pDIRECT, and pT7 can also be used for the subcloning and excision of cDNAs.

[0088]

An expression vector is especially useful for the type of vectors of the present invention. When an expression vector is expressed, for example, in *E. coli*, it should have the above characteristics in order to be amplified in *E. coli*. Additionally, when *E. coli*, such as JM109, DH5 α , HB101, or XL1-Blue are used as the host cell, the vector preferably has a promoter, for example, lacZ promoter (Ward *et al.* Nature (1989) 341: 544-546; FASEB J. (1992) 6: 2422-2427), araB promoter (Better *et al.* Science (1988) 240: 1041-1043), or T7 promoter, that

allows efficient expression of the desired gene in *E. coli*. Other examples of the vectors include pGEX-5X-1 (Pharmacia), "QIAexpress system" (QIAGEN), pEGFP, and pET (where BL21, a strain expressing T7 RNA polymerase, is preferably used as the host).

[0089]

5 Furthermore, the vector may comprise a signal sequence for polypeptide secretion. When producing polypeptides into the periplasm of *E. coli*, the pelB signal sequence (Lei, S. P. *et al.* J. Bacteriol. (1987) 169: 4379) may be used as a signal sequence for polypeptide secretion. For example, calcium chloride methods or electroporation methods may be used to introduce the vector into a host cell.

10 [0090]

In addition to *E. coli*, expression vectors derived from mammals (e.g., pCDNA3 (Invitrogen), pEGF-BOS (Nucleic Acids Res. (1990) 18 (17): 5322), pEF, pCDM8), insect cells (e.g., "Bac-to-BAC baculovirus expression system" (GIBCO-BRL), pBacPAK8), plants (e.g., pMH1, pMH2), animal viruses (e.g., pHSV, pMV, pAdexLcw), retroviruses (e.g., pZIPneo),
15 yeasts (e.g., "Pichia Expression Kit" (Invitrogen), pNV11, SP-Q01), and *Bacillus subtilis* (e.g., pPL608, pKTH50) may also be used as a vector of the present invention.

[0091]

In order to express proteins in animal cells such as CHO, COS, and NIH3T3 cells, the vector preferably has a promoter necessary for expression in such cells, for example, an SV40
20 promoter (Mulligan *et al.*, Nature (1979) 277: 108), MMLV-LTR promoter, EF1 α promoter (Mizushima *et al.*, Nucleic Acids Res. (1990) 18: 5322), CMV promoter, etc.). It is even more preferable that the vector also carries a marker gene for selecting transformants (for example, a drug-resistance gene selected by a drug such as neomycin and G418). Examples of vectors with such characteristics include pMAM, pDR2, pBK-RSV, pBK-CMV, pOPRSV, and pOP13,
25 and such.

[0092]

In addition, to stably express a gene and amplify the gene copy number in cells, CHO cells that are defective in the nucleic acid synthesis pathway are introduced with a vector containing a DHFR gene (for example, pCHOI) to compensate for the defect, and the copy
30 number is amplified using methotrexate (MTX). Alternatively, a COS cell, which carries an SV40 T antigen-expressing gene on its chromosome, can be transformed with a vector containing the SV40 replication origin (for example, pcD) for transient gene expression. The replication origin may be derived from polyoma virus, adenovirus, bovine papilloma virus (BPV), and such. Furthermore, to increase the gene copy number in host cells, the expression
35 vector may contain, as a selection marker, aminoglycoside transferase (APH) gene, thymidine kinase (TK) gene, *E. coli* xanthine guanine phosphoribosyl transferase (Ecogpt) gene,

dihydrofolate reductase (dhfr) gene, and such.

[0093]

Next, the vector is introduced into a host cell. The host cells into which the vector is introduced are not particularly limited, for example, *E. coli* and various animal cells are available for this purpose. The host cells may be used, for example, as a production system to produce and express the antibodies of the present invention. *In vitro* and *in vivo* production systems are available for polypeptide production systems. Production systems that use eukaryotic cells or prokaryotic cells are examples of *in vitro* production systems.

[0094]

Eukaryotic cells that can be used are, for example, animal cells, plant cells, and fungal cells. Known animal cells include: mammalian cells, for example, CHO (J. Exp. Med. (1995) 108: 945), COS, 3T3, myeloma, BHK (baby hamster kidney), HeLa, Vero, amphibian cells such as *Xenopus laevis* oocytes (Valle, *et al.*, Nature (1981) 291: 358-340), or insect cells (e.g., Sf9, Sf21, and Tn5). In the present invention, CHO-DG44, CHO-DXB11, COS7 cells, and BHK cells can be suitably used. Among animal cells, CHO cells are particularly favorable for large-scale expression. Vectors can be introduced into a host cell by, for example, calcium phosphate methods, the DEAE-dextran methods, methods using cationic liposome DOTAP (Boehringer-Mannheim), electroporation methods, lipofection methods.

[0095]

Plant cells include, for example, *Nicotiana tabacum*-derived cells known as a protein production system. Calluses may be cultured from these cells. Known fungal cells include yeast cells, for example, genus *Saccharomyces* such as *Saccharomyces cerevisiae* and *Saccharomyces pombe*; and filamentous fungi, for example, genus *Aspergillus* such as *Aspergillus niger*.

[0096]

Bacterial cells can be used in the prokaryotic production systems. Examples of bacterial cells include *E. coli* (for example, JM109, DH5 α , HB101 and such); and *Bacillus subtilis*.

[0097]

Next, the above host cells are cultured. Antibodies can be obtained by transforming the cells with a polynucleotide of interest and *in vitro* culturing of these transformants. Transformants can be cultured using known methods. For example, DMEM, MEM, RPMI 1640, or IMDM may be used as the culture medium for animal cells, and may be used with or without serum supplements such as FBS or fetal calf serum (FCS). Serum-free cultures are also acceptable. The preferred pH is about 6 to 8 during the course of culturing. Incubation is carried out typically at a temperature of about 30 to 40°C for about 15 to 200 hours. Medium is

exchanged, aerated, or agitated, as necessary.

[0098]

On the other hand, production systems using animal or plant hosts may be used as systems for producing polypeptides *in vivo*. For example, a polynucleotide of interest is introduced into an animal or plant and the polypeptide is produced in the body of the animal or plant and then recovered. The "hosts" of the present invention includes such animals and plants.

[0099]

Animals to be used for the production system include mammals or insects. Mammals such as goats, pigs, sheep, mice, and cattle may be used (Vicki Glaser SPECTRUM Biotechnology Applications (1993)). Alternatively, the mammals may be transgenic animals.

[0100]

For example, a polynucleotide of interest is prepared as a fusion gene with a gene encoding a polypeptide specifically produced in milk, such as the goat β -casein gene. DNA fragments containing the fusion gene are injected into goat embryos, which are then introduced back to female goats. The desired antibody can be obtained from milk produced by the transgenic goats, which are born from the goats that received the embryos, or from their offspring. Appropriate hormones may be administered to increase the volume of milk containing the antibody produced by the transgenic goats (Ebert, K.M. *et al.*, Bio/Technology (1994) 12: 699-702).

[0101]

Insects, such as silkworms, may also be used. Baculoviruses carrying a polynucleotide encoding an antibody of interest can be used to infect silkworms, and the antibody of interest can be obtained from the body fluids (Susumu, M. *et al.*, Nature (1985) 315: 592-594).

[0102]

Plants used in the production system include, for example, tobacco. When tobacco is used, a polynucleotide encoding an antibody of interest is inserted into a plant expression vector, for example, pMON 530, and then the vector is introduced into a bacterium, such as *Agrobacterium tumefaciens*. The bacteria are then used to infect tobacco such as *Nicotiana tabacum*, and the desired antibodies can be recovered from the leaves (Julian K.-C. Ma *et al.*, Eur. J. Immunol. (1994) 24: 131-138).

[0103]

The resulting antibody may be isolated from the inside or outside (such as the medium) of host cells, and purified as a substantially pure and homogenous antibody. Methods are not limited to any specific method and any standard method for isolating and purifying antibodies may be used. Polypeptides may be isolated and purified, by selecting an appropriate

combination of, for example, chromatographic columns, filtration, ultrafiltration, salting out, solvent precipitation, solvent extraction, distillation, immunoprecipitation, SDS-polyacrylamide gel electrophoresis, isoelectric focusing, dialysis, recrystallization, and others.

[0104]

5 Chromatographies include, for example, affinity chromatographies, ion exchange chromatographies, hydrophobic chromatographies, gel filtrations, reverse-phase chromatographies, and adsorption chromatographies (Strategies for Protein Purification and Characterization: A Laboratory Course Manual. Ed Daniel R. Marshak *et al.*, Cold Spring Harbor Laboratory Press, 1996). These chromatographies can be carried out using liquid phase
10 chromatographies such as HPLC and FPLC. Examples of the affinity chromatography columns include protein A columns and protein G columns. Examples of the proteins A columns include Hyper D, POROS, and Sepharose F. F. (Pharmacia).

[0105]

15 An antibody can be modified freely and peptide portions deleted by treating the antibody with an appropriate protein modifying enzyme before or after antibody purification. Such protein modifying enzymes include, for example, trypsins, chymotrypsins, lysyl endopeptidases, protein kinases, and glucosidases.

[0106]

20 Antibodies that bind to Mpl can be prepared by methods known to those skilled in the art.

For example, monoclonal antibody-producing hybridomas can be essentially generated by known technologies as follows: immunizing animals with Mpl proteins or Mpl-expressing cells as sensitized antigens using conventional immunological methods; fusing the obtained immunocytes with known parental cells by conventional cell fusion methods; and screening for
25 monoclonal antibody-producing cells by conventional methods.

[0107]

Specifically, monoclonal antibodies can be prepared by the method below.

30 First, Mpl protein, which is used as a sensitized antigen for preparing antibodies, is prepared by expressing the Mpl gene/amino acid sequence (GenBank accession number: NM_005373). More specifically, the gene sequence encoding Mpl is inserted into a known expression vector, which is then transfected into an appropriate host cell. The subject human Mpl protein is purified from the host cell or culture supernatant using known methods.

[0108]

35 The purified Mpl protein is then used as a sensitized antigen. Alternatively, a partial Mpl peptide may be used as a sensitized antigen. In this case, the partial peptide can also be chemically synthesized based on the amino acid sequence of human Mpl.

[0109]

The epitopes of Mpl molecule that are recognized by an anti-Mpl antibody of the present invention are not limited to a particular epitope, and may be any epitope on the Mpl molecule. Thus, any fragment can be used as an antigen for preparing anti-Mpl antibodies of the present invention, as long as the fragment comprises an epitope of the Mpl molecule.

[0110]

There is no limitation as to the type of mammalian species to be immunized with the sensitized antigen. However, a mammal is preferably selected based on its compatibility with the parental cell to be used in cell fusion. Generally, rodents (for example, mice, rats, and hamsters), rabbits, and monkeys can be used.

[0111]

Animals can be immunized with a sensitized antigen by known methods such as a routine method of injecting a sensitized antigen into a mammal intraperitoneally or subcutaneously. Specifically, the sensitized antigen is diluted appropriately with phosphate-buffered saline (PBS), physiological saline and such, and then suspended. An adequate amount of a conventional adjuvant, for example, Freund's complete adjuvant, is mixed with the suspension, as necessary. An emulsion is then prepared for administering to a mammal several times over a 4- to 21-day interval. An appropriate carrier may be used for the sensitized antigen in immunization.

[0112]

A mammal is immunized as described above. After a titer increase of target antibody in the serum is confirmed, immunocytes are collected from the mammal and then subjected to cell fusion. Spleen cells are the preferred immunocytes.

[0113]

Mammalian myeloma cells are used as the parental cells to be fused with the above immunocytes. Preferable myeloma cells to be used include various known cell lines, for example, P3 (P3x63Ag8.653) (Kearney JF, *et al.*, J. Immunol. (1979) 123: 1548-1550), P3x63Ag8U.1 (Yelton DE, *et al.*, Current Topics in Microbiology and Immunology (1978) 81: 1-7), NS-1 (Kohler, G. and Milstein, C. Eur. J. Immunol. (1976) 6: 511-519), MPC-11 (Margulies, D. H. *et al.*, Cell (1976) 8: 405-415), SP2/0 (Shulman, M. *et al.*, Nature (1978) 276: 269-270), FO (deSt. Groth, S. F. *et al.*, J. Immunol. Methods (1980) 35: 1-21), S194 (Trowbridge, I. S., J. Exp. Med. (1978) 148: 313-323), and R210 (Galfré, G. *et al.*, Nature (1979) 277: 131-133).

[0114]

Cell fusions between the immunocytes and the myeloma cells as described above can be essentially carried out using known methods, for example, a method by Kohler and Milstein (Kohler, G. and Milstein, C., Methods Enzymol. (1981) 73: 3-46).

[0115]

More specifically, the above-described cell fusions are carried out, for example, in a conventional culture medium in the presence of a cell fusion-promoting agent. The fusion-promoting agents include, for example, polyethylene glycol (PEG) and Sendai virus (HVJ). If required, an auxiliary substance such as dimethyl sulfoxide may also be added to improve fusion efficiency.

[0116]

The ratio of immunocytes to myeloma cells may be determined at one's own discretion, preferably, for example, one myeloma cell for every one to ten immunocytes. Culture media to be used for the above cell fusions include, for example, media that are suitable for the growth of the above myeloma cell lines, such as RPMI 1640 media and MEM media, and other conventional culture media used for this type of cell culture. In addition, serum supplements such as fetal calf serum (FCS) may also be used in combination.

[0117]

Cell fusion is carried out as follows. As described above, predetermined amounts of immunocytes and myeloma cells are mixed well in the culture medium. PEG solution (for example, mean molecular weight of about 1,000-6,000) pre-heated to 37°C is added to the cell suspension typically at a concentration of 30% to 60% (w/v), and mixed to produce fused cells (hybridomas). Then, an appropriate culture medium is successively added to the mixture, and the sample is centrifuged to remove supernatant. This treatment is repeated several times to remove the unwanted cell fusion-promoting agent and others that are unfavorable to hybridoma growth.

[0118]

Screening of the resulting hybridomas can be carried out by culturing them in a conventional selective medium, for example, hypoxanthine, aminopterin, and thymidine (HAT) medium. Culturing in the above-described HAT medium is continued for a period long enough (typically, for several days to several weeks) to kill cells (non-fused cells) other than the desired hybridomas. Then, hybridomas are screened for single-cell clones capable of producing the target antibody by conventional limiting dilution methods.

[0119]

In addition to the method for preparing the above-described hybridomas by immunizing non-human animals with antigens, preferred human antibodies having binding activity to Mpl can also be obtained by: sensitizing human lymphocytes with Mpl *in vitro*; and fusing the sensitized lymphocytes with human myeloma cells capable of dividing permanently (see, Japanese Patent Application Kokoku Publication No. (JP-B) H01-59878 (examined, approved Japanese patent application published for opposition)). Alternatively, it is possible to obtain

human antibodies against Mpl from immortalized cells producing anti-Mpl antibodies. In this method, the cells producing anti-Mpl antibodies are prepared by administering Mpl as an antigen to transgenic animals comprising a repertoire of the entire human antibody genes (see, WO 94/25585, WO 93/12227, WO 92/03918, and WO 94/02602).

5 [0120]

The monoclonal antibody-producing hybridomas thus prepared can be passaged in a conventional culture medium, and stored in liquid nitrogen over long periods of time.

[0121]

10 Monoclonal antibodies can be prepared from the above-described hybridomas by, for example, a routine procedure of culturing the hybridomas and obtaining antibodies from the culture supernatants. Alternatively, monoclonal antibodies can be prepared by injecting the hybridomas into a compatible mammal; growing these hybridomas in the mammal; and obtaining antibodies from the mammal's ascites. The former method is suitable for preparing highly purified antibodies, while the latter is suitable for preparing antibodies on a large scale.

15 [0122]

Recombinant antibodies can also be prepared by: cloning an antibody gene from a hybridoma; inserting the gene into an appropriate vector; introducing the vector into a host; and producing the antibodies by using genetic recombination techniques (see, for example, Vandamme, A. M. *et al.*, *Eur. J. Biochem.* (1990) 192: 767-775).

20 [0123]

Specifically, an mRNA encoding the variable (V) region of anti-Mpl antibody is isolated from hybridomas producing the anti-Mpl antibodies. For mRNA isolation, total RNAs are first prepared by conventional methods such as guanidine ultracentrifugation methods (Chirgwin, J. M. *et al.*, *Biochemistry* (1979) 18: 5294-5299), or acid guanidinium thiocyanate-phenol-chloroform (AGPC) methods (Chomczynski, P. *et al.*, *Anal. Biochem.* (1987) 162: 156-159), and then the target mRNA is prepared using an mRNA Purification Kit (Pharmacia) and such. Alternatively, the mRNA can be directly prepared using the QuickPrep mRNA Purification Kit (Pharmacia).

[0124]

30 A cDNA of the antibody V region is synthesized from the resulting mRNA using reverse transcriptase. cDNA synthesis is carried out using the AMV Reverse Transcriptase First-strand cDNA Synthesis Kit (Seikagaku Co.), or such. Alternatively, cDNA can be synthesized and amplified by the 5'-RACE method (Frohman, M. A. *et al.*, *Proc. Natl. Acad. Sci. USA* (1988) 85: 8998-9002; Belyavsky, A. *et al.*, *Nucleic Acids Res.* (1989) 17: 2919-2932) using the 5'-Ampli
35 FINDER RACE Kit (Clontech) and PCR.

[0125]

Target DNA fragments are purified from the obtained PCR products and then ligated with vector DNAs to prepare recombinant vectors. The vectors are introduced into *E. coli* and such, and colonies are selected for preparing the recombinant vector of interest. The target DNA nucleotide sequence is then confirmed by conventional methods such as the
5 dideoxynucleotide chain termination method.

Once a DNA encoding the V region of target anti-Mpl antibody is obtained, the DNA is inserted into an expression vector which comprises a DNA encoding the constant region (C region) of a desired antibody.

[0126]

10 The method for producing anti-Mpl antibodies to be used in the present invention typically comprises the steps of: inserting an antibody gene into an expression vector, so that the gene is expressed under the regulation of expression regulatory regions, such as enhancer and promoter; and transforming host cells with the resulting vectors to express antibodies.

[0127]

15 For expressing the antibody gene, polynucleotides encoding H chain and L chain, respectively, are inserted into separate expression vectors and co-transfected into a host cell. Alternatively, polynucleotides encoding both H chain and L chain are inserted into a single expression vector and transfected into a host cell (see WO 94/11523).

[0128]

20 The term “agonistic activity” refers to an activity to induce changes in some biological activities through signal transduction into cells and such, due to the binding of an antibody to a receptor antigen. The biological activities include, for example, proliferation-promoting activities, proliferation activities, viability activities, differentiation-inducing activities, differentiation activities, transcriptional activities, membrane transport activities, binding
25 activities, proteolytic activities, phosphorylation/dephosphorylation activities, oxidation/reduction activities, transfer activities, nucleolytic activities, dehydration activities, cell death-inducing activities, and apoptosis-inducing activities, but is not limited thereto.

[0129]

30 The term “agonistic activity against Mpl” typically refers to the activity of promoting the differentiation of megakaryocytes or their parental hemopoietic stem cells into platelets, or the activity of stimulating platelet proliferation.

Agonistic activity can be assayed by methods known to those skilled in the art. The agonistic activity may be determined using the original activity or a different activity as an indicator.

35 [0130]

For example, agonistic activity can be determined by a method using cell growth as an

indicator as described in Examples. More specifically, an antibody whose agonistic activity is to be determined is added to cells which proliferate in an agonist-dependent manner, followed by incubation of the cells. Then, a reagent such as WST-8 which shows a coloring reaction at specific wavelengths depending on the viable cell count, is added to the culture and absorbance is measured. The agonistic activity can be determined using the measured absorbance as an indicator.

[0131]

Cells that proliferate in an agonist-dependent manner can also be prepared by methods known to those skilled in the art. For example, when the antigen is a receptor capable of transducing cell growth signals, cells expressing the receptor may be used. Alternatively, when the antigen is a receptor that cannot transduce signals, a chimeric receptor consisting of the intracellular domain of a receptor that transduces cell growth signals and the extracellular domain of a receptor that does not transduce cell growth signals can be prepared for cellular expression. Receptors that transduce cell growth signals include, for example, G-CSF receptors, mpl, neu, GM-CSF receptors, EPO receptors, c-kit, and FLT-3. Cells that can be used to express a receptor include, for example, BaF3, NFS60, FDCP-1, FDCP-2, CTLL-2, DA-1, and KT-3.

[0132]

There is no limitation as to the type of detection indicators to be used for determining agonistic activity, as long as the indicator can monitor quantitative and/or qualitative changes. For example, it is possible to use cell-free assay indicators, cell-based assay indicators, tissue-based assay indicators, and *in vivo* assay indicators. Indicators that can be used in cell-free assays include enzymatic reactions, quantitative and/or qualitative changes in proteins, DNAs, or RNAs. Such enzymatic reactions include, for example, amino acid transfers, sugar transfers, dehydrations, dehydrogenations, and substrate cleavages. Alternatively, protein phosphorylations, dephosphorylations, dimerizations, multimerizations, hydrolyses, dissociations and such; DNA or RNA amplifications, cleavages, and extensions can be used as the indicator in cell-free assays. For example, protein phosphorylations downstream of a signal transduction pathway may be used as a detection indicator. Alterations in cell phenotype, for example, quantitative and/or qualitative alterations in products, alterations in growth activity, alterations in cell number, morphological alterations, or alterations in cellular properties, can be used as the indicator in cell-based assays. The products include, for example, secretory proteins, surface antigens, intracellular proteins, and mRNAs. The morphological alterations include, for example, alterations in dendrite formation and/or dendrite number, alteration in cell flatness, alteration in cell elongation/axial ratio, alterations in cell size, alterations in intracellular structure, heterogeneity/homogeneity of cell populations, and alterations in cell density. Such

morphological alterations can be observed under a microscope. Cellular properties to be used as the indicator include anchor dependency, cytokine-dependent response, hormone dependency, drug resistance, cell motility, cell migration activity, pulsatory activity, and alteration in intracellular substances. Cell motility includes cell infiltration activity and cell migration activity. The alterations in intracellular substances include, for example, alterations in enzyme activity, mRNA levels, levels of intracellular signaling molecules such as Ca^{2+} and cAMP, and intracellular protein levels. When a cell membrane receptor is used, alterations in the cell proliferating activity induced by receptor stimulation can be used as the indicator. The indicators to be used in tissue-based assays include functional alterations adequate for the subject tissue. In *in vivo* assays, alterations in tissue weight, alterations in the blood system (for example, alterations in blood cell counts, protein contents, or enzyme activities), alterations in electrolyte levels, and alterations in the circulating system (for example, alterations in blood pressure or heart rate).

[0133]

The methods for measuring such detection indices are not particularly limited. For example, absorbance, luminescence, color development, fluorescence, radioactivity, fluorescence polarization, surface plasmon resonance signal, time-resolved fluorescence, mass, absorption spectrum, light scattering, and fluorescence resonance energy transfer may be used. These measurement methods are known to those skilled in the art and may be selected appropriately depending on the purpose. For example, absorption spectra can be obtained by using a conventional photometer, plate reader, or such; luminescence can be measured with a luminometer or such; and fluorescence can be measured with a fluorometer or such. Mass can be determined with a mass spectrometer. Radioactivity can be determined with a device such as a gamma counter depending on the type of radiation. Fluorescence polarization can be measured with BEACON (TaKaRa). Surface plasmon resonance signals can be obtained with BIACORE. Time-resolved fluorescence, fluorescence resonance energy transfer, or such can be measured with ARVO or such. Furthermore, a flow cytometer can also be used for measuring. It is possible to use one of the above methods to measure two or more different types of detection indices. A greater number of detection indices may also be examined by using two or more measurement methods simultaneously and/or consecutively. For example, fluorescence and fluorescence resonance energy transfer can be measured at the same time with a fluorometer.

[0134]

The present invention provides pharmaceutical compositions comprising antibodies of this invention. The pharmaceutical compositions comprising antibodies of the present invention are useful for treating and/or preventing thrombocytopenia and such. Time required

for the platelet count to recover to the normal level can be shortened by administering an antibody of the present invention after donation of platelet components. The amount of platelet components at the time of blood collection can be increased by pre-administering an antibody of the present invention.

5 [0135]

When used as pharmaceutical compositions, the antibodies of the present invention can be formulated by methods known to those skilled in the art. For example, the antibodies can be administered parenterally by injection of a sterile solution or suspension in water or other pharmaceutically acceptable solvents. For example, the antibodies can be formulated by appropriately combining with pharmaceutically-acceptable carriers or solvents, specifically, sterile water or physiological saline, vegetable oils, emulsifiers, suspending agents, surfactants, stabilizers, flavoring agents, excipients, vehicles, preservatives, binding agents, and such, and mixing at a unit dosage and form required by accepted pharmaceutical implementations. In such formulations, the amount of the thus obtained active ingredient should be within the required range.

15 [0136]

A sterile composition to be injected can be formulated using a vehicle such as distilled water used for injection, according to standard protocols.

Aqueous solutions used for injections include, for example, physiological saline and isotonic solutions comprising glucose or other adjunctive agents such as D-sorbitol, D-mannose, D-mannitol, and sodium chloride. They may also be combined with an appropriate solubilizing agent such as alcohol, specifically, ethanol, polyalcohol such as propylene glycol or polyethylene glycol, or non-ionic detergent such as polysorbate 80TM or HCO-50, as necessary.

20 [0137]

Oil solutions include sesame oils and soybean oils, and can be combined with solubilizing agents such as benzyl benzoate or benzyl alcohol. Injection solutions may also be formulated with buffers, for example, phosphate buffers or sodium acetate buffers; analgesics, for example, procaine hydrochloride; stabilizers, for example, benzyl alcohol or phenol; or anti-oxidants. The prepared injections are typically aliquoted into appropriate ampules.

30 [0138]

The administration is preferably carried out parenterally, specifically, by injection, intranasal administration, intrapulmonary administration, percutaneous administration, or such. Injections include, for example, intravenous injections, intramuscular injections, intraperitoneal injections, and subcutaneous injections. The injection solutions can be also administered systemically or locally.

35 [0139]

The administration methods can be selected properly according to the patient's age, condition, and such. The applied dose of a pharmaceutical composition comprising an antibody or polynucleotide encoding the antibody may be, for example, in the range of 0.0001 to 1,000 mg/kg body weight. Alternatively, the dosage may be, for example, in the range of 0.001 to 100,000 mg/kg body weight. However, the dosage is not restricted to the values described above. The dosage and administration methods depend on the patient's weight, age, and condition, and are appropriately selected by those skilled in the art.

[Examples]

[0140]

The present invention is specifically illustrated below with reference to Examples, but it is not to be construed as being limited thereto.

[0141]

[Example 1] Preparation of anti-human Mpl antibodies

1.1 Establishment of Mpl-expressing BaF3 cell lines

BaF3 cell lines expressing the full-length Mpl gene were established to obtain cell lines that proliferate in a TPO-dependent manner.

A full-length human Mpl cDNA (Palacios, R. *et al.*, Cell (1985) 41: 727-734) (GenBank accession NO. NM_005373) was amplified by PCR. The cDNA was cloned into a pCOS2 expression vector to construct pCOS2-hMplfull. The expression vector pCOS2 was constructed by removing the DHFR gene expression region from pCHOI (Hirata, Y. *et al.*, FEBS Letter (1994) 356: 244-248), where the expression region of the neomycin resistance gene HEF-VH-gy1 (Sato, K. *et al.*, Mol Immunol. (1994) 31: 371-381) is inserted.

[0142]

The cynomolgus monkey Mpl cDNA (SEQ ID NO: 164) was cloned from total RNA extracted from the bone marrow cells of cynomolgus monkey, using a SMART RACE cDNA Amplification Kit (Clontech). The resulting cynomolgus monkey cDNA was inserted into pCOS2 to construct pCOS2-monkeyMplfull.

Then, the full-length mouse Mpl cDNA (GenBank accession NO. NM_010823) was amplified by PCR, and inserted into pCOS2 to construct pCOS2-mouseMplfull.

[0143]

Each vector (20 μ g) prepared as described above was mixed with BaF3 cells (1×10^7 cells/mL) suspended in PBS in Gene Pulser cuvettes. This mixture was then pulsed at 0.33 kV and 950 μ FD using a Gene Pulser II (Bio-Rad). The BaF3 cells introduced with the above DNAs by electroporation were added to RPMI 1640 medium (Invitrogen) containing 1 ng/mL mouse interleukin 3 (hereinafter abbreviated as mIL-3; Peprotech), 500 μ g/mL Geneticin (Invitrogen), and 10% FBS (Invitrogen), and selected to establish a human Mpl-expressing BaF3

cell line (hereinafter abbreviated as “BaF3-human Mpl”), monkey Mpl-expressing BaF3 cell line (hereinafter abbreviated as BaF3-monkey Mpl), and mouse Mpl-expressing BaF3 cell line (hereinafter abbreviated as “BaF3-mouse Mpl”). Following selection, these cells were cultured and maintained in RPMI 1640 containing 1 ng/mL rhTPO (R&D) and 10% FBS.

5 [0144]

1.2 Establishment of Mpl-expressing CHO cell lines

CHO cell lines expressing the full-length Mpl gene were established to obtain cell lines to be used for assessing binding activity by flow cytometry.

10 First, the DHFR gene expression site from pCHOI was inserted into pCXN2 (Niwa, H. *et al.*, Gene (1991) 108: 193-199) at the *Hind*III site to prepare a pCXND3 expression vector. The respective Mpl genes were amplified by PCR using pCOS2-hMplfull, pCOS2-monkeyMplfull, and pCOS2-mouseMplfull as templates, and primers with a His-tag sequence. The PCR products were cloned into pCXND3 to construct pCXND3-hMpl-His, pCXND3-monkey Mpl-His, and pCXND3-mouse Mpl-His, respectively.

15 [0145]

Vectors thus prepared (25 µg each) were mixed with a PBS suspension of CHO-DG44 cells (1×10^7 cells/mL) in Gene Pulser cuvettes. The mixture was then pulsed at 1.5 kV and 25 µFD using Gene Pulser II (Bio-Rad). The CHO cells introduced with these DNAs by electroporation were added to CHO-S-SFMII medium (Invitrogen) containing 500 µg/mL Geneticin and 1x HT (Invitrogen). A human Mpl-expressing CHO cell line (hereinafter abbreviated as “CHO-human Mpl”), monkey Mpl-expressing CHO cell line (hereinafter abbreviated as “CHO-monkey Mpl”), and mouse Mpl-expressing CHO cell line (hereinafter abbreviated as “CHO-mouse Mpl”) were established through selection.

[0146]

25 1.3 Preparation of soluble human Mpl protein

To prepare soluble human Mpl protein, an expression system using insect Sf9 cells for production and secretion of the protein was constructed as described below.

A DNA construct encoding the extracellular region of human Mpl (Gln 26 to Trp 491) with a downstream FLAG tag was prepared. The construct was inserted into a pBACSurf-1 Transfer Plasmid (Novagen) between the *Pst*I and *Sma*I sites to prepare pBACSurf1-hMpl-FLAG. Then, Sf9 cells were transformed with 4 µg of pBACSurf1-hMpl-FLAG using the Bac-N-Blue Transfection Kit (Invitrogen). The culture supernatant was collected after three-day incubation. Recombinant virus was isolated by plaque assays. The prepared virus stock was used to infect Sf9 cells, and the culture supernatant was collected.

35 [0147]

Soluble human Mpl protein was purified from the obtained culture supernatant as

described below. The culture supernatant was loaded onto a Q Sepharose Fast Flow (Amersham Biosciences) for adsorption, and the adsorbed protein was then eluted with 50 mM Na-phosphate buffer (pH7.2) containing 0.01% (v/v) Tween20 and 500 mM NaCl. After the eluates were loaded onto a FLAG M2-Agarose (Sigma-Aldrich) for adsorption, the protein
5 adsorbed was eluted with 100 mM glycine-HCl buffer (pH3.5) containing 0.01% (v/v) Tween20. Immediately after elution, the fraction obtained was neutralized with 1 M Tris-Cl (pH8.0) and the buffer was exchanged with PBS (-) and 0.01% (v/v) Tween20 using PD-10 columns (Amersham Biosciences). The purified soluble Mpl protein was referred to as “shMpl-FLAG”.

[0148]

10 1.4 Preparation of human Mpl-IgG Fc fusion protein

Human fusion protein Mpl-IgG Fc gene was prepared according to the method by Bennett *et al.* (Bennett, B. D. *et al.*, J. Biol. Chem. (1991) 266: 23060-23067). A nucleotide sequence encoding the extracellular region of human Mpl (Gln 26 to Trp 491) was linked to a nucleotide sequence encoding the Fc region of human IgG- γ 1 (a region downstream of Asp 216).
15 A *Bst*EII sequence (amino acids: Val-Thr) was attached to the junction as a fusion linker between these two regions. A 19-amino acid signal peptide derived from human IgG H chain variable region was used as the signal sequence. The resulting human fusion protein Mpl-IgG Fc gene was cloned into pCXND3 to construct pCXND3-hMpl-Fc.

[0149]

20 The vector thus prepared (25 μ g) was mixed with a PBS suspension of CHO-DG44 cells (1×10^7 cells/mL) in Gene Pulser cuvettes. The mixture was then pulsed at 1.5 kV and 25 μ FD using Gene Pulser II (Bio-Rad). The CHO cells introduced with the DNA by electroporation were added to CHO-S-SFMII medium containing 500 μ g/mL Geneticin and 1x HT (Invitrogen). shMPL-Fc-expressing CHO cell line (CHO-hMpl-Fc) was then established through selection.

25 [0150]

Human Mpl-IgG Fc fusion protein was purified from the culture supernatant as described below.

The culture supernatant was loaded onto a Q Sepharose Fast Flow (Amersham Biosciences) for adsorption, and then the adsorbed protein were eluted with 50 mM
30 Na-phosphate buffer (pH7.6) containing 0.01% (v/v) Tween20 and 1 M NaCl. After the eluates were loaded onto a HiTrap protein G HP column (Amersham Biosciences) for adsorption, the adsorbed protein was eluted with 0.1 M glycine-HCl buffer (pH2.7) containing 150 mM NaCl and 0.01% (v/v) Tween20. Immediately after elution, the obtained fraction was neutralized with 1 M Tris-Cl (pH8.0) and the buffer was exchanged with PBS (-) and 0.01% (v/v) Tween20
35 using PD-10 columns (Amersham Biosciences). The purified soluble Mpl protein was referred to as “hMpl-Fc”.

[0151]

1.5 Immunization with shMpl-FLAG or BaF3-human Mpl and hybridoma selection

MRL/MpJUmmCrj-lpr/lpr mice (hereinafter abbreviated as "MRL/lpr mice"; purchased from Charles River, Japan) were immunized; the primary immunization was carried out at eight weeks of age. For every single mouse, an emulsion containing 100 µg of shMPL-FLAG combined with Freund's complete adjuvant (H37 Ra; Beckton Dickinson), was administered subcutaneously as the primary injection. As a booster injection, an emulsion containing shMPL-FLAG (50 µg per mouse) combined with Freund's incomplete adjuvant (Beckton Dickinson) was administered subcutaneously. Three mice which have been immunized six times in total were subjected to a final injection of shMPL-FLAG (50 µg per mouse) through the caudal vein. Cell fusion was achieved by mixing the mouse myeloma P3-X63Ag8U1 cells (P3U1; purchased from ATCC) and mouse splenocytes using polyethylene glycol 1500 (Roche Diagnostics). Hybridoma selection in HAT medium began the following day and culture supernatants were obtained. Screening was carried out by ELISA, using immunoplates immobilized with shMpl-FLAG or hMpl-Fc and the assayed cell growth activity of BaF3-human Mpl as an index. In addition, Balb/C mice were immunized eleven times in total by administering BaF3-human Mpl (1.0×10^7 cells per mouse) intraperitoneally over a period of one week to five months. Hybridomas were similarly prepared by cell fusion, and screened using the assayed cell growth activity of BaF3-human Mpl as an index. Positive clones were isolated as single clones by limiting dilution and then cultured in a large scale. The culture supernatants were collected.

[0152]

1.6 Analyses of anti-human Mpl antibodies

Antibody concentrations were determined by carrying out a mouse IgG sandwich ELISA using goat anti-mouse IgG (gamma) (ZYMED) and alkaline phosphatase-goat anti-mouse IgG (gamma) (ZYMED), generating a calibration curve by GraphPad Prism (GraphPad Software; USA), and calculating the antibody concentrations from the calibration curve. Commercially available antibodies of the same isotype were used as standards.

[0153]

Antibody isotypes were determined by antigen-dependent ELISA using isotype-specific secondary antibodies. hMpl-Fc was diluted to 1 µg/mL with a coating buffer (0.1 mM NaHCO₃, pH9.6) containing 0.02% (w/v) NaN₃, and then added to ELISA plates. The plates were incubated overnight at 4°C for coating. The plates were blocked with a diluent buffer (50 mM Tris-HCl (pH8.1) containing 1 mM MgCl₂, 150 mM NaCl, 0.05% (v/v) Tween20, 0.02% (w/v) NaN₃, 1% (w/v) BSA). After the addition of hybridoma culture supernatants, the plates were allowed to stand at room temperature for 1 hr. After washing with a rinse buffer (0.05% (v/v)

Tween20 in PBS), alkaline phosphatase-labeled isotype-specific secondary antibodies were added to the plates. Then, the plates were allowed to stand at room temperature for 1 hr. Color development was carried out using SIGMA104 (Sigma-Aldrich) diluted to 1 mg/mL with a substrate buffer (50 mM NaHCO₃, pH9.8) containing 10 mM MgCl₂, and absorbance was measured at 405 nm using Benchmark Plus (Bio-Rad).

[0154]

The binding activities of an antibody to shMpl-FLAG and hMPL-Fc were determined by ELISA. ELISA plates were coated with 1 µg/mL of purified shMpl-FLAG or hMPL-Fc, and blocked with a diluent buffer. Hybridoma culture supernatants were added to the plates, and the plates were allowed to stand at room temperature for 1 hr. Then, alkaline phosphatase-labeled anti-mouse IgG antibodies (Zymed) were added to the plates. Color development was similarly carried out using the above method. Following a one-hour coloring reaction at room temperature, absorbance was measured at 405 nm and EC₅₀ values were computed using GraphPad Prism.

[0155]

CHO-human Mpl cells and CHO-monkey Mpl cells were harvested, and suspended in FACS Buffer (1% FBS/ PBS) to a final concentration of 1 x 10⁶ cells/mL. The suspensions were aliquoted into Multiscreen (Millipore) at 100 µl/well, and the culture supernatants were removed by centrifugation. Culture supernatants diluted to 5 µg/mL were added to the plates and incubated on ice for 30 min. The cells were washed once with FACS buffer, and incubated on ice for 30 min following the addition of an FITC-labeled anti-mouse IgG antibody (Beckman Coulter). After incubation, the mixture was centrifuged at 500 rpm for 1 min. The supernatants were removed, and then the cells were suspended in 400 µL of FACS buffer. The samples were analyzed by flow cytometry using EPICS ELITE ESP (Beckman Coulter). An analysis gate was set on the forward and side scatters of a histogram to include viable cell populations.

[0156]

Agonistic activities of an antibody were evaluated using BaF3-human Mpl and BaF3-monkey Mpl which proliferate in a TPO-dependent manner. Cells of each cell line were suspended at 4 x 10⁵ cells/ml in RPMI 1640/10% FBS (Invitrogen), and each suspension was aliquoted into a 96-well plate at 60µl/well. A 40-µL aliquot of rhTPO (R&D) and hybridoma culture supernatants prepared at various concentrations was added into each well. The plates were then incubated at 37°C under 5% CO₂ for 24 hr. A 10-µL aliquot of the Cell Count Reagent SF (Nacalai Tesque) was added into each well. After incubation for 2 hr, absorbance was measured at 450 nm (and at 655 nm as a control) using a Benchmark Plus. EC₅₀ values were calculated using GraphPad Prism.

The above analysis yielded a total of 163 clones of mouse monoclonal antibodies that bind to human Mpl.

Among the anti-human Mpl antibodies to be described, TA136 was established from mice immunized with BaF-human Mpl and the others were established from mice immunized
5 with shMpl-Flag.

[0157]

1.7 Purification of anti-human Mpl antibodies

Anti-human Mpl antibodies were purified from hybridoma culture supernatants as described below.

10 After the culture supernatants were loaded onto HiTrap protein G HP columns (Amersham Biosciences) for adsorption, the antibodies were eluted with 0.1 M glycine-HCl (pH2.7). Immediately after elution, the fractions were neutralized with 1 M Tris-Cl (pH9.0), dialyzed against PBS for one day, and the buffer was replaced.

[0158]

15 1.8 Determination of epitopes for the anti-human Mpl antibody VB22B

Since the anti-human Mpl antibody VB22B can be used for Western blotting, a GST-fusion protein containing a partial sequence of human Mpl was constructed for VB22B epitope analysis. MG1 (Gln26 to Trp491) and MG2 (Gln26 to Leu274) regions were each amplified by PCR, and cloned into pGEX-4T-3 (Amersham Biosciences) to be expressed as GST
20 fusion proteins. The resulting plasmid DNAs were transformed into DH5 α to give transformants. A final concentration of 1 mM IPTG was added to the transformants in their logarithmic growth phase to induce the expression of GST fusion proteins. The bacterial cells were harvested after two hours of incubation. The cells were lysed by sonication. The lysates were centrifuged in XL-80 Ultracentrifuge (Beckman, Rotor 70.1Ti) at 35,000 rpm for 30 min.
25 The culture supernatants were removed, and then the fusion proteins were purified using GST Purification Modules (Amersham Biosciences). The samples were separated by 10%-SDS-PAGE, and then transferred onto a PVDF membrane. The membrane was Western blotted with the murine antibody VB22B. VB22B was found to recognize both MG-1 and MG-2, indicating that the VB22B epitope is located in the (Gln26 to Leu274) region.

30 [0159]

Then, GST fusion proteins containing the respective regions of human Mpl: MG3 (Gln26 to Ala189), MG4 (Gln26 to Pro106), MG5 (Gln26 to Glu259), and MG6 (Gln26 to Gly245) were prepared and analyzed by Western blotting using the same procedure described above. VB22B was found to recognize MG5 and MG6, but not MG3 and MG4. This
35 suggests that the VB22B epitope is located within the (Ala189 to Gly245) region. In addition, GST was fused with MG7 (Gln26 to Ala231) and MG8 (Gln26 to Pro217) to prepare GST fusion

proteins. VB22B recognized MG7 but not MG8, suggesting that the VB22B epitope is located in the (Gln217 to Ala231) region. Furthermore, GST fusion protein containing MG10 (Gln213 to Ala231) was recognized by VB22B, suggesting that the VB22B epitope is located within the limited region of 19 amino acids between Gln213 and Ala231.

5 [0160]

1.9 Kinetic analyses of the antigen-antibody reaction for anti-human Mpl antibody VB22B

Since the anti-human Mpl antibody VB22B binds to soluble recombinant Mpl, kinetic analyses of the antigen-antibody reaction between VB22B IgG and human Mpl-IgG Fc fusion protein were carried out as described in Example 1.4. The Sensor Chip CM5 (Biacore) was placed in Biacore 2000 (Biacore), and human Mpl-IgG Fc fusion protein was immobilized onto the chip by amine-coupling methods. Then, 1.25 to 20 $\mu\text{g/mL}$ of VB22B IgG solution was prepared using HBS-EP Buffer (Biacore), and injected over the chip surface for 2 min to reveal the binding region. Then, HBS-EP Buffer was injected over the chip surface for 2 min to reveal the dissociation region. VB22B IgG bound to the human Mpl-IgG Fc fusion protein on the sensor chip was removed by injecting 10 mM NaOH over the sensor chip for 15 sec, and the chip was recovered. HBS-EP Buffer was used as the running buffer, and the flow rate was 20 $\mu\text{L/min}$. Using the BIAevaluation Version 3.1 (Biacore) software, the reaction rate constant at each concentration was calculated from the sensorgrams. The dissociation constant (KD) for VB22B IgG was determined to be $1.67 \pm 0.713 \times 10^{-9}$ M.

20 [0161]

[Example 2] Preparation of single-chain anti-human Mpl antibodies

Among the prepared anti-human Mpl antibodies, 23 types of antibodies, which exhibit higher binding activities and agonistic activities, were selected to construct expression systems for single-chain antibodies using genetic engineering techniques. An exemplary method for constructing a single-chain antibody derived from the anti-human Mpl antibody VB22B is described below.

[0162]

2.1 Cloning of the anti-human Mpl antibody variable region

The variable region was amplified by RT-PCR using total RNA extracted from hybridomas producing anti-human Mpl antibodies. Total RNA was extracted from 1×10^7 hybridoma cells using the RNeasy Plant Mini Kit (QIAGEN).

[0163]

A 5'-terminal fragment of the gene was amplified from 1 μg of total RNA by the SMART RACE cDNA Amplification Kit (Clontech), using a synthetic oligonucleotide MHC-IgG2b (SEQ ID NO: 166) complementary to mouse IgG2b constant region or a synthetic oligonucleotide kappa (SEQ ID NO: 167) complementary to mouse κ chain constant region.

Reverse transcription was carried out at 42°C for 1.5 hr.

[0164]

The composition of the PCR reaction solution (50 µL in total) is shown below.

10x Advantage 2 PCR Buffer (Clontech)	5 µL
10x Universal Primer A Mix (Clontech)	5 µL
dNTPs (dATP, dGTP, dCTP, and dTTP) (Clontech)	0.2 mM
Advantage 2 Polymerase Mix (Clontech)	1 µL
Reverse transcription product	2.5 µL
Synthetic oligonucleotide, MHC-IgG2b or kappa	10 pmol

[0165]

5

The PCR reaction conditions were:

94°C (initial temperature) for 30 sec;

five cycles of 94°C for 5 sec and 72°C for 3 min;

five cycles of 94°C for 5 sec, 70°C for 10 sec, and 72°C for 3 min;

25 cycles of 94°C for 5 sec, 68°C for 10 sec, and 72°C for 3 min;

10

and final extension was at 72°C for 7 min.

[0166]

The PCR products were purified from agarose gel using the QIAquick Gel Extraction Kit (QIAGEN), and cloned into a pGEM-T Easy Vector (Promega). The nucleotide sequence was then determined using the ABI 3700 DNA Analyzer (Perkin Elmer).

15

[0167]

The nucleotide sequence of cloned VB22B H chain variable region (hereinafter abbreviated as "VB22B-VH") is shown in SEQ ID NO: 117, and its amino acid sequence is shown in SEQ ID NO: 118. The nucleotide sequence of the L chain variable region (hereinafter abbreviated as "VB22B-VL") is shown in SEQ ID NO: 119, and its amino acid sequence is shown in SEQ ID NO: 120.

20

[0168]

2.2 Preparation of expression vectors for anti-human Mpl diabodies

The gene encoding VB22B single-chain Fv (hereinafter abbreviated as "VB22B diabody") containing a five-amino acid linker sequence was constructed, by linking a nucleotide sequence encoding a (Gly4Ser)₁ linker to the VB22B-VH-encoding gene at its 3' end and to the VB22B-VL-encoding gene at its 5' end; both of which have been amplified by PCR.

25

[0169]

The VB22B-VH forward primer, 70-115HF, (SEQ ID NO: 168) was designed to contain an *EcoRI* site. The VB22B-VH reverse primer, 33-115HR, (SEQ ID NO: 169) was designed to hybridize to a DNA encoding the C terminus of VB22B-VH, and to have a nucleotide sequence

30

encoding the (Gly4Ser)₁ linker and a nucleotide sequence hybridizing to the DNA encoding the N terminus of VB22B-VL. The VB22B-VL forward primer, 33-115LF, (SEQ ID NO: 170) was designed to have a nucleotide sequence encoding the N terminus of VB22B-VL, a nucleotide sequence encoding the (Gly4Ser)₁ linker, and a nucleotide sequence encoding the C terminus of VB22B-VH. The VB22B-VL reverse primer, 33-115LR, (SEQ ID NO: 171) was designed to hybridize to a DNA encoding the C terminus of VB22B-VL and to have a nucleotide sequence encoding a FLAG tag (Asp Tyr Lys Asp Asp Asp Asp Lys/SEQ ID NO: 172) and a *NotI* site.

[0170]

In the first round of PCR, two PCR products: one containing VB22B-VH and a linker sequence, and the other containing VB22B-VL and the identical linker sequence, were synthesized by the procedure described below.

The composition of the PCR reaction solution (50 μ L in total) is shown below.

10x PCR Buffer (TaKaRa)	5 μ L
dNTPs (dATP, dGTP, dCTP, and dTTP) (TaKaRa)	0.4 mM
DNA polymerase TaKaRa Ex Taq (TaKaRa)	2.5 units
pGEM-T Easy vector comprising VB22B-VH or VB22B-VL gene	10 ng
Synthetic oligonucleotides, 70-115HF and 33-115HR, or 33-115LF and 33-115LR	10 pmol

[0171]

The PCR reaction conditions were:

94°C (initial temperature) for 30 sec;
 five cycles of: 94°C for 15 sec and 72°C for 2 min;
 five cycles of 94°C for 15 sec and 70°C for 2 min;
 28 cycles of 94°C for 15 sec and 68°C for 2 min;
 and final extension was at 72°C for 5 min.

[0172]

After the PCR products of about 400 bp were purified from agarose gel using the QIAquick Gel Extraction Kit (QIAGEN), the second-round PCR was carried out using aliquots of the respective PCR products according to the protocol described below.

The composition of the PCR reaction solution (50 μ L in total) is shown below.

10x PCR Buffer (TaKaRa)	5 μ L
dNTPs (dATP, dGTP, dCTP, and dTTP) (TaKaRa)	0.4 mM
DNA polymerase TaKaRa Ex Taq (TaKaRa)	2.5 unit
First-round PCR products (two types)	1 μ L
Synthetic oligonucleotides, 70-115HF and 33-115LR	10 pmol

[0173]

The reaction conditions were:

94°C (initial temperature) for 30 sec;

five cycles of 94°C for 15 sec and 72°C for 2 min;

five cycles of 94°C for 15 sec and 70°C for 2 min;

5 28 cycles of 94°C for 15 sec and 68°C for 2 min;

and final extension was at 72°C for 5 min.

[0174]

The PCR products of about 800 bp were purified from agarose gel using the QIAquick Gel Extraction Kit (QIAGEN), and then digested with *EcoRI* and *NotI* (both from TaKaRa).

10 The resulting DNA fragments were purified using the QIAquick PCR Purification Kit (QIAGEN), and then cloned into pCXND3 to prepare pCXND3-VB22B db.

[0175]

2.3 Preparation of expression vectors for anti-human Mpl antibody sc(Fv)₂

To prepare expression plasmids for the modified antibody [sc(Fv)₂] comprising two units of H chain variable region and two units of L chain variable region derived from VB22B, the above-described pCXND3-VB22B db was modified by PCR using the procedure shown below. The process for constructing the sc(Fv)₂ gene is illustrated in Fig. 1.

[0176]

First, PCR method was carried out to amplify (a) the VB22B-VH-encoding gene in which a nucleotide sequence encoding a 15-amino acid linker (Gly₄Ser)₃ was added to its 3' end; and (b) the VB22B-VL-encoding gene containing the identical linker nucleotide sequence added to its 5' end. The desired construct was prepared by linking these amplified genes. Three new primers were designed in this construction process. The VB22B-VH forward primer, VB22B-fpvu, (primer A; SEQ ID NO: 173) was designed to have an *EcoRI* site at its 5' end and to convert Gln22 and Leu23 of VB22B db into a *PvuII* site. The VB22B-VH reverse primer, sc-rL15, (primer B; SEQ ID NO: 174) was designed to hybridize to a DNA encoding the C terminus of VB22B-VH, and to have a nucleotide sequence encoding the (Gly₄Ser)₃ linker, as well as a nucleotide sequence hybridizing to a DNA encoding the N terminus of VB22B-VL. The VB22B-VL forward primer, sc-fL15, (primer C; SEQ ID NO: 175) was designed to have a nucleotide sequence encoding the N terminus of VB22B-VL, a nucleotide sequence encoding the (Gly₄Ser)₃ linker, and a nucleotide sequence encoding the C terminus of VB22B-VH.

[0177]

In the first-round PCR, two PCR products: one comprising VB22B-VH and a linker sequence, and the other comprising VB22B-VL and the identical linker sequence, were synthesized by the procedure described below.

The composition of the PCR reaction solution (50 μL in total) is shown below.

10x PCR Buffer (TaKaRa)	5 μ L
dNTPs (dATP, dGTP, dCTP, and dTTP) (TaKaRa)	0.4 mM
DNA polymerase TaKaRa Ex Taq (TaKaRa)	2.5 units
pCXND3-VB22B db	10 ng
Synthetic oligonucleotides, VB22B-fpvu, sc-rL15 or sc-fL15, and 33-115LR (primer D)	10 pmol

[0178]

The reaction conditions were:

94°C (initial temperature) for 30 sec;
 five cycles of 94°C for 15 sec and 72°C for 2 min;
 5 five cycles of 94°C for 15 sec and 70°C for 2 min;
 28 cycles of 94°C for 15 sec and 68°C for 2 min;
 and final extension was at 72°C for 5 min.

[0179]

10 After the PCR products of about 400 bp were purified from agarose gel using the QIAquick Gel Extraction Kit (QIAGEN), the second-round PCR was carried out using aliquots of the respective PCR products according to the protocol described below.

The composition of the PCR reaction solution (50 μ L in total) is shown below.

10x PCR Buffer (TaKaRa)	5 μ L
dNTPs (dATP, dGTP, dCTP, and dTTP) (TaKaRa)	0.4 mM
DNA polymerase TaKaRa Ex Taq (TaKaRa)	2.5 units
First-round PCR product (two types)	1 μ L
Synthetic oligonucleotide, 70-115HF and 33-115LR	10 pmol

[0180]

The reaction conditions were:

15 94°C (initial temperature) for 30 sec;
 five cycles of 94°C for 15 sec and 72°C for 2 min;
 five cycles of 94°C for 15 sec and 70°C for 2 min;
 28 cycles of 94°C for 15 sec and 68°C for 2 min;
 and final extension was at 72°C for 5 min.

20 [0181]

The PCR products of about 800 bp were purified from agarose gel using the QIAquick Gel Extraction Kit (QIAGEN), and then digested with *Eco*RI and *Not*I (both from TaKaRa). The resulting DNA fragments were purified using the QIAquick PCR Purification Kit (QIAGEN), and then cloned into pBacPAK9 (Clontech) to construct pBacPAK9-scVB22B.

25 [0182]

A fragment to be inserted into the *PvuII* site of pBacPAK9-scVB22B was prepared. Specifically, the fragment has a *PvuII* recognition site at both ends and a nucleotide sequence, in which a gene encoding the VB22B-VH N-terminus is linked, *via* a (Gly₄Ser)₃ linker-encoding nucleotide sequence, to a gene encoding the amino acid sequence of an N-terminus-deleted VB22B-VH linked to VB22B-VL *via* the (Gly₄Ser)₃ linker. Two primers were newly designed to prepare the fragment by PCR. The forward primer for the fragment of interest, Fv2-f (primer E; SEQ ID NO: 176), was designed to have a *PvuII* site at its 5' end and a VB22B-VH 5'-end sequence. The reverse primer for the fragment of interest, Fv2-r (primer F; SEQ ID NO: 177), was designed to hybridize to a DNA encoding the C terminus of VB22B-VL, and to have a *PvuII* site, a nucleotide sequence encoding the (Gly₄Ser)₃ linker, and a nucleotide sequence hybridizing to a DNA encoding the N terminus of VB22B-VH. PCR was carried out using pBacPAK9-scVB22B as a template as described below.

[0183]

The composition of the PCR reaction solution (50 μ L in total) is shown below.

10x PCR Buffer (TaKaRa)	5 μ L
dNTPs (dATP, dGTP, dCTP, and dTTP) (TaKaRa)	0.4 mM
DNA polymerase TaKaRa Ex Taq (TaKaRa)	2.5 units
pBacPAK9-scVB22B	10 μ g
Synthetic oligonucleotide, Fv2-f and Fv2-r	10 pmol

[0184]

The reaction conditions were:

94°C (initial temperature) for 30 sec;
 five cycles of 94°C for 15 sec and 72°C for 2 min;
 five cycles of 94°C for 15 sec and 70°C for 2 min;
 28 cycles of 94°C for 15 sec and 68°C for 2 min;
 and final extension was at 72°C for 5 min.

[0185]

The PCR products of about 800 bp were purified from agarose gel using the QIAquick Gel Extraction Kit (QIAGEN), and then cloned into the pGEM-T Easy Vector (Promega).

After sequencing, the plasmid was digested with *PvuII* (TaKaRa), and the fragment of interest was recovered. The recovered fragment was ligated to pBacPAK9-scVB22B pre-digested with *PvuII* (TaKaRa) to construct pBacPAK9-VB22B sc(Fv)₂. After the resulting vector was digested with *EcoRI* and *NotI* (both from TaKaRa), the fragment of about 1,600 bp was purified from agarose gel using the QIAquick Gel Extraction Kit (QIAGEN). The fragment was then cloned into a pCXND3 expression vector to construct pCXND3-VB22B sc(Fv)₂.

[0186]

2.4 Expression of single-chain anti-human Mpl antibody in animal cells

A cell line stably expressing the single-chain antibody was prepared from CHO-DG44 cells as described below. Gene transfer was achieved by electroporation using a Gene Pulser II (Bio-Rad). An expression vector (25 μ g) and 0.75 mL of CHO-DG44 cells suspended in PBS (1 x 10⁷ cells/mL) were mixed. The resulting mixture was cooled on ice for 10 min, transferred into a cuvette, and pulsed at 1.5-kV and 25 μ FD. After a ten-minute restoration period at room temperature, the electroporated cells were plated in CHO-S-SFMII medium (Invitrogen) containing 500 μ g/mL Geneticin (Invitrogen). CHO cell lines expressing the single-chain antibody were established through selection. A cell line stably expressing VB22B sc(Fv)₂ and its culture supernatants were obtained by this method.

[0187]

The transient expression of the single-chain antibody was achieved using COS7 cells as described below. An expression vector (10 μ g) and 0.75 mL of COS7 cells suspended in PBS (1 x 10⁷ cells/mL) were mixed. The resulting mixture was cooled on ice for 10 min, transferred into a cuvette, and then pulsed at 1.5-kV and 25 μ FD. After a ten-minute restoration period at room temperature, the electroporated cells were plated in DMEM/10% FBS medium (Invitrogen). The cells were incubated overnight and then washed with PBS. CHO-S-SFMII medium was added and the cells were cultured for about three days. The culture supernatants for preparing the VB22B diabody were thus prepared.

[0188]

2.5 Quantitation of single-chain anti-human Mpl antibodies in culture supernatants

The culture supernatant concentration of the single-chain anti-human Mpl antibody transiently expressed in COS cells was determined using surface plasmon resonance. A sensor chip CM5 (Biacore) was placed in Biacore 2000 (Biacore). ANTI-FLAG® M2 Monoclonal Antibody (Sigma-Aldrich) was immobilized onto the chip. An appropriate concentration of sample was injected over the chip surface at a flow rate of 5 mL/sec, and 50 mM diethylamine was used to dissociate the bound antibody. Changes in the mass during sample injection were recorded, and the sample concentration was calculated from the calibration curve prepared using the mass changes of a standard sample. db12E10 (see WO 02/33073 and WO 02/33072) was used as the diabody standard, and 12E10 sc(Fv)₂ which has the same gene structure as that of sc(Fv)₂ was used as the sc(Fv)₂ standard.

[0189]

2.6 Purification of anti-human Mpl diabodies and single-chain antibodies

The culture supernatants of VB22B diabody-expressing COS7 cells or CHO cells was loaded onto an Anti-Flag M2 Affinity Gel (Sigma-Aldrich) column equilibrated with a 50 mM Tris-HCl buffer (pH7.4) containing 150 mM NaCl and 0.05% Tween20. The absorbed

antibodies were eluted with 100 mM glycine-HCl (pH3.5). The fractions eluted were immediately neutralized with 1 M Tris-HCl (pH8.0), and loaded onto a HiLoad 26/60 Superdex 200 pg (Amersham Biosciences) column for gel filtration chromatography. PBS/0.01% Tween20 was used in the gel filtration chromatography.

5 [0190]

VB22B sc(Fv)₂ was purified from the culture supernatants of VB22B sc(Fv)₂-expressing COS7 cells or CHO cells under the same conditions used for purifying the diabodies. A large-scale preparation of VB22B sc(Fv)₂ was prepared by loading the CHO cell culture supernatants onto a Macro-Prep Ceramic Hydroxyapatite Type I (Bio-Rad) column equilibrated with a 20 mM phosphate buffer (pH6.8), and eluting the VB22B sc(Fv)₂ in a stepwise manner with 250 mM phosphate buffer (pH6.8). The eluted fraction was concentrated on an ultrafilter, and then fractionated by gel filtration chromatography using a HiLoad 26/60 Superdex 200 pg (Amersham Biosciences) column, and a fraction corresponding to the molecular weight range of about 40 kD to 70 kD was obtained. The fraction was loaded onto an Anti-Flag M2 Affinity Gel column equilibrated with a 50 mM Tris-HCl buffer (pH7.4) containing 150 mM NaCl and 0.05% Tween20. The absorbed antibody was eluted with 100 mM glycine-HCl (pH3.5). The eluted fraction was immediately neutralized with 1 M Tris-HCl (pH8.0), and loaded onto a HiLoad 26/60 Superdex 200 pg (Amersham Biosciences) column for gel filtration chromatography. 20 mM acetate buffer (pH6.0) containing 150 mM NaCl and 0.01% Tween80 was used in the gel filtration chromatography. In each purification step, the presence of the diabody and sc(Fv)₂ in the samples was confirmed by SDS-PAGE and Western blotting using an anti-Flag antibody (Sigma-Aldrich).

[0191]

2.7 Binding activity analyses of single-chain anti-human Mpl antibodies by flow cytometry

5 CHO-human Mpl, CHO-monkey Mpl, and CHO-mouse Mpl cells were recovered and suspended in FACS buffer (1% FBS/PBS) to a final concentration of 1×10^6 cells/mL. Cell suspensions were aliquoted at 100- μ L/well into the Multiscreen-HV Filter Plates (Millipore). After centrifugation, the supernatant was removed. An appropriate concentration of diabody or sc(Fv)₂ was added into each well and incubated on ice for 30 min. The cells were washed once with 200 μ L of FACS buffer, and incubated on ice for 30 min following the addition of 10 μ g/mL ANTI-FLAG® M2 Monoclonal Antibody (Sigma-Aldrich). The cells were then washed once with 200 μ L of FACS buffer, and a 100x-diluted FITC-labeled anti-mouse IgG antibody (Beckman Coulter) was added to the plate. The plate was incubated on ice for 30 min. After centrifugation, the supernatant was removed. The cells were suspended in 400 μ L of FACS Buffer, and then analyzed by flow cytometry using EPICS ELITE ESP (Beckman Coulter). An analysis gate was set on the forward and side scatters of a histogram to include viable cell

populations.

[0192]

The binding activity of the purified VB22B sc(Fv)₂ to various Mpl molecules expressed in CHO cells was determined (Fig. 2). VB22B sc(Fv)₂ was found to specifically bind to
5 CHO-human Mpl and CHO-monkey Mpl but not to the host cell CHO or CHO-mouse Mpl. This binding characteristic of VB22B sc(Fv)₂ is comparable to those of VB22B IgG, indicating that the antibody binding site remains unaltered by reduction of molecular weight.

[0193]

2.8 Analyses of TPO-like agonistic activity for single-chain anti-human Mpl antibodies

10 TPO-like agonistic activity was assessed using BaF3-human Mpls or BaF3-monkey Mpls that proliferate in a TPO-dependent manner.

Cells from each cell line were washed twice with RPMI 1640/1% FBS (fetal bovine serum) (Invitrogen), and then suspended in RPMI 1640/10% FBS to a concentration of 4×10^5 cells/mL. Cell suspensions were aliquoted at 60- μ L/well into a 96-well plate. Various
15 concentrations of rhTPO (R&D) and COS7 culture supernatants or purified samples were prepared, and a 40- μ L aliquot was added into each well. The plates were then incubated at 37°C under 5% CO₂ for 24 hr. Immediately after a 10- μ L aliquot of WST-8 reagent (Cell Count Reagent SF; Nacalai Tesque) was added into each well, absorbance was measured at 450 nm (and at 655 nm as a control) using Benchmark Plus. After two hours of incubation,
20 absorbance was again measured at 450 nm (and at 655 nm as a control). The WST-8 reagent changes colors at 450 nm in a color reaction that reflects the viable cell count. The TPO-like agonistic activity was assessed using the change in absorbance during the two-hour incubation as an index. EC₅₀ values were computed using GraphPad Prism.

[0194]

25 TPO-like agonistic activity was assayed using the human leukemia cell line M-07e (purchased from DSMZ) which proliferates TPO-dependently. M-07e cells were washed twice with RPMI 1640/1% FBS, and then suspended in RPMI 1640/10% FBS to a concentration of 5×10^5 cells/mL. The resulting cell suspension was aliquoted at 50- μ L/well into a 96-well plate. Various concentrations of rhTPO and COS7 culture supernatants or purified samples were
30 prepared, and a 50- μ L aliquot was added into each well. The plates were then incubated at 37°C under 5% CO₂ for 48 hr. Immediately after a 10- μ L aliquot of WST-8 reagent (Cell Count Reagent SF; Nacalai Tesque) was added to each well, absorbance of was measured at 450 nm (and at 655 nm as a control) using a Benchmark Plus. After four hours of incubation, absorbance was again measured at 450 nm (and at 655 nm as a control). The TPO-like
35 agonistic activity was assayed using the change in absorbance during the four-hour incubation as an index.

[0195]

Purified VB22B IgG, VB22B diabody, and VB22B sc(Fv)₂ were assayed for their TPO-like agonistic activities using BaF3-human Mpl, BaF3-monkey Mpl, and M-07e. The results are shown in Figures 3, 4, and 5, respectively. The presence of bivalent antigen-binding domains in a single antibody molecule is essential for its agonistic activity. The distance and angle between two antigen-binding domains can also be important factors (see WO 02/33073 and WO 02/33072). Similar results were obtained for the newly isolated anti-human Mpl antibodies. Specifically, the agonistic activities of VB22B diabody and VB22B sc(Fv)₂ (EC₅₀ = 61 pM and 27 pM in BaF-human Mpl, respectively) were higher than that of VB22B IgG (EC₅₀ > 30 nM in BaF-human Mpl), and were equivalent to or higher than that of the naturally-occurring human TPO ligand (EC₅₀ = 76 pM in BaF-human Mpl). The VB22B diabody activity was lower than that of VB22B sc(Fv)₂. This suggests that the structure of a single-chain antibody is greatly altered by its molecular shape and the length of the linker sequence, which in turn changes the agonistic activity. Sixteen types of the single-chain anti-human Mpl antibodies were obtained, each exhibiting a high agonistic activity. The amino acid sequences of the H chain and L chain variable regions of the representative antibodies are shown in Figures 6 and 7, respectively.

[0196]

2.9 Humanization of single-chain anti-human Mpl antibody

Antibody sequence data for the humanization of VB22B sc(Fv)₂ were obtained from the Kabat Database (<ftp://ftp.ebi.ac.uk/pub/databases/kabat/>), and homology searches were carried out independently for the H chain variable region and the L chain variable region. As a result, the H chain variable region was found to be highly homologous to DN13 (Smithson S. L. *et al.*, *Mol Immunol.* (1999) 36: 113-124). The L chain variable region was found to be highly homologous to ToP027 (Hougs L. *et al.*, *J. Immunol.* (1999) 162: 224-237). Humanized antibodies were prepared by inserting a complementarity-determining region (hereinafter abbreviated as "CDR") into the framework regions (hereinafter abbreviated as "FR") of the above antibodies. The humanized antibody sc(Fv)₂ was expressed in CHO-DG44 cells, and its agonistic activity was assessed using BaF-human Mpl. The agonistic activity was used as an index to generate a humanized VB22B sc(Fv)₂ which has agonistic activity equivalent to that of murine VB22B sc(Fv)₂ by replacing one or more amino acids in its framework region.

[0197]

Specifically, synthetic oligo-DNAs of approximately 50 nucleotides in length were designed as to make 20 of these nucleotides available for hybridization, and the synthetic oligo-DNAs were assembled by PCR to prepare genes that encode the respective variable regions. Using the resulting genes, sc(Fv)₂ was similarly prepared by the method described in

Example 2.3. The respective DNAs were cloned into a pCXND3 expression vector to construct three kinds of expression vectors, pCXND3-hVB22B p-z sc(Fv)₂, pCXND3-hVB22B g-e sc(Fv)₂, and pCXND3-hVB22B e sc(Fv)₂, to which the humanized VB22B sc(Fv)₂ is inserted. The nucleotide sequence and the amino acid sequence of hVB22B p-z sc(Fv)₂ in the plasmid are shown in SEQ ID NOs: 1 and 2. The nucleotide sequence and the amino acid sequence of hVB22B g-e sc(Fv)₂ are shown in SEQ ID NOs: 253 and 254. The nucleotide sequence and the amino acid sequence of hVB22B e sc(Fv)₂ are shown in SEQ ID NOs: 259 and 260. The nucleotide sequence and the amino acid sequence of murine VB22B sc(Fv)₂ are shown in SEQ ID NOs: 263 and 264. The plasmids were expressed in CHO-DG44 cells by the method described in Example 2.4 and the purification was done using the method described in Example 2.6. The TPO-like agonistic activities of the purified samples were similarly determined using the method described in Example 2.8. The TPO-like agonistic activities of the purified murine VB22B sc(Fv)₂, and humanized hVB22B e sc(Fv)₂ and hVB22B g-e sc(Fv)₂ in BaF3-human Mpl were assessed. The results are shown in Figures 19. The humanized VB22B sc(Fv)₂ showed comparable agonistic activities, suggesting that the humanization has no influence on the activity.

[0198]

[Example 3] Preparation of anti-Mpl diabodies by the AGS method

Anti-Mpl diabodies having agonistic activity were prepared by an Autocrine Growth Selection (AGS) method (see, WO 03/91424).

[0199]

3.1 Construction of a retrovirus library

Spleens were isolated from MRL/lpr mice immunized with shMPL-Flag by the method described in Example 1.5, and homogenized in TRIZOL Reagent (Invitrogen) using a Dounce homogenizer. After chloroform addition, the homogenized sample was shaken vigorously, the aqueous phase was removed and total RNA was extracted by isopropanol precipitation. mRNA was purified using a PolyAtract System 1000 (Promega). Reverse transcription of 2.5 µg mRNA was carried out at 42°C for 50 min using the Superscript First strand synthesis system for RT-PCR (Invitrogen) and the included oligo-dT primers to prepare cDNA.

[0200]

The composition of the PCR reaction solution (250 µL) is shown below.

10x KOD Plus Buffer (Toyobo)	25 µL
2 mM dNTPs (dATP, dGTP, dCTP, and dTTP) (Toyobo)	25 µL
2.5 mM MgSO ₄ (Toyobo)	10 µL
KOD Plus (Toyobo)	7.5 µL
Reverse transcription products	25 µL

Mixed primers complementary to H chain or L chain variable region 500 pmol
[0201]

The reaction conditions were:

98°C (initial temperature) for 3 min;

32 cycles of 98°C for 20 sec, 58°C for 20 sec, and 72°C for 30 sec;

5 and final extension was at 72°C for 6 min.

[0202]

The H chain primer mix contained HS1 to HS19 (SEQ ID NOs: 178 to 196) and HA1 to HA4 (SEQ ID NOs: 197 to 200), which were mixed at the indicated ratios next to the sequence names in Table 1. The L chain primer mix contained LS1 to LS17 (SEQ ID NOs: 201 to 217), LSlambda (SEQ ID NO: 218), LA1 to LA5 (SEQ ID NOs: 219 to 222), and LAlambda (SEQ ID NO: 223). The respective PCR products were purified from agarose gel using the QIAquick Gel Extraction Kit (QIAGEN). The H chain and L chain variable regions were linked *via* the (Gly₄Ser)₁ linker sequence by PCR using sc-S (SEQ ID NO: 224) and sc-AS (SEQ ID NO: 225) as described below.

15 [0203]

The composition of the PCR reaction solution (100 µL in total) is shown below.

10x KOD Plus Buffer (Toyobo)	10 µL
2 mM dNTPs (dATP, dGTP, dCTP, and dTTP) (Toyobo)	10 µL
2.5 mM MgSO ₄ (Toyobo)	4 µL
KOD Plus (Toyobo)	2 µL
Fragment of H chain variable region	4 µL
Fragment of L chain variable region	4 µL

[0204]

The first-round PCR conditions were:

94°C (initial temperature) for 3 min; and

20 seven cycles of 94°C for 1 min and 63°C for 4 min.

Then, sc-S and sc-AS (25 pmol each) were added to the first-round products.

The second-round PCR conditions were:

30 cycles of 94°C for 30 sec, 55°C for 2 min, and 72°C for 2 min;

and final extension was at 72°C for 6 min.

25 [0205]

The resulting product with an *Sfi*I restriction site at both ends was purified using the QIAquick PCR Purification Kit (QIAGEN), and incubated with the *Sfi*I restriction enzyme (TaKaRa) overnight at 50°C. The PCR product purified from agarose gel using the QIAquick Gel Extraction Kit (QIAGEN) was inserted into the *Sfi*I site of the viral vector

pMX/IL3ssGFPHis.

[0206]

The resulting plasmid was constructed by inserting a GFP gene, which has an *EcoRI* site, mouse IL-3 signal sequence and *SfiI* site at its 5' end; and an *SfiI* site, His tag sequence, 5 termination codon, and *NotI* site at its 3' end, between the *EcoRI* and *NotI* sites on the pMX viral vector (Onishi, M. *et al.*, Mol. Cell. Biol. 18: 3871-3879). The plasmid was introduced into the ElectroMAX DH10B T1 phage resistant cells (Invitrogen) by electroporation (settings: 2.5 kV, 25 μ F, and 100 Ω) using a Gene Pulser II (Bio-Rad). The cells were plated onto an LB-Agar 10 plate containing 100 μ g/mL ampicillin. After overnight incubation, 1×10^7 colonies were obtained. Colonies were recovered from the plate and plasmids were then extracted using the QIAGEN Plasmid Maxi Kit (QIAGEN).

[0207]

[Table 1]

SEQ ID NO:178 (HS1 (4))	GCCCAGCCGGCCATGGCGGAKGTRMAGCTTCAGGAGTC
SEQ ID NO:179 (HS2 (4))	GCCCAGCCGGCCATGGCGGAGGTBCAGCTBCAGCAGTC
SEQ ID NO:180 (HS3 (3))	GCCCAGCCGGCCATGGCGCAGGTGCAGCTGAAGSASTC
SEQ ID NO:181 (HS4 (4))	GCCCAGCCGGCCATGGCGGAGGTCCARCTGCAACARTC
SEQ ID NO:182 (HS5 (7))	GCCCAGCCGGCCATGGCGCAGGTYCAGCTBCAGCARTC
SEQ ID NO:183 (HS6 (2))	GCCCAGCCGGCCATGGCGCAGGTYCARCTGCAGCAGTC
SEQ ID NO:184 (HS7 (1))	GCCCAGCCGGCCATGGCGCAGGTCCACGTGAAGCAGTC
SEQ ID NO:185 (HS8 (2))	GCCCAGCCGGCCATGGCGGAGGTGAASSTGGTGGAAATC
SEQ ID NO:186 (HS9 (5))	GCCCAGCCGGCCATGGCGGAVGTGAWGYTGGTGGAGTC
SEQ ID NO:187 (HS10 (2))	GCCCAGCCGGCCATGGCGGAGGTGCAGSKGGTGGAGTC
SEQ ID NO:188 (HS11 (2))	GCCCAGCCGGCCATGGCGGAKGTGCAMCTGGTGGAGTC
SEQ ID NO:189 (HS12 (2))	GCCCAGCCGGCCATGGCGGAGGTGAAGCTGATGGARTC
SEQ ID NO:190 (HS13 (1))	GCCCAGCCGGCCATGGCGGAGGTGCARCTTGTTGAGTC
SEQ ID NO:191 (HS14 (2))	GCCCAGCCGGCCATGGCGGARGTRAAGCTTCTCGAGTC
SEQ ID NO:192 (HS15 (2))	GCCCAGCCGGCCATGGCGGAAGTGAARSTTGAGGAGTC
SEQ ID NO:193 (HS16 (5))	GCCCAGCCGGCCATGGCGCAGGTTACTCTRAAAGWGTSTG
SEQ ID NO:194 (HS17 (3.5))	GCCCAGCCGGCCATGGCGCAGGTCCAACVTCAGCARCC
SEQ ID NO:195 (HS18 (0.7))	GCCCAGCCGGCCATGGCGGATGTGAACTTGGAAAGTGTC
SEQ ID NO:196 (HS19 (0.7))	GCCCAGCCGGCCATGGCGGAGGTGAAGGTCATCGAGTC
SEQ ID NO:197 (HA1 (1))	GGAGCCGCCCGCCGCCCGAGGAAACGGTGACCGTGGT
SEQ ID NO:198 (HA2 (1))	GGAGCCGCCCGCCGCCCGAGGAGACTGTGAGAGTGGT
SEQ ID NO:199 (HA3 (1))	GGAGCCGCCCGCCGCCCGCAGAGACAGTGACCAGAGT
SEQ ID NO:200 (HA4 (1))	GGAGCCGCCCGCCGCCCGAGGAGACGGTGACTGAGGT
SEQ ID NO:201 (LS1 (1))	GGCGGCGGCGGCTCCGAYATCCAGCTGACTCAGCC
SEQ ID NO:202 (LS2 (2))	GGCGGCGGCGGCTCCGAYATTGTTCTCWCCAGTC
SEQ ID NO:203 (LS3 (5))	GGCGGCGGCGGCTCCGAYATTGTGMTMACTCAGTC
SEQ ID NO:204 (LS4 (3.5))	GGCGGCGGCGGCTCCGAYATTGTGYTRACACAGTC
SEQ ID NO:205 (LS5 (4))	GGCGGCGGCGGCTCCGAYATTGTRATGACMCAGTC
SEQ ID NO:206 (LS6 (7))	GGCGGCGGCGGCTCCGAYATTMAGATRAMCCAGTC
SEQ ID NO:207 (LS7 (6))	GGCGGCGGCGGCTCCGAYATTCAGATGAYDCAGTC
SEQ ID NO:208 (LS8 (1.5))	GGCGGCGGCGGCTCCGAYATYCAGATGACACAGAC
SEQ ID NO:209 (LS9 (2))	GGCGGCGGCGGCTCCGAYATTGTTCTCAWCCAGTC
SEQ ID NO:210 (LS10 (3.5))	GGCGGCGGCGGCTCCGAYATTGWGCTSACCCAATC
SEQ ID NO:211 (LS11 (8))	GGCGGCGGCGGCTCCGAYATTSTRATGACCCARTC
SEQ ID NO:212 (LS12 (8))	GGCGGCGGCGGCTCCGAYRTTKTGATGACCCARAC
SEQ ID NO:213 (LS13 (6))	GGCGGCGGCGGCTCCGAYATTGTGATGACBCAGKC
SEQ ID NO:214 (LS14 (2))	GGCGGCGGCGGCTCCGAYATTGTGATAACYCAGGA
SEQ ID NO:215 (LS15 (2))	GGCGGCGGCGGCTCCGAYATTGTGATGACCCAGWT
SEQ ID NO:216 (LS16 (1))	GGCGGCGGCGGCTCCGAYATTGTGATGACACAACC
SEQ ID NO:217 (LS17 (1))	GGCGGCGGCGGCTCCGAYATTTTGTGACTCAGTC
SEQ ID NO:218 (LS1lambda (1))	GGCGGCGGCGGCTCCGATGCTGTTGTGACTCAGGAATC
SEQ ID NO:219 (LA1 (4))	GGAATTCGGCCCCGAGGCCTTGATTTCCAGCTTGG
SEQ ID NO:220 (LA2 (4))	GGAATTCGGCCCCGAGGCCTTTATTTCCAGCTTGG
SEQ ID NO:221 (LA4 (4))	GGAATTCGGCCCCGAGGCCTTTATTTCCAACCTTG
SEQ ID NO:222 (LA5 (4))	GGAATTCGGCCCCGAGGCCTTCAGCTCCAGCTTGG
SEQ ID NO:223 (LA1lambda (1))	GGAATTCGGCCCCGAGGCCCTAGGACAGTCAGTTGG

[0208]

3.2 Establishment of autonomously replicating cell lines by the AGS method

The resulting library was transfected into a packaging cell, Pt-E, (Morita, S. *et al.*, Gene therapy 7: 1063-1066) using FuGENE 6 (Roche Diagnostics). Specifically, Pt-E was plated
 5 onto 6-cm dishes and cultured in DMEM/10% FBS (Invitrogen). A mixture of FuGENE 6 and the library was added to the plate the following day. The culture medium was exchanged the next day, and the culture supernatant was collected 24 hours after that. 10 µg/mL polybrene (Hexadimethrine Bromide; Sigma) and 2 ng/mL mIL-3 were added to the culture supernatant containing recombinant virus particles. The viral solution was used to infect the BaF-monkey
 10 Mpl target cells. The cells were washed with PBS the following day, and suspended in RPMI 1640/10% FBS without mIL-3. The suspension was plated onto a 96-well plate at a cell density of 1,000 cells/well. Autonomously replicating cell lines (AB317 and AB324) were obtained after seven days of incubation. Genomic DNAs were extracted from these cells using a
 15 DNeasy Tissue Kit (QIAGEN), and the antibody genes were amplified by PCR.

[0209]

The composition of the PCR reaction solution (50 µL in total) is shown below.

10x LA Taq Buffer (TaKaRa)	5 µL
2 mM dNTPs (dATP, dGTP, dCTP, and dTTP) (TaKaRa)	5 µL
2.5 mM MgCl ₄ (TaKaRa)	5 µL
TaKaRa LA Taq (TaKaRa)	0.5 µL
Genomic DNA	0.5 µg
AGSdbS1 (SEQ ID NO: 226) and AGSdbA1 (SEQ ID NO: 227)	25 pmol

[0210]

The reaction conditions were:

94°C (initial temperature) for 1 min;
 20 30 cycles of 94°C for 30 sec, 60°C for 30 sec, and 70°C for 1 min;
 and final extension was at 72°C for 6 min.

[0211]

The nucleotide sequence and the amino acid sequence of the H chain of cloned AB317 are shown in SEQ ID NOs: 154 and 155. The nucleotide sequence and the amino acid
 25 sequence of AB317 L chain are shown in SEQ ID NOs: 156 and 157. The nucleotide sequence and the amino acid sequence of AB324 H chain are shown in SEQ ID NOs: 158 and 159. The nucleotide sequence and the amino acid sequence of AB324 L chain are shown in SEQ ID NOs: 160 and 161.

[0212]

30 3.3 Activity assays of the diabodies obtained by AGS method

Each of the anti-Mpl diabodies obtained above was inserted into the pCXND3 expression vector. The PCR primers used are a synthetic oligonucleotide complementary to the 5' end of the diabody and containing an *EcoRI* site, and a synthetic oligonucleotide complementary to the nucleotide sequence of the 3' end of the diabody and containing a FLAG tag and a *NotI* site. The PCR product thus obtained was inserted into pCXND3 between the *EcoRI* and *NotI* sites. The diabody was expressed transiently in COS7 cells by the method described in Example 2.4. The culture supernatant was removed and the activity of the diabody was evaluated.

[0213]

The binding activities of the diabodies were assessed by flow cytometry using CHO cells that express Mpl derived from various species (Fig. 8). AB317 was proven to bind to CHO-mouse Mpl.

[0214]

The TPO-like agonistic activities of the diabodies were evaluated using BaF-human Mpl, BaF-monkey Mpl, and BaF-mouse Mpl (Figures 9, 10, and 11). AB317 had the highest agonistic activity against human, monkey, and mouse Mpl, whereas AB324 showed the highest agonistic activity against human and monkey Mpl.

[0215]

This proves that anti-Mpl diabodies having high agonistic activity can be obtained by the AGS method.

[0216]

[Example 4] Agonistic activity assays of the anti-Mpl antibodies against mutant Mpl in congenital amegakaryocytic thrombocytopenia (CAMT) patients

4.1 Establishment of BaF3 cell lines introduced with the mutant Mpl observed in CAMT patients

Mutations on G305C (R102P), C769T (R257C), and C823A (P275T) have been reported in the Mpl gene of CAMT patients. The respective expression vectors carrying the Mpl gene mutations were constructed and introduced into BaF3 cells. The following Mpl gene fragments were constructed: normal Mpl gene (nucleotide sequence, SEQ ID NO: 246; amino acid sequence, SEQ ID NO: 123); gene G305C in which C is substituted for 305th nucleotide G relative to the initiation codon (nucleotide sequence, SEQ ID NO: 247; amino acid sequence, SEQ ID NO: 248); gene C769T in which T is substituted for 769th nucleotide C (nucleotide sequence, SEQ ID NO: 249; amino acid sequence, SEQ ID NO: 250); and gene C823A in which A is substituted for 823rd nucleotide C (nucleotide sequence, SEQ ID NO: 251; amino acid sequence, SEQ ID NO: 252). These DNA fragments were digested with *EcoRI* and *SalI*, and inserted between the *EcoRI* and *SalI* sites on the animal cell expression vector pCOS2-Ha to prepare pCOS2-hMPLfullG305C, pCOS2-hMPLfullC769T, and pCOS2-hMPLfullC823A.

[0217]

The genes were introduced into BaF3 cells by the procedure described in Example 1.1.1 to establish BaF3 cell lines expressing each Mpl gene: BaF3-human MPL (G305C), BaF3-human MPL (C769T), and BaF3-human MPL (C823A). After the selection, the cells
5 were cultured and passaged using RPMI 1640 containing 1 ng/mL mIL-3 and 10% FBS.

[0218]

4.2 Preparation of anti-human Mpl diabody and sc(Fv)₂

Among the amino acid sequences shown in Figures 6 and 7, expression vectors were prepared for the diabodies VB8B, VB45B, VB33, VB140, VB157, and TA136 using the same
10 procedure described in Example 2.2.2. The prepared expression vectors were introduced into COS7 cells by the same procedure described in Example 2.2.4. The supernatant concentration of each diabody was determined by the method of Example 2.2.5. The sc(Fv)₂ expression vector for TA136 was prepared by the same procedure described in Example 2.2.3. The vector was introduced into CHO-DG44 cells by the same procedure described in Example 2.2.4.
15 sc(Fv)₂ was purified from the culture supernatant thus obtained using the same method described in Example 2.2.6.

[0219]

4.3 Agonistic activity assays of sc(Fv)₂ and the anti-human Mpl diabodies

The prepared diabodies and sc(Fv)₂ were assayed for their agonistic activities in normal
20 Mpl and mutant Mpl in BaF3 cells by the same procedure described in Example 2.2.8. The agonistic activities in BaF3-human Mpl and BaF3-human Mpl (G305C) were compared using the culture supernatants of cells expressing the diabodies. The TA136 diabody (TA136 db) was shown to have a low agonistic activity in BaF3-human Mpl cells expressing the normal Mpl gene, and a high agonistic activity in BaF3-human Mpl (G305C) cells expressing the mutant Mpl gene.
25 hTPO and the rest of the diabodies did not show a high agonistic activity in BaF3-human Mpl (G305C) cells (Figures 12 and 13).

[0220]

In addition, the agonistic activities of the TA136 diabody and TA136 sc(Fv)₂ in
30 BaF3-human Mpl, BaF3-human Mpl (G305C), BaF3-human Mpl (C769T), and BaF3-human Mpl (C823A) cells were assessed using a purified sample of the diabody. Compared with hTPO and the TA136 diabody, TA136 sc(Fv)₂ exhibited a higher agonistic activity in all three types of the TPO receptor mutant cell lines (Figures 15, 16 and 17). Furthermore, it was shown that in BaF3-human Mpl cells expressing the normal Mpl gene, the TA136 diabody exhibited a lower activity than hTPO. However, an agonistic activity equivalent to that of hTPO was
35 achieved by converting the diabody into sc(Fv)₂ (Fig. 14).

[Brief Description of the Drawings]

[0221]

[Fig. 1] Fig. 1 demonstrates the strategy for preparing single-chain antibody sc(Fv)₂.

[Fig. 2] Fig. 2 illustrates the assessment of VB22B sc(Fv)₂ binding activity using an
5 Mpl-expressing CHO cell line. Purified VB22B sc(Fv)₂ was used.

[Fig. 3] Fig. 3 illustrates the assessment of VB22B antibody agonistic activity using
BaF-human Mpl.

[Fig. 4] Fig. 4 illustrates the assessment of VB22B antibody agonistic activity using
BaF-monkey Mpl.

10 [Fig. 5] Fig. 5 illustrates the assessment of VB22B antibody agonistic activity using
M-07e.

[Fig. 6] Fig. 6 shows the amino acid sequences of anti-human Mpl antibodies (H chains)
that exhibit higher agonistic activities when converted into minibodies.

[Fig. 7] Fig. 7 shows the amino acid sequences of anti-human Mpl antibodies (L chains)
15 which exhibit higher agonistic activities when converted into minibodies.

[Fig. 8] Fig. 8 illustrates the binding activity assessment of AB317 diabody using
Mpl-expressing CHO cells. Both VB22B diabody (solid line) and AB317 diabody (broken
line) were obtained from COS7 culture supernatants.

[Fig. 9] Fig. 9 illustrates the agonistic activity assessment of AB324 and AB317
20 diabodies using BaF-human Mpl.

[Fig. 10] Fig. 10 illustrates the agonistic activity assessment of AB324 and AB317
diabodies using BaF-monkey Mpl.

[Fig. 11] Fig. 11 illustrates the agonistic activity assessment of AB324 and AB317
diabodies using BaF-mouse Mpl.

25 [Fig. 12] Fig. 12 shows the agonistic activities of diabodies and hTPO in BaF3-human
Mpl cells. The Y-axis shows OD at 450/655 nm, and the X-axis represents concentration.

[Fig. 13] Fig. 13 shows the agonistic activities of diabodies and hTPO in BaF3-human
Mpl (G305C) cells. The Y-axis shows OD at 450/655 nm, and the X-axis represents
concentration.

30 [Fig. 14] Fig. 14 shows the agonistic activities of TA136 db and TA136 sc(Fv)₂ in
BaF3-human Mpl cells. The Y-axis shows OD at 450/655 nm and the X-axis represents
concentration.

[Fig. 15] Fig. 15 shows the agonistic activities of TA136 db and TA136 sc(Fv)₂ in
BaF3-human Mpl (G305C) cells. The Y-axis shows OD at 450/655 nm, and the X-axis
35 represents concentration.

[Fig. 16] Fig. 16 shows the agonistic activities of TA136 db and TA136 sc(Fv)₂ in

BaF3-human Mpl (C769T) cells. The Y-axis shows OD at 450/655 nm, and the X-axis represents concentration.

[Fig. 17] Fig. 17 shows the agonistic activities of TA136 db and TA136 sc(Fv)₂ in BaF3-human Mpl (C823A) cells. The Y-axis shows OD at 450/655 nm, and the X-axis

5 represents concentration.

[Fig. 18] Fig. 18 shows the positions of FRs and CDRs in humanized heavy chain sequences (hVB22B p-z: VH), and humanized light chain sequences (hVB22B p-z: VL).

[Fig. 19] Fig. 19 shows the TPO-like agonistic activities of murine VB22B sc(Fv)₂, hVB22B e sc(Fv)₂, and hVB22B g-e sc(Fv)₂ in BaF3-human Mpl. The Y-axis shows

10 absorbance ratio (450nm/655nm), and the X-axis represents concentration.

[Sequence Listing]

SEQUENCE LISTING

5 <110> CHUGAI SEIYAKU KABUSHIKI KAISHA

<120> anti-Mpl antibody

<130> C1-A0320Y1

10 <150> JP 2003-415746

<151> 2003-12-12

<160> 285

15 <170> PatentIn version 3.1

<210> 1

<211> 1572

20 <212> DNA

<213> Homo sapiens

<400> 1

atggactgga cctggagggtt cctctttgtg gtggcagcag ctacaggtgt ccagtcccag 60

25 gtgcagctgg tgcagtctgg acctgagggtg aagaagcctg gggcctcagt gaaggtctcc 120

tgcaaggctt ctggatacac cttcaccaac tcctggatga actgggtgag gcagaggcct 180

30 ggaaagggtc ttgagtggat gggacggatt tctcctggag atggagaaac tatctacaat 240

gggaaattca gggtcagagt cacgattacc gcggacgaat ccacgagcac agcctacatg 300

gagctgagca gcctgagatc tgaggacaag gccgtgtatt actgtgogag aggctatgat 360

35 gattactcgt ttgcttactg gggccaggga accacgtca cctctcttc aggtggtggt 420

ggatcggag gtggtggatc gggtggtgga ggatcggata ttgtgatgac tcagtctgca 480
 ctctccctgc ccgtcacccc tggagagccg gcctccatct cctgcaggtc tagtaagagt 540
 5 ctctgcata gtaatggcaa cacttacttg tattggttcc agcagaagcc agggcagtct 600
 ccacagctcc tgatctatcg gatgtccaac cttgcctcag ggtccctga caggttcagt 660
 10 ggcagtggat caggcacagc ttttacctg aaaatcagca gaggaggc tgaggatggt 720
 ggggtttatt actgcatgca acatatagaa tacccttta cgttcggcca agggaccaa 780
 ctggaaatca aaggaggtgg tggatcgggt ggtggtggtt cgggaggcgg tggatcgag 840
 15 gtgcagctgg tgcagtctgg acctgaggtg aagaagcctg gggcctcagt gaaggtctcc 900
 tgcaaggctt ctggatacac cttaccaac tcctggatga actgggtgag gcagaggcct 960
 20 ggaaaggctc ttgagtggat gggacggatt taccctggag atggagaaac tatctacaat 1020
 gggaaatca ggtcagagt cagattacc gcggacgaat ccacagcac agcctacatg 1080
 gagctgagca gcctgagatc tgaggacagc gccgtgtatt actgtgcgag aggctatgat 1140
 25 gattactcgt ttgcttactg gggccagga accacggtca ccgtctcttc aggtggtggt 1200
 ggatcggag gtggtggatc gggtggtgga ggatcggata ttgtgatgac tcagtctgca 1260
 30 ctctccctgc ccgtcacccc tggagagccg gcctccatct cctgcaggtc tagtaagagt 1320
 ctctgcata gtaatggcaa cacttacttg tattggttcc agcagaagcc agggcagtct 1380
 ccacagctcc tgatctatcg gatgtccaac cttgcctcag ggtccctga caggttcagt 1440
 35 ggcagtggat caggcacagc ttttacctg aaaatcagca gaggaggc tgaggatggt 1500

ggggtttatt actgcatgca acatatagaa tatcctttta cgttcggcca agggaccaaa 1560

ctggaaatca aa 1572

5

<210> 2

<211> 524

<212> PRT

10 <213> Homo sapiens

<400> 2

Met Asp Trp Thr Trp Arg Phe Leu Phe Val Val Ala Ala Ala Thr Gly

1 5 10 15

15

Val Gln Ser Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys

20 25 30

Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe

20 35 40 45

Thr Asn Ser Trp Met Asn Trp Val Arg Gln Arg Pro Gly Lys Gly Leu

50 55 60

25 Glu Trp Met Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Ile Tyr Asn

65 70 75 80

Gly Lys Phe Arg Val Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser

85 90 95

30

Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val

100 105 110

Tyr Tyr Cys Ala Arg Gly Tyr Asp Asp Tyr Ser Phe Ala Tyr Trp Gly

35 115 120 125

Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
 130 135 140

Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Ala
 5 145 150 155 160

Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg
 165 170 175

10 Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr Trp
 180 185 190

Phe Gln Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Arg Met
 195 200 205

15 Ser Asn Leu Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser
 210 215 220

Gly Thr Ala Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val
 20 225 230 235 240

Gly Val Tyr Tyr Cys Met Gln His Ile Glu Tyr Pro Phe Thr Phe Gly
 245 250 255

25 Gln Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly
 260 265 270

Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Pro
 275 280 285

30 Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
 290 295 300

Gly Tyr Thr Phe Thr Asn Ser Trp Met Asn Trp Val Arg Gln Arg Pro
 35 305 310 315 320

Gly Lys Gly Leu Glu Trp Met Gly Arg Ile Tyr Pro Gly Asp Gly Glu
 325 330 335

5 Thr Ile Tyr Asn Gly Lys Phe Arg Val Arg Val Thr Ile Thr Ala Asp
 340 345 350

Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
 355 360 365

10 Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Tyr Asp Asp Tyr Ser Phe
 370 375 380

Ala Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly
 385 390 395 400

15 Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met
 405 410 415

20 Thr Gln Ser Ala Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser
 420 425 430

Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr
 435 440 445

25 Tyr Leu Tyr Trp Phe Gln Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu
 450 455 460

Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro Asp Arg Phe Ser
 465 470 475 480

30 Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Lys Ile Ser Arg Val Glu
 485 490 495

Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His Ile Glu Tyr Pro
 35 500 505 510

Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
 515 520

- 5 <210> 3
 <211> 5
 <212> PRT
 <213> Mus musculus
- 10 <400> 3
 Ser Ser Trp Met Asn
 1 5
- 15 <210> 4
 <211> 17
 <212> PRT
 <213> Mus musculus
- 20 <400> 4
 Arg Thr Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys
 1 5 10 15
- Gly
- 25
- <210> 5
 <211> 13
- 30 <212> PRT
 <213> Mus musculus
- <400> 5
 Gly Trp Ile Leu Ala Asp Gly Gly Tyr Ser Phe Ala Tyr
 35 1 5 10

<210> 6

<211> 5

<212> PRT

5 <213> *Mus musculus*

<400> 6

Ser Ser Trp Met Asn

1 5

10

<210> 7

<211> 17

<212> PRT

15 <213> *Mus musculus*

<400> 7

Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys

1 5 10 15

20

Gly

25 <210> 8

<211> 9

<212> PRT

<213> *Mus musculus*

30 <400> 8

Gly Tyr Ala Asp Tyr Ser Phe Ala Tyr

1 5

35 <210> 9

<211> 5

<212> PRT

<213> Mus musculus

<400> 9

5 Ser Ser Trp Met Asn
1 5

<210> 10

10 <211> 17

<212> PRT

<213> Mus musculus

<400> 10

15 Arg Ile Tyr Pro Gly Asp Gly Glu Thr Asn Tyr Asn Gly Lys Phe Lys
1 5 10 15

Gly

20

<210> 11

<211> 9

<212> PRT

25 <213> Mus musculus

<400> 11

Gly Phe Gly Asp Tyr Ser Phe Ala Tyr
1 5

30

<210> 12

<211> 5

<212> PRT

35 <213> Mus musculus

<400> 12

Ser Ser Trp Met Asn

1 5

5

<210> 13

<211> 17

<212> PRT

<213> Mus musculus

10

<400> 13

Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys

1 5 10 15

15 Gly

<210> 14

20 <211> 9

<212> PRT

<213> Mus musculus

<400> 14

25 Gly Tyr Ala Asp Tyr Ser Phe Ala Tyr

1 5

<210> 15

30 <211> 5

<212> PRT

<213> Mus musculus

<400> 15

35 Arg Ser Trp Met Asn

1 5

<210> 16
<211> 17
5 <212> PRT
<213> Mus musculus

<400> 16
Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys
10 1 5 10 15

Gly

15

<210> 17
<211> 9
<212> PRT
<213> Mus musculus

20

<400> 17
Gly Tyr Asp Asp Tyr Ser Phe Ala Tyr
1 5

25

<210> 18
<211> 5
<212> PRT
<213> Mus musculus

30

<400> 18
Asn Ser Trp Met Asn
1 5

35

<210> 19

<211> 17
 <212> PRT
 <213> Mus musculus

5 <400> 19
 Arg Ile Tyr Pro Gly Asp Gly Glu Thr Asn Asn Asn Gly Lys Phe Lys
 1 5 10 15

Gly
 10

<210> 20
 <211> 9
 15 <212> PRT
 <213> Mus musculus

<400> 20
 Gly Tyr Gly Asp Tyr Ser Phe Ala Tyr
 20 1 5

<210> 21
 <211> 5
 25 <212> PRT
 <213> Mus musculus

<400> 21
 Asn Tyr Trp Val Asn
 30 1 5

<210> 22
 <211> 17
 35 <212> PRT
 <213> Mus musculus

<400> 22

Arg Ile His Pro Ser Asp Ser Glu Thr His Cys Asn Gln Lys Phe Lys

1 5 10 15

5

Arg

10 <210> 23

<211> 6

<212> PRT

<213> Mus musculus

15 <400> 23

Gly Gly Trp Phe Ala Tyr

1 5

20 <210> 24

<211> 5

<212> PRT

<213> Mus musculus

25 <400> 24

Ser Ser Trp Met Asn

1 5

30 <210> 25

<211> 17

<212> PRT

<213> Mus musculus

35 <400> 25

Arg Ile Tyr Pro Gly Asp Gly Glu Thr Asn Asn Asn Gly Lys Phe Lys

1 5 10 15

Gly

5

<210> 26

<211> 9

<212> PRT

10 <213> Mus musculus

<400> 26

Gly Tyr Gly Asp Tyr Ser Phe Ala Tyr

1 5

15

<210> 27

<211> 5

<212> PRT

20 <213> Mus musculus

<400> 27

Thr Ser Trp Met Asn

1 5

25

<210> 28

<211> 17

<212> PRT

30 <213> Mus musculus

<400> 28

Arg Ile Tyr Pro Gly Asp Gly Glu Ala Asn Tyr Asn Gly Lys Phe Lys

1 5 10 15

35

Gly

<210> 29
5 <211> 9
<212> PRT
<213> Mus musculus

<400> 29
10 Gly Tyr Gly Asp Tyr Ser Phe Ala Tyr
1 5

<210> 30
15 <211> 5
<212> PRT
<213> Mus musculus

<400> 30
20 Ser Ser Trp Met Asn
1 5

<210> 31
25 <211> 17
<212> PRT
<213> Mus musculus

<400> 31
30 Arg Ile Tyr Pro Gly Asp Gly Glu Thr Asn Tyr Asn Gly Lys Phe Lys
1 5 10 15

Gly
35

<210> 32
<211> 9
<212> PRT
<213> Mus musculus

5

<400> 32
Gly Tyr Gly Asp Tyr Ser Phe Ala Tyr
1 5

10

<210> 33
<211> 5
<212> PRT
<213> Mus musculus

15

<400> 33
Arg Ser Trp Met Asn
1 5

20

<210> 34
<211> 17
<212> PRT
<213> Mus musculus

25

<400> 34
Arg Ile Tyr Pro Gly Asp Gly Glu Thr Asn Tyr Asn Gly Lys Phe Lys
1 5 10 15

30 Gly

<210> 35
35 <211> 9
<212> PRT

<213> Mus musculus

<400> 35

Gly Asp Gly Asp Tyr Ser Phe Ala Tyr

5 1 5

<210> 36

<211> 5

10 <212> PRT

<213> Mus musculus

<400> 36

Asn Ser Trp Met Asn

15 1 5

<210> 37

<211> 17

20 <212> PRT

<213> Mus musculus

<400> 37

Arg Ile Tyr Pro Gly Asp Gly Glu Thr Ile Tyr Asn Gly Lys Phe Arg

25 1 5 10 15

Val

30

<210> 38

<211> 9

<212> PRT

<213> Mus musculus

35

<400> 38

Gly Tyr Asp Asp Tyr Ser Phe Ala Tyr

1 5

5 <210> 39
 <211> 5
 <212> PRT
 <213> Mus musculus

10 <400> 39
 Asp Tyr Trp Val Asn
 1 5

15 <210> 40
 <211> 17
 <212> PRT
 <213> Mus musculus

20 <400> 40
 Arg Ile His Pro Tyr Asp Ser Glu Thr His Tyr Asn Gln Lys Phe Lys
 1 5 10 15

Asn

25

<210> 41
 <211> 6
 30 <212> PRT
 <213> Mus musculus

<400> 41
 Gly Gly Trp Phe Ala Ser

35 1 5

<210> 42

<211> 5

<212> PRT

5 <213> Mus musculus

<400> 42

Asp Tyr Trp Met Asn

1 5

10

<210> 43

<211> 17

<212> PRT

15 <213> Mus musculus

<400> 43

Arg Ile His Pro Phe Asp Ser Glu Thr His Cys Ser Gln Lys Phe Lys

1 5 10 15

20

Asn

25 <210> 44

<211> 6

<212> PRT

<213> Mus musculus

30 <400> 44

Gly Gly Trp Phe Ala Tyr

1 5

35 <210> 45

<211> 5

<212> PRT

<213> Mus musculus

<400> 45

5 Asn Ser Trp Met Asn
1 5

<210> 46

10 <211> 17

<212> PRT

<213> Mus musculus

<400> 46

15 Arg Ile Tyr Pro Gly Asp Gly Glu Thr Ile Tyr Asn Gly Lys Phe Arg
1 5 10 15

Val

20

<210> 47

<211> 9

<212> PRT

25 <213> Mus musculus

<400> 47

Gly Tyr Asp Asp Tyr Ser Phe Ala Tyr
1 5

30

<210> 48

<211> 5

<212> PRT

35 <213> Mus musculus

<400> 48

Asn Ser Trp Met Asn

1 5

5

<210> 49

<211> 17

<212> PRT

<213> Mus musculus

10

<400> 49

Arg Ile Tyr Pro Gly Asp Gly Asp Thr Ile Tyr Asn Gly Asn Phe Lys

1 5 10 15

15 Gly

<210> 50

20 <211> 9

<212> PRT

<213> Mus musculus

<400> 50

25 Gly Tyr Asp Asp Tyr Ser Phe Ala Tyr

1 5

<210> 51

30 <211> 5

<212> PRT

<213> Mus musculus

<400> 51

35 Ser Tyr Thr Met Ser

1 5

<210> 52
<211> 17
5 <212> PRT
<213> Mus musculus

<400> 52
Thr Ile Ser Ser Gly Ser Ser Thr Ile Tyr Tyr Ala Asp Thr Val Lys
10 1 5 10 15

Gly

15

<210> 53
<211> 6
<212> PRT
<213> Mus musculus

20

<400> 53
Arg Trp Phe Leu Asp Cys
1 5

25

<210> 54
<211> 5
<212> PRT
<213> Mus musculus

30

<400> 54
Ser Ser Trp Met Asn
1 5

35

<210> 55

<211> 17
<212> PRT
<213> Mus musculus

5 <400> 55
Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys
1 5 10 15

Gly
10

<210> 56
<211> 9
15 <212> PRT
<213> Mus musculus

<400> 56
Ala Arg Lys Thr Ser Trp Phe Ala Tyr
20 1 5

<210> 57
<211> 6
25 <212> PRT
<213> Mus musculus

<400> 57
Ser Asp Tyr Ala Trp Ser
30 1 5

<210> 58
<211> 16
35 <212> PRT
<213> Mus musculus

<400> 58

Tyr Ile Thr Tyr Ser Gly Tyr Ser Ile Tyr Asn Pro Ser Leu Lys Ser

1 5 10 15

5

<210> 59

<211> 7

<212> PRT

10 <213> Mus musculus

<400> 59

Gly Tyr Asp Asn Met Asp Tyr

1 5

15

<210> 60

<211> 16

<212> PRT

20 <213> Mus musculus

<400> 60

Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr

1 5 10 15

25

<210> 61

<211> 7

<212> PRT

30 <213> Mus musculus

<400> 61

Arg Met Ser Asn Leu Ala Ser

1 5

35

<210> 62
<211> 9
<212> PRT
<213> Mus musculus

5

<400> 62
Met Gln His Leu Glu Tyr Pro Phe Thr
1 5

10

<210> 63
<211> 16
<212> PRT
<213> Mus musculus

15

<400> 63
Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr
1 5 10 15

20

<210> 64
<211> 7
<212> PRT
<213> Mus musculus

25

<400> 64
Arg Met Ser Asn Leu Ala Ser
1 5

30

<210> 65
<211> 9
<212> PRT
<213> Mus musculus

35

<400> 65

Met Gln His Leu Glu Tyr Pro Tyr Thr

1 5

5 <210> 66
<211> 16
<212> PRT
<213> Mus musculus

10 <400> 66
Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr
1 5 10 15

15 <210> 67
<211> 7
<212> PRT
<213> Mus musculus

20 <400> 67
Arg Met Ser Asn Leu Ala Ser
1 5

25 <210> 68
<211> 9
<212> PRT
<213> Mus musculus

30 <400> 68
Met Gln His Leu Glu Tyr Pro Tyr Thr
1 5

35 <210> 69
<211> 16

<212> PRT

<213> Mus musculus

<400> 69

5 Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr
1 5 10 15

<210> 70

10 <211> 7

<212> PRT

<213> Mus musculus

<400> 70

15 Arg Met Ser Asn Leu Ala Ser
1 5

<210> 71

20 <211> 9

<212> PRT

<213> Mus musculus

<400> 71

25 Met Gln His Leu Glu Tyr Pro Tyr Thr
1 5

<210> 72

30 <211> 16

<212> PRT

<213> Mus musculus

<400> 72

35 Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr
1 5 10 15

<210> 73

<211> 7

5 <212> PRT

<213> Mus musculus

<400> 73

Arg Met Ser Asn Leu Ala Ser

10 1 5

<210> 74

<211> 9

15 <212> PRT

<213> Mus musculus

<400> 74

Met Gln His Leu Glu Tyr Pro Tyr Thr

20 1 5

<210> 75

<211> 16

25 <212> PRT

<213> Mus musculus

<400> 75

Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr

30 1 5 10 15

<210> 76

<211> 7

35 <212> PRT

<213> Mus musculus

<400> 76

Arg Met Ser Asn Leu Ala Ser

1 5

5

<210> 77

<211> 9

<212> PRT

10 <213> Mus musculus

<400> 77

Met Gln His Leu Glu Tyr Pro Tyr Thr

1 5

15

<210> 78

<211> 16

<212> PRT

20 <213> Mus musculus

<400> 78

Arg Ser Ser Lys Ser Leu Leu Tyr Ser Asn Gly Asn Ile Tyr Leu Tyr

1 5 10 15

25

<210> 79

<211> 7

<212> PRT

30 <213> Mus musculus

<400> 79

Arg Met Ser Asn Leu Ala Ser

1 5

35

<210> 80
<211> 9
<212> PRT
<213> Mus musculus

5

<400> 80
Met Gln His Leu Glu Tyr Pro Tyr Thr
1 5

10

<210> 81
<211> 16
<212> PRT
<213> Mus musculus

15

<400> 81
Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr
1 5 10 15

20

<210> 82
<211> 7
<212> PRT
<213> Mus musculus

25

<400> 82
Arg Met Ser Asn Leu Ala Ser
1 5

30

<210> 83
<211> 9
<212> PRT
<213> Mus musculus

35

<400> 83

Met Gln His Leu Glu Tyr Pro Tyr Thr

1 5

5 <210> 84
<211> 16
<212> PRT
<213> Mus musculus

10 <400> 84
Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr
1 5 10 15

15 <210> 85
<211> 7
<212> PRT
<213> Mus musculus

20 <400> 85
Arg Met Ser Asn Leu Ala Ser
1 5

25 <210> 86
<211> 9
<212> PRT
<213> Mus musculus

30 <400> 86
Met Gln His Val Glu Tyr Pro Tyr Thr
1 5

35 <210> 87
<211> 16

<212> PRT

<213> Mus musculus

<400> 87

5 Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr
1 5 10 15

<210> 88

10 <211> 7

<212> PRT

<213> Mus musculus

<400> 88

15 Arg Met Ser Asn Leu Ala Ser
1 5

<210> 89

20 <211> 9

<212> PRT

<213> Mus musculus

<400> 89

25 Met Gln His Leu Glu Tyr Pro Tyr Thr
1 5

<210> 90

30 <211> 16

<212> PRT

<213> Mus musculus

<400> 90

35 Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr
1 5 10 15

<210> 91

<211> 7

5 <212> PRT

<213> Mus musculus

<400> 91

Arg Met Ser Asn Leu Ala Ser

10 1 5

<210> 92

<211> 9

15 <212> PRT

<213> Mus musculus

<400> 92

Met Gln His Leu Glu Tyr Pro Tyr Thr

20 1 5

<210> 93

<211> 16

25 <212> PRT

<213> Mus musculus

<400> 93

Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr

30 1 5 10 15

<210> 94

<211> 7

35 <212> PRT

<213> Mus musculus

<400> 94

Arg Met Ser Asn Leu Ala Ser

1 5

5

<210> 95

<211> 9

<212> PRT

10 <213> Mus musculus

<400> 95

Met Gln His Ile Glu Tyr Pro Phe Thr

1 5

15

<210> 96

<211> 16

<212> PRT

20 <213> Mus musculus

<400> 96

Arg Ser Ser Lys Ser Leu Leu Tyr Ser Asn Gly Asn Thr Tyr Leu Tyr

1 5 10 15

25

<210> 97

<211> 7

<212> PRT

30 <213> Mus musculus

<400> 97

Arg Met Ser Asn Leu Ala Ser

1 5

35

<210> 98
<211> 9
<212> PRT
<213> Mus musculus

5

<400> 98
Met Gln His Leu Glu Tyr Pro Tyr Thr
1 5

10

<210> 99
<211> 16
<212> PRT
<213> Mus musculus

15

<400> 99
Arg Ser Ser Lys Ser Leu Leu Tyr Ser Asn Gly Asn Ile Tyr Leu Tyr
1 5 10 15

20

<210> 100
<211> 7
<212> PRT
<213> Mus musculus

25

<400> 100
Arg Met Ser Asn Leu Ala Ser
1 5

30

<210> 101
<211> 9
<212> PRT
<213> Mus musculus

35

<400> 101

Met Gln His Leu Glu Tyr Pro Tyr Thr

1 5

5 <210> 102

<211> 16

<212> PRT

<213> Mus musculus

10 <400> 102

Arg Ser Ser Lys Ser Leu Leu His Asn Asn Gly Asn Thr Tyr Leu Tyr

1 5 10 15

15 <210> 103

<211> 7

<212> PRT

<213> Mus musculus

20 <400> 103

Arg Met Ser Asn Leu Ala Ser

1 5

25 <210> 104

<211> 9

<212> PRT

<213> Mus musculus

30 <400> 104

Met Gln His Ile Glu Tyr Pro Phe Thr

1 5

35 <210> 105

<211> 16

<212> PRT

<213> Mus musculus

<400> 105

5 Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr
1 5 10 15

<210> 106

10 <211> 7

<212> PRT

<213> Mus musculus

<400> 106

15 Arg Met Ser Asn Leu Ala Ser
1 5

<210> 107

20 <211> 9

<212> PRT

<213> Mus musculus

<400> 107

25 Met Gln His Leu Glu Tyr Pro Tyr Thr
1 5

<210> 108

30 <211> 15

<212> PRT

<213> Mus musculus

<400> 108

35 Arg Ala Ser Glu Ser Val Glu Tyr Tyr Gly Thr Ser Leu Met Gln
1 5 10 15

<210> 109
<211> 7
5 <212> PRT
<213> Mus musculus

<400> 109
Gly Ala Ser Asn Val Glu Ser
10 1 5

<210> 110
<211> 9
15 <212> PRT
<213> Mus musculus

<400> 110
Gln Gln Ser Arg Lys Val Pro Trp Thr
20 1 5

<210> 111
<211> 11
25 <212> PRT
<213> Mus musculus

<400> 111
Lys Ala Ser Gln Asn Val Gly Asn Ile Ile Ala
30 1 5 10

<210> 112
<211> 7
35 <212> PRT
<213> Mus musculus

<400> 112

Leu Ala Ser Tyr Arg Tyr Ser

1 5

5

<210> 113

<211> 9

<212> PRT

10 <213> Mus musculus

<400> 113

Gln Gln Tyr Ser Ser Ser Pro Leu Thr

1 5

15

<210> 114

<211> 12

<212> PRT

20 <213> Mus musculus

<400> 114

Ser Ala Ser Ser Ser Val Ser Ser Ser His Leu Tyr

1 5 10

25

<210> 115

<211> 7

<212> PRT

30 <213> Mus musculus

<400> 115

Ser Thr Ser Asn Leu Ala Ser

1 5

35

<210> 116
 <211> 9
 <212> PRT
 <213> Mus musculus

5

<400> 116
 His Gln Trp Ser Ser Tyr Pro Trp Thr
 1 5

10

<210> 117
 <211> 411
 <212> DNA
 <213> Mus musculus

15

<220>
 <221> CDS
 <222> (1)..(411)
 <223>

20

<400> 117
 atg gaa tgg cct ttg atc ttt ctc ttc ctc ctg tca gga act gca ggt 48
 Met Glu Trp Pro Leu Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly
 1 5 10 15

25

gtc cac tcc cag gtt cag ctg cag cag tct gga cct gag ctg gtg aag 96
 Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys
 20 25 30

30

cct ggg gcc tca gtg aag att tcc tgc aag gct tct ggc tat gca ttc 144
 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe
 35 40 45

35

act aac tcc tgg atg aac tgg gtg aag cag agg cct gga aag ggt ctt 192
 Thr Asn Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu
 50 55 60

gag tgg att gga cgg att tat cct gga gat gga gaa act atc tac aat 240
 Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Ile Tyr Asn
 65 70 75 80

5

ggg aaa ttc agg gtc aag gcc aca ctg act gca gac aaa tcc tcc agc 288
 Gly Lys Phe Arg Val Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser
 85 90 95

10

aca gcc tac atg gat atc agc agc ctg aca tct gag gac tct gcg gtc 336
 Thr Ala Tyr Met Asp Ile Ser Ser Leu Thr Ser Glu Asp Ser Ala Val
 100 105 110

15

tac ttc tgt gca aga ggc tat gat gat tac tcg ttt gct tac tgg ggc 384
 Tyr Phe Cys Ala Arg Gly Tyr Asp Asp Tyr Ser Phe Ala Tyr Trp Gly
 115 120 125

20

caa ggg act ctg gtc act gtc tct gca 411
 Gln Gly Thr Leu Val Thr Val Ser Ala
 130 135

<210> 118
 <211> 137
 25 <212> PRT
 <213> Mus musculus

<400> 118
 Met Glu Trp Pro Leu Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly
 30 1 5 10 15

Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys
 20 25 30

35

Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe
 35 40 45

Thr Asn Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu
 50 55 60

5 Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Ile Tyr Asn
 65 70 75 80

Gly Lys Phe Arg Val Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser
 85 90 95

10 Thr Ala Tyr Met Asp Ile Ser Ser Leu Thr Ser Glu Asp Ser Ala Val
 100 105 110

Tyr Phe Cys Ala Arg Gly Tyr Asp Asp Tyr Ser Phe Ala Tyr Trp Gly
 15 115 120 125

Gln Gly Thr Leu Val Thr Val Ser Ala
 130 135

20 <210> 119
 <211> 396
 <212> DNA
 <213> Mus musculus

25 <220>
 <221> CDS
 <222> (1).. (396)
 <223>

30 <400> 119
 atg agg tgc cta gct gag ttc ctg ggg ctg ctt gtg ttc tgg att cct 48
 Met Arg Cys Leu Ala Glu Phe Leu Gly Leu Leu Val Phe Trp Ile Pro
 1 5 10 15

35 gga gcc att ggg gat att gtg atg act cag gct gca ccc tct ata cct 96

	Gly Ala Ile Gly Asp Ile Val Met Thr Gln Ala Ala Pro Ser Ile Pro	
	20 25 30	
	gtc act cct gga gag tca gta tcc atc tcc tgt agg tct agt aag agt	144
5	Val Thr Pro Gly Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser	
	35 40 45	
	ctc ctg cat agt aat ggc aac act tac ttg tat tgg ttc ctg cag agg	192
10	Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg	
	50 55 60	
	cca ggc cag tct cct caa ctc ctg ata tat cgg atg tcc aac ctt gcc	240
15	Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala	
	65 70 75 80	
	tca gga gtc cca gat agg ttc agt ggc agt ggg tca gga act gct ttc	288
	Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe	
	85 90 95	
20	aca ctg aga atc agt aga gtg gag gct gag gat gtg ggt gtt tat tac	336
	Thr Leu Arg Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr	
	100 105 110	
	tgt atg caa cat ata gaa tat cct ttt acg ttc gga tcg ggg acc aag	384
25	Cys Met Gln His Ile Glu Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys	
	115 120 125	
	ctg gaa ata aaa	396
30	Leu Glu Ile Lys	
	130	
	<210> 120	
	<211> 132	
35	<212> PRT	
	<213> Mus musculus	

<400> 120

Met Arg Cys Leu Ala Glu Phe Leu Gly Leu Leu Val Phe Trp Ile Pro
1 5 10 15

5

Gly Ala Ile Gly Asp Ile Val Met Thr Gln Ala Ala Pro Ser Ile Pro
20 25 30

10

Val Thr Pro Gly Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser
35 40 45

Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg
50 55 60

15

Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala
65 70 75 80

Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe
85 90 95

20

Thr Leu Arg Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr
100 105 110

25

Cys Met Gln His Ile Glu Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys
115 120 125

Leu Glu Ile Lys
130

30

<210> 121

<211> 762

<212> DNA

<213> *Mus musculus*

35

<400> 121

atggaatggc ctttgatott tctcttccto ctgtcaggaa ctgcagggtg ccaactcccag 60
 gttcagctgc agcagtctgg acctgagctg gtgaagcctg gggcctcagt gaagatttcc 120
 5 tgcaaggctt ctggctatgc attcactaac tcttgatga actgggtgaa gcagaggcct 180
 ggaaagggtc ttgagtggat tggacggatt tatcctggag atggagaaac tatctacaat 240
 gggaaattca gggtaaggc cacactgact gcagacaaat cctccagcac agcctacatg 300
 10 gatatcagca gcctgacatc tgaggactct gcggtctact tctgtgcaag aggctatgat 360
 gattactcgt ttgcttactg gggccaaggg actctgggtca ctgtctctgc aggtggtggt 420
 15 ggttcggata ttgtgatgac tcaggctgca ccctctatac ctgtcactcc tggagagtca 480
 gtatccatct cctgtaggtc tagtaagagt ctctgcata gtaatggcaa cacttacttg 540
 tattggttcc tgcagaggcc aggccagtct cctcaactcc tgatatatcg gatgtccaac 600
 20 ottgcctcag gagtcccaga taggttcagt ggcagtgggt caggaactgc tttcacactg 660
 agaatcagta gagtggaggc tgaggatgtg ggtgtttatt actgtatgca acatatagaa 720
 25 taccctttta cgttcggatc ggggaccaag ctggaataa aa 762

<210> 122

<211> 254

30 <212> PRT

<213> Mus musculus

<400> 122

Met Glu Trp Pro Leu Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly

35 1 5 10 15

Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys
 20 25 30

Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe
 5 35 40 45

Thr Asn Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu
 50 55 60

10 Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Ile Tyr Asn
 65 70 75 80

Gly Lys Phe Arg Val Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser
 85 90 95

15 Thr Ala Tyr Met Asp Ile Ser Ser Leu Thr Ser Glu Asp Ser Ala Val
 100 105 110

Tyr Phe Cys Ala Arg Gly Tyr Asp Asp Tyr Ser Phe Ala Tyr Trp Gly
 20 115 120 125

Gln Gly Thr Leu Val Thr Val Ser Ala Gly Gly Gly Gly Ser Asp Ile
 130 135 140

25 Val Met Thr Gln Ala Ala Pro Ser Ile Pro Val Thr Pro Gly Glu Ser
 145 150 155 160

Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly
 165 170 175

30 Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser Pro Gln
 180 185 190

Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro Asp Arg
 35 195 200 205

Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg Ile Ser Arg
 210 215 220

Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His Ile Glu
 5 225 230 235 240

Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 245 250

10

<210> 123
 <211> 635
 <212> PRT
 <213> Homo sapiens

15

<400> 123
 Met Pro Ser Trp Ala Leu Phe Met Val Thr Ser Cys Leu Leu Leu Ala
 1 5 10 15

20 Pro Gln Asn Leu Ala Gln Val Ser Ser Gln Asp Val Ser Leu Leu Ala
 20 25 30

Ser Asp Ser Glu Pro Leu Lys Cys Phe Ser Arg Thr Phe Glu Asp Leu
 35 40 45

25

Thr Cys Phe Trp Asp Glu Glu Glu Ala Ala Pro Ser Gly Thr Tyr Gln
 50 55 60

30 Leu Leu Tyr Ala Tyr Pro Arg Glu Lys Pro Arg Ala Cys Pro Leu Ser
 65 70 75 80

Ser Gln Ser Met Pro His Phe Gly Thr Arg Tyr Val Cys Gln Phe Pro
 85 90 95

35 Asp Gln Glu Glu Val Arg Leu Phe Phe Pro Leu His Leu Trp Val Lys
 100 105 110

Asn Val Phe Leu Asn Gln Thr Arg Thr Gln Arg Val Leu Phe Val Asp
 115 120 125

5 Ser Val Gly Leu Pro Ala Pro Pro Ser Ile Ile Lys Ala Met Gly Gly
 130 135 140

Ser Gln Pro Gly Glu Leu Gln Ile Ser Trp Glu Glu Pro Ala Pro Glu
 145 150 155 160

10 Ile Ser Asp Phe Leu Arg Tyr Glu Leu Arg Tyr Gly Pro Arg Asp Pro
 165 170 175

Lys Asn Ser Thr Gly Pro Thr Val Ile Gln Leu Ile Ala Thr Glu Thr
 15 180 185 190

Cys Cys Pro Ala Leu Gln Arg Pro His Ser Ala Ser Ala Leu Asp Gln
 195 200 205

20 Ser Pro Cys Ala Gln Pro Thr Met Pro Trp Gln Asp Gly Pro Lys Gln
 210 215 220

Thr Ser Pro Ser Arg Glu Ala Ser Ala Leu Thr Ala Glu Gly Gly Ser
 225 230 235 240

25 Cys Leu Ile Ser Gly Leu Gln Pro Gly Asn Ser Tyr Trp Leu Gln Leu
 245 250 255

Arg Ser Glu Pro Asp Gly Ile Ser Leu Gly Gly Ser Trp Gly Ser Trp
 30 260 265 270

Ser Leu Pro Val Thr Val Asp Leu Pro Gly Asp Ala Val Ala Leu Gly
 275 280 285

35 Leu Gln Cys Phe Thr Leu Asp Leu Lys Asn Val Thr Cys Gln Trp Gln
 290 295 300

Gln Gln Asp His Ala Ser Ser Gln Gly Phe Phe Tyr His Ser Arg Ala
 305 310 315 320

5 Arg Cys Cys Pro Arg Asp Arg Tyr Pro Ile Trp Glu Asn Cys Glu Glu
 325 330 335

Glu Glu Lys Thr Asn Pro Gly Leu Gln Thr Pro Gln Phe Ser Arg Cys
 340 345 350

10 His Phe Lys Ser Arg Asn Asp Ser Ile Ile His Ile Leu Val Glu Val
 355 360 365

Thr Thr Ala Pro Gly Thr Val His Ser Tyr Leu Gly Ser Pro Phe Trp
 15 370 375 380

Ile His Gln Ala Val Arg Leu Pro Thr Pro Asn Leu His Trp Arg Glu
 385 390 395 400

20 Ile Ser Ser Gly His Leu Glu Leu Glu Trp Gln His Pro Ser Ser Trp
 405 410 415

Ala Ala Gln Glu Thr Cys Tyr Gln Leu Arg Tyr Thr Gly Glu Gly His
 420 425 430

25 Gln Asp Trp Lys Val Leu Glu Pro Pro Leu Gly Ala Arg Gly Gly Thr
 435 440 445

Leu Glu Leu Arg Pro Arg Ser Arg Tyr Arg Leu Gln Leu Arg Ala Arg
 30 450 455 460

Leu Asn Gly Pro Thr Tyr Gln Gly Pro Trp Ser Ser Trp Ser Asp Pro
 465 470 475 480

35 Thr Arg Val Glu Thr Ala Thr Glu Thr Ala Trp Ile Ser Leu Val Thr
 485 490 495

Ala Leu His Leu Val Leu Gly Leu Ser Ala Val Leu Gly Leu Leu Leu
500 505 510

5 Leu Arg Trp Gln Phe Pro Ala His Tyr Arg Arg Leu Arg His Ala Leu
515 520 525

Trp Pro Ser Leu Pro Asp Leu His Arg Val Leu Gly Gln Tyr Leu Arg
530 535 540

10 Asp Thr Ala Ala Leu Ser Pro Pro Lys Ala Thr Val Ser Asp Thr Cys
545 550 555 560

Glu Glu Val Glu Pro Ser Leu Leu Glu Ile Leu Pro Lys Ser Ser Glu
15 565 570 575

Arg Thr Pro Leu Pro Leu Cys Ser Ser Gln Ala Gln Met Asp Tyr Arg
580 585 590

20 Arg Leu Gln Pro Ser Cys Leu Gly Thr Met Pro Leu Ser Val Cys Pro
595 600 605

Pro Met Ala Glu Ser Gly Ser Cys Cys Thr Thr His Ile Ala Asn His
610 615 620

25 Ser Tyr Leu Pro Leu Ser Tyr Trp Gln Gln Pro
625 630 635

30 <210> 124
<211> 122
<212> PRT
<213> Mus musculus

35 <400> 124
Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala

1 5 10 15
 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser
 20 25 30
 5
 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45
 Gly Arg Thr Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe
 10 50 55 60
 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80
 15 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
 85 90 95
 Ala Arg Gly Trp Ile Leu Ala Asp Gly Gly Tyr Ser Phe Ala Tyr Trp
 100 105 110
 20 Gly Gln Gly Thr Leu Val Thr Val Ser Ala
 115 120
 25 <210> 125
 <211> 112
 <212> PRT
 <213> Mus musculus
 30 <400> 125
 Asp Ile Val Met Thr Gln Ala Ala Pro Ser Ile Pro Val Thr Pro Gly
 1 5 10 15
 Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
 35 20 25 30

Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser
 35 40 45

Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro
 5 50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg Ile
 65 70 75 80

10 Ser Arg Val Glu Ala Glu Asp Val Gly Ile Tyr Tyr Cys Met Gln His
 85 90 95

Leu Glu Tyr Pro Phe Thr Phe Gly Thr Gly Thr Lys Leu Glu Ile Lys
 100 105 110

15

<210> 126
 <211> 118
 <212> PRT
 20 <213> Mus musculus

<400> 126
 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15

25 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser
 20 25 30

Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile
 30 35 40 45

Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe
 50 55 60

35 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80

Ile Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
 85 90 95

5 Ala Arg Gly Tyr Ala Asp Tyr Ser Phe Ala Tyr Trp Gly Gln Gly Thr
 100 105 110

Leu Val Thr Val Ser Ala
 115

10

<210> 127

<211> 112

<212> PRT

15 <213> Mus musculus

<400> 127

Asp Ile Val Met Thr Gln Ala Ala Pro Ser Val Pro Val Thr Pro Gly
 1 5 10 15

20

Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
 20 25 30

25

Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser
 35 40 45

Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro
 50 55 60

30

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg Ile
 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His
 85 90 95

35

Leu Glu Tyr Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys

100

105

110

<210> 128

5 <211> 118

<212> PRT

<213> Mus musculus

<400> 128

10 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser
 20 25 30

15

Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

20 Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Asn Tyr Asn Gly Lys Phe
 50 55 60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Asn Thr Ala Tyr
 65 70 75 80

25 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
 85 90 95

Ala Arg Gly Phe Gly Asp Tyr Ser Phe Ala Tyr Trp Gly Gln Gly Thr
 100 105 110

30

Leu Val Thr Val Ser Ala
 115

35 <210> 129

<211> 112

<212> PRT

<213> Mus musculus

<400> 129

5 Asp Ile Val Met Thr Gln Ala Ala Pro Ser Val Pro Val Thr Pro Gly
1 5 10 15

Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
20 25 30

10 Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser
35 40 45

15 Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Ala Pro
50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg Ile
65 70 75 80

20 Ser Arg Val Glu Thr Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His
85 90 95

Leu Glu Tyr Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

25

<210> 130

<211> 118

<212> PRT

30 <213> Mus musculus

<400> 130

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15

35

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Thr Phe Ser Ser Ser

20

25

30

Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile
35 40 45

5

Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe
50 55 60

10

Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
85 90 95

15

Ala Ser Gly Tyr Ala Asp Tyr Ser Phe Ala Tyr Trp Gly Gln Gly Thr
100 105 110

Leu Val Thr Val Ser Ala
115

20

<210> 131

<211> 112

<212> PRT

25

<213> *Mus musculus*

<400> 131

Asp Ile Val Met Thr Gln Ala Ala Pro Ser Val Pro Val Thr Pro Gly
1 5 10 15

30

Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
20 25 30

Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser
35 40 45

Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro
 50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg Ile
 5 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His
 85 90 95

10 Leu Glu Tyr Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 100 105 110

<210> 132
 15 <211> 118
 <212> PRT
 <213> Mus musculus

<400> 132
 20 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Arg Ser
 20 25 30

25 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe
 30 50 55 60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80

35 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
 85 90 95

Ala Ser Gly Tyr Asp Asp Tyr Ser Phe Ala Tyr Trp Gly Gln Gly Thr
100 105 110

5 Leu Val Thr Val Ser Ala
115

<210> 133
10 <211> 112
<212> PRT
<213> Mus musculus

<400> 133
15 Asp Ile Val Met Thr Gln Ala Ala Pro Ser Val Pro Val Thr Pro Gly
1 5 10 15

Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
20 25 30

20 Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser
35 40 45

Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro
25 50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg Ile
65 70 75 80

30 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His
85 90 95

Leu Glu Tyr Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
100 105 110

35

<210> 134

<211> 118

<212> PRT

<213> *Mus musculus*

5

<400> 134

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
1 5 10 15

10 Ser Val Lys Ile Ser Cys Arg Ala Phe Gly Tyr Ala Phe Ser Asn Ser
 20 25 30

Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

15

Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Asn Asn Asn Gly Lys Phe
 50 55 60

20 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
 85 90 95

25 Ala Arg Gly Tyr Gly Asp Tyr Ser Phe Ala Tyr Trp Gly Gln Gly Thr
 100 105 110

Leu Val Thr Val Ser Ala
 115

30

<210> 135

<211> 112

<212> PRT

35 <213> *Mus musculus*

<400> 135

Asp Ile Val Met Thr Gln Ala Ala Pro Ser Val Pro Val Thr Pro Gly
 1 5 10 15

5 Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
 20 25 30

Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser
 35 40 45

10

Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro
 50 55 60

15 Asp Arg Phe Ser Gly Ser Gly Ser Gly Ala Ala Phe Thr Leu Arg Ile
 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His
 85 90 95

20 Leu Glu Tyr Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 100 105 110

<210> 136

25 <211> 115

<212> PRT

<213> Mus musculus

<400> 136

30 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Tyr
 20 25 30

35

Trp Val Asn Trp Val Lys Gln Arg Pro Gly Arg Gly Leu Glu Trp Ile

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg Ile
 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His
 5 85 90 95

Leu Glu Tyr Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 100 105 110

10

<210> 138
 <211> 118
 <212> PRT
 <213> Mus musculus

15

<400> 138
 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser
 20 25 30

Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

25

Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Asn Asn Asn Gly Lys Phe
 50 55 60

Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Thr Thr Ala Tyr
 30 65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
 85 90 95

Ala Arg Gly Tyr Gly Asp Tyr Ser Phe Ala Tyr Trp Gly Gln Gly Thr
 100 105 110

Leu Val Thr Val Ser Ala

115

5

<210> 139

<211> 112

<212> PRT

<213> Mus musculus

10

<400> 139

Asp Ile Val Met Thr Gln Ala Ala Pro Ser Val Pro Val Thr Pro Gly

1 5 10 15

15

Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser

20 25 30

Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser

35 40 45

20

Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro

50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Ala Ala Phe Thr Leu Arg Ile

25 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His

85 90 95

30

Leu Glu Tyr Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys

100 105 110

<210> 140

35 <211> 118

<212> PRT

<213> Mus musculus

<400> 140

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 5 1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Thr Ser
 20 25 30

10 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

Gly Arg Ile Tyr Pro Gly Asp Gly Glu Ala Asn Tyr Asn Gly Lys Phe
 50 55 60

15 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Ser Ala Tyr
 65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
 20 85 90 95

Ala Arg Gly Tyr Gly Asp Tyr Ser Phe Ala Tyr Trp Gly Gln Gly Thr
 100 105 110

25 Leu Val Thr Val Ser Ala
 115

<210> 141

30 <211> 112

<212> PRT

<213> Mus musculus

<400> 141

35 Asp Ile Val Met Thr Gln Ala Ala Pro Ser Val Pro Val Thr Pro Gly
 1 5 10 15

Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
 20 25 30

5 Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Met Gln Arg Pro Gly Gln Ser
 35 40 45

Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro
 50 55 60

10 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg Ile
 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His
 15 85 90 95

Val Glu Tyr Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 100 105 110

20

<210> 142
 <211> 118
 <212> PRT
 <213> Mus musculus

25

<400> 142
 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15

30 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser
 20 25 30

Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Pro Glu Trp Ile
 35 40 45

35 Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Asn Tyr Asn Gly Lys Phe

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His
 85 90 95

Leu Glu Tyr Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 5 100 105 110

<210> 144
 <211> 118
 10 <212> PRT
 <213> Mus musculus

<400> 144
 Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Leu Asn Pro Gly Ala
 15 1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Arg Ser
 20 25 30

20 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Asn Tyr Asn Gly Lys Phe
 50 55 60

25 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Thr Thr Ala Tyr
 65 70 75 80

Met Gln Phe Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
 30 85 90 95

Ala Arg Gly Asp Gly Asp Tyr Ser Phe Ala Tyr Trp Gly Gln Gly Thr
 100 105 110

35 Leu Val Thr Val Ser Ala
 115

<210> 145
 <211> 112
 5 <212> PRT
 <213> *Mus musculus*

 <400> 145
 Asp Ile Val Met Thr Gln Ala Ala Pro Ser Val Pro Val Thr Pro Gly
 10 1 5 10 15

 Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
 20 25 30

 15 Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser
 35 40 45

 Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro
 50 55 60
 20
 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg Ile
 65 70 75 80

 Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His
 25 85 90 95

 Leu Glu Tyr Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 100 105 110

 30
 <210> 146
 <211> 115
 <212> PRT
 <213> *Mus musculus*

 35
 <400> 146

Gln Val Gln Leu Gln Gln Pro Gly Thr Glu Leu Val Arg Pro Gly Ala
 1 5 10 15

Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 5 20 25 30

Trp Val Asn Trp Val Lys Gln Arg Pro Gly Arg Gly Leu Glu Trp Ile
 35 40 45

10 Gly Arg Ile His Pro Tyr Asp Ser Glu Thr His Tyr Asn Gln Lys Phe
 50 55 60

Lys Asn Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80

15 Ile Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Tyr Cys
 85 90 95

Ala Ser Gly Gly Trp Phe Ala Ser Trp Gly Gln Gly Thr Leu Val Thr
 20 100 105 110

Val Ser Ala
 115

25 <210> 147
 <211> 112
 <212> PRT
 <213> Mus musculus

30 <400> 147
 Asp Ile Val Met Thr Gln Ala Ala Pro Ser Val Pro Val Thr Pro Gly
 1 5 10 15

35 Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu Tyr Ser
 20 25 30

Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser
 35 40 45

5 Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro
 50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Thr Ile
 65 70 75 80

10 Ser Ser Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His
 85 90 95

Leu Glu Tyr Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 15 100 105 110

<210> 148
 <211> 115
 20 <212> PRT
 <213> Mus musculus

<400> 148
 Gln Val Gln Leu Gln Gln Pro Gly Ala Glu Leu Val Lys Pro Gly Ala
 25 1 5 10 15

Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asp Tyr
 20 25 30

30 Trp Met Asn Trp Val Lys Gln Arg Pro Gly Arg Gly Leu Glu Trp Ile
 35 40 45

Gly Arg Ile His Pro Phe Asp Ser Glu Thr His Cys Ser Gln Lys Phe
 50 55 60

35 Lys Asn Lys Ala Thr Leu Thr Val Asp Lys Ser Ser Asn Thr Ala Tyr

Leu Glu Tyr Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 100 105 110

5 <210> 150

<211> 118

<212> PRT

<213> Mus musculus

10 <400> 150

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala
 1 5 10 15

15 Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Thr Asn Ser
 20 25 30

Trp Met Asn Trp Val Arg Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile
 35 40 45

20 Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Ile Tyr Asn Gly Lys Phe
 50 55 60

Arg Val Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr
 65 70 75 80

25

Met Glu Ile Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
 85 90 95

30 Ala Arg Gly Tyr Asp Asp Tyr Ser Phe Ala Tyr Trp Gly Gln Gly Thr
 100 105 110

Leu Val Thr Val Ser Ala
 115

35

<210> 151

<211> 112

<212> PRT

<213> Mus musculus

5 <400> 151

Asp Ile Val Met Thr Gln Ala Ala Pro Ser Val Pro Val Thr Pro Gly

1 5 10 15

Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Asn

10 20 25 30

Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser

35 40 45

15 Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro

50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg Ile

65 70 75 80

20

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His

85 90 95

Ile Glu Tyr Pro Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys

25 100 105 110

<210> 152

<211> 118

30 <212> PRT

<213> Mus musculus

<400> 152

Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys Pro Gly Ala

35 1 5 10 15

Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe Ser Asn Ser
 20 25 30

Trp Met Asn Trp Val Asn Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile
 5 35 40 45

Gly Arg Ile Tyr Pro Gly Asp Gly Asp Thr Ile Tyr Asn Gly Asn Phe
 50 55 60

10 Lys Gly Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser Ile Ala Tyr
 65 70 75 80

Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys
 85 90 95

15 Thr Ser Gly Tyr Asp Asp Tyr Ser Phe Ala Tyr Trp Gly Gln Gly Thr
 100 105 110

Leu Val Thr Val Ser Ala
 20 115

<210> 153
 <211> 112
 25 <212> PRT
 <213> Mus musculus

<400> 153
 Asp Ile Val Met Thr Gln Ala Ala Pro Ser Leu Pro Val Thr Pro Gly
 30 1 5 10 15

Glu Ser Val Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser
 20 25 30

35 Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Leu Gln Arg Pro Gly Gln Ser
 35 40 45

Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro
 50 55 60

5 Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Arg Ile
 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His
 85 90 95

10 Leu Glu Tyr Pro Tyr Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 100 105 110

15 <210> 154
 <211> 423
 <212> DNA
 <213> *Mus musculus*

20 <220>
 <221> CDS
 <222> (1)..(423)
 <223>

25 <400> 154
 atg gtt ctt gcc agc tct acc acc agc atc cac acc atg ctg ctc ctg 48
 Met Val Leu Ala Ser Ser Thr Thr Ser Ile His Thr Met Leu Leu Leu
 1 5 10 15

30 ctc ctg atg ctg gcc cag ccg gcc atg gcg gaa gtg aag ctg gtg gag 96
 Leu Leu Met Leu Ala Gln Pro Ala Met Ala Glu Val Lys Leu Val Glu
 20 25 30

tct ggg gga ggc tta gtg aag cct gga ggg tcc cgg aaa ctc tcc tgt 144
 35 Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Arg Lys Leu Ser Cys
 35 40 45

gca gcc tct gga ttc act ttc agt agc tat acc atg tct tgg gtt cgc 192
 Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Thr Met Ser Trp Val Arg
 50 55 60
 5
 cag act ccg gcg aag agg ctg gag tgg gtc gca acc att agt agt ggc 240
 Gln Thr Pro Ala Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Ser Gly
 65 70 75 80
 10
 agt agt acc atc tac tat gca gac aca gtg aag ggc cga ttc acc atc 288
 Ser Ser Thr Ile Tyr Tyr Ala Asp Thr Val Lys Gly Arg Phe Thr Ile
 85 90 95
 tcc aga gac aat gcc aag aac acc ctg ttc ctg caa atg acc agt cta 336
 15 Ser Arg Asp Asn Ala Lys Asn Thr Leu Phe Leu Gln Met Thr Ser Leu
 100 105 110
 agg tct gag gac aca gcc atg tat tac tgt gca agg aga tgg ttt ctt 384
 Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg Arg Trp Phe Leu
 20 115 120 125
 gac tgc tgg ggc caa ggc acc act ctc aca gtc tcc tcg 423
 Asp Cys Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser
 130 135 140
 25
 <210> 155
 <211> 141
 <212> PRT
 30 <213> Mus musculus
 <400> 155
 Met Val Leu Ala Ser Ser Thr Thr Ser Ile His Thr Met Leu Leu Leu
 1 5 10 15
 35
 Leu Leu Met Leu Ala Gln Pro Ala Met Ala Glu Val Lys Leu Val Glu

	20		25		30	
	Ser Gly Gly Gly Leu Val Lys Pro Gly Gly Ser Arg Lys Leu Ser Cys					
	35		40		45	
5	Ala Ala Ser Gly Phe Thr Phe Ser Ser Tyr Thr Met Ser Trp Val Arg					
	50		55		60	
	Gln Thr Pro Ala Lys Arg Leu Glu Trp Val Ala Thr Ile Ser Ser Gly					
10	65		70		75	80
	Ser Ser Thr Ile Tyr Tyr Ala Asp Thr Val Lys Gly Arg Phe Thr Ile					
		85		90		95
15	Ser Arg Asp Asn Ala Lys Asn Thr Leu Phe Leu Gln Met Thr Ser Leu					
		100		105		110
	Arg Ser Glu Asp Thr Ala Met Tyr Tyr Cys Ala Arg Arg Trp Phe Leu					
		115		120		125
20	Asp Cys Trp Gly Gln Gly Thr Thr Leu Thr Val Ser Ser					
		130		135		140
25	<210> 156					
	<211> 357					
	<212> DNA					
	<213> Mus musculus					
30	<220>					
	<221> CDS					
	<222> (1).. (357)					
	<223>					
35	<400> 156					
	gat att gtg ctc acc caa tct cca gct tct ttg gct gtg tct cta ggg					

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
 1 5 10 15

cag agt gtc acc atc tcc tgc aga gcc agt gaa agt gtt gaa tat tat 96
 5 Gln Ser Val Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Tyr
 20 25 30

ggc act agt tta atg cag tgg tac caa cag aaa cca gga cag cca ccc 144
 10 Gly Thr Ser Leu Met Gln Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
 35 40 45

aaa ctc ctc atc tat ggt gca tcc aac gta gaa tct ggg gtc cct gcc 192
 15 Lys Leu Leu Ile Tyr Gly Ala Ser Asn Val Glu Ser Gly Val Pro Ala
 50 55 60

agg ttt agt ggc agt ggg tct ggg aca gac ttc agc ctc aac atc cat 240
 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His
 65 70 75 80

cct gtg gag gag gat gat att gca atg tat ttc tgt cag caa agt agg 288
 20 Pro Val Glu Glu Asp Asp Ile Ala Met Tyr Phe Cys Gln Gln Ser Arg
 85 90 95

aag gtt ccg tgg acg ttc ggt gga ggc acc aag ctg gaa ata aag gac 336
 25 Lys Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Asp
 100 105 110

tac aag gat gac gac gat aag 357
 Tyr Lys Asp Asp Asp Asp Lys
 30 115

<210> 157
 <211> 119
 35 <212> PRT
 <213> Mus musculus

<400> 157

Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly
 1 5 10 15

5

Gln Ser Val Thr Ile Ser Cys Arg Ala Ser Glu Ser Val Glu Tyr Tyr
 20 25 30

10

Gly Thr Ser Leu Met Gln Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro
 35 40 45

Lys Leu Leu Ile Tyr Gly Ala Ser Asn Val Glu Ser Gly Val Pro Ala
 50 55 60

15

Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Asn Ile His
 65 70 75 80

Pro Val Glu Glu Asp Asp Ile Ala Met Tyr Phe Cys Gln Gln Ser Arg
 85 90 95

20

Lys Val Pro Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Asp
 100 105 110

25

Tyr Lys Asp Asp Asp Asp Lys
 115

<210> 158

<211> 432

30

<212> DNA

<213> Mus musculus

<220>

<221> CDS

35

<222> (1).. (432)

<223>

<400> 158

atg gtt ctt gcc agc tct acc acc agc atc cac acc atg ctg ctc ctg 48
 Met Val Leu Ala Ser Ser Thr Thr Ser Ile His Thr Met Leu Leu Leu

5 1 5 10 15

ctc ctg atg ctg gcc cag ccg gcc atg gcg cag gtt cag ctc cag caa 96
 Leu Leu Met Leu Ala Gln Pro Ala Met Ala Gln Val Gln Leu Gln Gln

20 25 30

10 tct gga cct gag ctg gtg aag cct ggg gcc tca gtg aag att tcc tgc 144
 Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys

35 40 45

15 aag gct tct ggc tat gca ttc agt agc tcc tgg atg aac tgg atg aag 192
 Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser Trp Met Asn Trp Met Lys

50 55 60

cag agg cct gga aag ggt ctt gag tgg att ggg cgg att tat cct gga 240
 Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly

20 65 70 75 80

gat gga gat act aac tac aat ggg aag ttc aag ggc aag gcc aca ctg 288
 Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu

25 85 90 95

act gca gac aaa tcc tcc agc aca gcc tac atg caa ctc agc agc ctg 336
 Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu

100 105 110

30 aca tct gag gac tct gcg gtc tac ttc tgt gca aga gcg agg aaa act 384
 Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Ala Arg Lys Thr

115 120 125

35 tcc tgg ttt gct tac tgg ggc caa ggg act ctg gtc act gtc tct gcg 432
 Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala

130

135

140

<210> 159

5 <211> 144

<212> PRT

<213> Mus musculus

<400> 159

10 Met Val Leu Ala Ser Ser Thr Thr Ser Ile His Thr Met Leu Leu Leu
 1 5 10 15

Leu Leu Met Leu Ala Gln Pro Ala Met Ala Gln Val Gln Leu Gln Gln
 20 25 30

15 Ser Gly Pro Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys
 35 40 45

Lys Ala Ser Gly Tyr Ala Phe Ser Ser Ser Trp Met Asn Trp Met Lys
 20 50 55 60

Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly Arg Ile Tyr Pro Gly
 65 70 75 80

25 Asp Gly Asp Thr Asn Tyr Asn Gly Lys Phe Lys Gly Lys Ala Thr Leu
 85 90 95

Thr Ala Asp Lys Ser Ser Ser Thr Ala Tyr Met Gln Leu Ser Ser Leu
 100 105 110

30 Thr Ser Glu Asp Ser Ala Val Tyr Phe Cys Ala Arg Ala Arg Lys Thr
 115 120 125

Ser Trp Phe Ala Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ala
 35 130 135 140

<210> 160
 <211> 345
 <212> DNA
 5 <213> Mus musculus

<220>
 <221> CDS
 <222> (1).. (345)
 10 <223>

<400> 160
 gac att gtg ttg aca cag tct caa aaa ttc atg tcc aca tca gta gga 48
 Asp Ile Val Leu Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly
 15 1 5 10 15
 gac agg gtc agc atc agc tgc aag gcc agt cag aat gtg ggt aat att 96
 Asp Arg Val Ser Ile Ser Cys Lys Ala Ser Gln Asn Val Gly Asn Ile
 20 20 25 30
 ata gcc tgg tat caa cag aaa cca ggg caa tct cct aaa gca ctg att 144
 Ile Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile
 35 40 45
 tac ttg gca tcc tac cgg tac agt gga gtc cct gat cgc ttc aca ggc 192
 Tyr Leu Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly
 50 55 60
 agt gga tct ggg aca gat ttc act ctc acc att agt aat gtg cag tct 240
 30 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser
 65 70 75 80
 gaa gac ttg gca gag tat ttc tgt cag caa tat agc agc tct ccg ctc 288
 Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Ser Ser Ser Pro Leu
 35 85 90 95

acg ttc ggt gct ggg acc aag ctg gaa ata aag gac tac aag gat gac 336
 Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile Lys Asp Tyr Lys Asp Asp
 100 105 110

5 gac gat aag 345
 Asp Asp Lys
 115

10 <210> 161
 <211> 115
 <212> PRT
 <213> Mus musculus

15 <400> 161
 Asp Ile Val Leu Thr Gln Ser Gln Lys Phe Met Ser Thr Ser Val Gly
 1 5 10 15

20 Asp Arg Val Ser Ile Ser Cys Lys Ala Ser Gln Asn Val Gly Asn Ile
 20 25 30

Ile Ala Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Ala Leu Ile
 35 40 45

25 Tyr Leu Ala Ser Tyr Arg Tyr Ser Gly Val Pro Asp Arg Phe Thr Gly
 50 55 60

Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser Asn Val Gln Ser
 65 70 75 80

30 Glu Asp Leu Ala Glu Tyr Phe Cys Gln Gln Tyr Ser Ser Ser Pro Leu
 85 90 95

35 Thr Phe Gly Ala Gly Thr Lys Leu Glu Ile Lys Asp Tyr Lys Asp Asp
 100 105 110

Asp Asp Lys
115

5 <210> 162
<211> 116
<212> PRT
<213> Mus musculus

10 <400> 162
Asp Val Gln Leu Gln Glu Ser Gly Pro Gly Leu Val Lys Pro Ser Gln
1 5 10 15

Ser Leu Ser Leu Thr Cys Thr Val Thr Gly Tyr Ser Ile Thr Ser Asp
15 20 25 30

Tyr Ala Trp Ser Trp Ile Arg Gln Leu Pro Gly Asn Lys Leu Glu Trp
35 40 45

20 Met Gly Tyr Ile Thr Tyr Ser Gly Tyr Ser Ile Tyr Asn Pro Ser Leu
50 55 60

Lys Ser Arg Ile Ser Ile Ser Arg Asp Thr Ser Lys Asn Gln Leu Phe
65 70 75 80

25 Leu Gln Leu Asn Ser Val Thr Thr Glu Asp Thr Ala Thr Tyr Tyr Cys
85 90 95

30 Val Gly Gly Tyr Asp Asn Met Asp Tyr Trp Gly Gln Gly Thr Ser Val
100 105 110

Thr Val Ser Ser
115

35 <210> 163

<211> 108

<212> PRT

<213> *Mus musculus*

5 <400> 163

Gln Ile Val Leu Thr Gln Ser Pro Ala Ile Met Ser Ala Ser Pro Gly

1 5 10 15

Glu Lys Val Thr Leu Thr Cys Ser Ala Ser Ser Ser Val Ser Ser Ser

10 20 25 30

His Leu Tyr Trp Tyr Gln Gln Lys Pro Gly Ser Ser Pro Lys Leu Trp

35 40 45

15 Ile Tyr Ser Thr Ser Asn Leu Ala Ser Gly Val Pro Ala Arg Phe Ser

50 55 60

Gly Ser Gly Ser Gly Thr Ser Tyr Ser Leu Thr Ile Ser Asn Met Glu

65 70 75 80

20

Thr Glu Asp Ala Ala Ser Tyr Phe Cys His Gln Trp Ser Ser Tyr Pro

85 90 95

Trp Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys

25 100 105

<210> 164

<211> 1924

30 <212> DNA

<213> *Macaca fascicularis*

<220>

<221> CDS

35 <222> (11).. (1918)

<223>

<400> 164

	gaattccacc atg ccc tcc tgg gcc ctc ttc atg gtc acc tcc tgc ctc	49
	Met Pro Ser Trp Ala Leu Phe Met Val Thr Ser Cys Leu	
5	1 5 10	
	ctc ctg gcc cct caa aac ctg gcc caa gtc agc agc caa gat gtc tcc	97
	Leu Leu Ala Pro Gln Asn Leu Ala Gln Val Ser Ser Gln Asp Val Ser	
	15 20 25	
10		
	ttg ctg gcc tcg gac tca gag ccc ctg aag tgt ttc tcc cga aca ttt	145
	Leu Leu Ala Ser Asp Ser Glu Pro Leu Lys Cys Phe Ser Arg Thr Phe	
	30 35 40 45	
15		
	gag gac ctc act tgc ttc tgg gat gag gaa gag gca gca ccc agt ggg	193
	Glu Asp Leu Thr Cys Phe Trp Asp Glu Glu Glu Ala Ala Pro Ser Gly	
	50 55 60	
20		
	aca tac cag ctg ctg tat gcc tac ccg ggg gag aag ccc cgt gcc tgc	241
	Thr Tyr Gln Leu Leu Tyr Ala Tyr Pro Gly Glu Lys Pro Arg Ala Cys	
	65 70 75	
25		
	ccc ctg agt tct cag agc gtg ccc cgc ttt gga acc cga tac gtg tgc	289
	Pro Leu Ser Ser Gln Ser Val Pro Arg Phe Gly Thr Arg Tyr Val Cys	
	80 85 90	
30		
	cag ttt oca gcc cag gaa gaa gtg cgt ctc ttc tct ccg ctg cac ctc	337
	Gln Phe Pro Ala Gln Glu Glu Val Arg Leu Phe Ser Pro Leu His Leu	
	95 100 105	
35		
	tgg gtg aag aat gtg ttc cta aac cag act cag att cag cga gtc ctc	385
	Trp Val Lys Asn Val Phe Leu Asn Gln Thr Gln Ile Gln Arg Val Leu	
	110 115 120 125	
40		
	ttt gtg gac agt gta ggc ctg ccg gct ccc ccc agt atc atc aag gcc	433
	Phe Val Asp Ser Val Gly Leu Pro Ala Pro Pro Ser Ile Ile Lys Ala	

	130	135	140	
	atg ggt ggg agc cag cca ggg gaa ctt cag atc agc tgg gag gcc cca			481
	Met Gly Gly Ser Gln Pro Gly Glu Leu Gln Ile Ser Trp Glu Ala Pro			
5	145	150	155	
	gct cca gaa atc agt gat ttc ctg agg tac gaa ctc cgc tat ggc ccc			529
	Ala Pro Glu Ile Ser Asp Phe Leu Arg Tyr Glu Leu Arg Tyr Gly Pro			
	160	165	170	
10	aaa gat ctc aag aac tcc act ggt ccc acg gtc ata cag ttg atc gcc			577
	Lys Asp Leu Lys Asn Ser Thr Gly Pro Thr Val Ile Gln Leu Ile Ala			
	175	180	185	
15	aca gaa acc tgc tgc cct gct ctg cag agg cca cac tca gcc tct gct			625
	Thr Glu Thr Cys Cys Pro Ala Leu Gln Arg Pro His Ser Ala Ser Ala			
	190	195	200	205
	ctg gac cag tct cca tgt gct cag ccc aca atg ccc tgg caa gat gga			673
20	Leu Asp Gln Ser Pro Cys Ala Gln Pro Thr Met Pro Trp Gln Asp Gly			
	210	215	220	
	cca aag cag acc tcc cca act aga gaa gct tca gct ctg aca gca gtg			721
	Pro Lys Gln Thr Ser Pro Thr Arg Glu Ala Ser Ala Leu Thr Ala Val			
25	225	230	235	
	ggt gga agc tgc ctc atc tca gga ctc cag cct ggc aac tcc tac tgg			769
	Gly Gly Ser Cys Leu Ile Ser Gly Leu Gln Pro Gly Asn Ser Tyr Trp			
	240	245	250	
30	ctg cag ctg cgc agc gaa cct gat ggg atc tcc ctc ggt ggc tcc tgg			817
	Leu Gln Leu Arg Ser Glu Pro Asp Gly Ile Ser Leu Gly Gly Ser Trp			
	255	260	265	
35	gga tcc tgg tcc ctc cct gtg act gtg gac ctg cct gga gat gca gtg			865
	Gly Ser Trp Ser Leu Pro Val Thr Val Asp Leu Pro Gly Asp Ala Val			

	270	275	280	285	
	gca att gga ctg caa tgc ttt acc ttg gac ctg aag aat gtt acc tgt				913
	Ala Ile Gly Leu Gln Cys Phe Thr Leu Asp Leu Lys Asn Val Thr Cys				
5		290	295	300	
	caa tgg cag caa gag gac cat gct agt tcc caa ggt ttc ttc tac cac				961
	Gln Trp Gln Gln Glu Asp His Ala Ser Ser Gln Gly Phe Phe Tyr His				
		305	310	315	
10	agc agg gca cgg tgc tgc ccc aga gac agg tac ccc atc tgg gag gac				1009
	Ser Arg Ala Arg Cys Cys Pro Arg Asp Arg Tyr Pro Ile Trp Glu Asp				
		320	325	330	
15	tgt gaa gag gaa gag aaa aca aat cca gga tta cag acc cca cag ttc				1057
	Cys Glu Glu Glu Glu Lys Thr Asn Pro Gly Leu Gln Thr Pro Gln Phe				
		335	340	345	
	tct cgc tgc cac ttc aag tca cga aat gac agc gtt att cac atc ctt				1105
20	Ser Arg Cys His Phe Lys Ser Arg Asn Asp Ser Val Ile His Ile Leu				
		350	355	360	365
	gtg gag gtg acc aca gcc ctg ggt gct gtt cac agt tac ctg ggc tcc				1153
	Val Glu Val Thr Thr Ala Leu Gly Ala Val His Ser Tyr Leu Gly Ser				
25		370	375	380	
	cct ttc tgg atc cac cag gct gtg cgc ctc ccc acc cca aac ttg cac				1201
	Pro Phe Trp Ile His Gln Ala Val Arg Leu Pro Thr Pro Asn Leu His				
		385	390	395	
30	tgg agg gag atc tcc agc ggg cat ctg gaa ttg gag tgg cag cac cca				1249
	Trp Arg Glu Ile Ser Ser Gly His Leu Glu Leu Glu Trp Gln His Pro				
		400	405	410	
35	tca tcc tgg gca gcc caa gag acc tgc tat caa ctc cga tac aca gga				1297
	Ser Ser Trp Ala Ala Gln Glu Thr Cys Tyr Gln Leu Arg Tyr Thr Gly				

	415	420	425	
	gaa ggc cat cag gac tgg aag gtg ctg gag ccg cct ctc ggg gcc cga			1345
	Glu Gly His Gln Asp Trp Lys Val Leu Glu Pro Pro Leu Gly Ala Arg			
5	430	435	440	445
	gga ggg acc ctg gag ctg cgc ccg cga tct cgc tac cgt tta cag ctg			1393
	Gly Gly Thr Leu Glu Leu Arg Pro Arg Ser Arg Tyr Arg Leu Gln Leu			
10		450	455	460
	cgc gcc agg ctc aat ggc ccc acc tac caa ggt ccc tgg agc tcg tgg			1441
	Arg Ala Arg Leu Asn Gly Pro Thr Tyr Gln Gly Pro Trp Ser Ser Trp			
		465	470	475
15	tcg gac cca gct agg gtg gag acc gcc acc gag acc gcc tgg att tcc			1489
	Ser Asp Pro Ala Arg Val Glu Thr Ala Thr Glu Thr Ala Trp Ile Ser			
		480	485	490
	ttg gtg acc gct ctg ctg cta gtg ctg ggc ctc agc gcc gtc ctg ggc			1537
20	Leu Val Thr Ala Leu Leu Leu Val Leu Gly Leu Ser Ala Val Leu Gly			
		495	500	505
	ctg ctg ctg ctg agg tgg cag ttt cct gca cac tac agg aga ctg agg			1585
	Leu Leu Leu Leu Arg Trp Gln Phe Pro Ala His Tyr Arg Arg Leu Arg			
25	510	515	520	525
	cat gcc ctg tgg ccc tca ctt cca gat ctg cac cga gtc cta ggc cag			1633
	His Ala Leu Trp Pro Ser Leu Pro Asp Leu His Arg Val Leu Gly Gln			
		530	535	540
30	tac ctt agg gac act gca gcc ctg agt ccg ccc aag gcc aca gtc tca			1681
	Tyr Leu Arg Asp Thr Ala Ala Leu Ser Pro Pro Lys Ala Thr Val Ser			
		545	550	555
35	gat acc tgt gaa gaa gtg gaa ccc agc ctc ctt gaa atc ctc ccc aag			1729
	Asp Thr Cys Glu Glu Val Glu Pro Ser Leu Leu Glu Ile Leu Pro Lys			

	560	565	570	
	tcc tca gag agg act cct ttg ccc ctg tgt tcc tcc cag tcc cag atg			1777
	Ser Ser Glu Arg Thr Pro Leu Pro Leu Cys Ser Ser Gln Ser Gln Met			
5	575	580	585	
	gac tac cga aga ttg cag cct tct tgc ctg ggg acc atg ccc ctg tct			1825
	Asp Tyr Arg Arg Leu Gln Pro Ser Cys Leu Gly Thr Met Pro Leu Ser			
10	590	595	600	605
	gtg tgc cca ccc atg gct gag tca ggg tcc tgc tgt acc acc cac att			1873
	Val Cys Pro Pro Met Ala Glu Ser Gly Ser Cys Cys Thr Thr His Ile			
		610	615	620
15	gcc aac cat tcc tac cta cca cta agc tat tgg cag cag cct tga			1918
	Ala Asn His Ser Tyr Leu Pro Leu Ser Tyr Trp Gln Gln Pro			
		625	630	635
20	gtcgac			1924
	<210> 165			
	<211> 635			
	<212> PRT			
25	<213> <i>Macaca fascicularis</i>			
	<400> 165			
	Met Pro Ser Trp Ala Leu Phe Met Val Thr Ser Cys Leu Leu Leu Ala			
	1	5	10	15
30	Pro Gln Asn Leu Ala Gln Val Ser Ser Gln Asp Val Ser Leu Leu Ala			
		20	25	30
35	Ser Asp Ser Glu Pro Leu Lys Cys Phe Ser Arg Thr Phe Glu Asp Leu			
		35	40	45

Thr Cys Phe Trp Asp Glu Glu Glu Ala Ala Pro Ser Gly Thr Tyr Gln
 50 55 60

Leu Leu Tyr Ala Tyr Pro Gly Glu Lys Pro Arg Ala Cys Pro Leu Ser
 5 65 70 75 80

Ser Gln Ser Val Pro Arg Phe Gly Thr Arg Tyr Val Cys Gln Phe Pro
 85 90 95

10 Ala Gln Glu Glu Val Arg Leu Phe Ser Pro Leu His Leu Trp Val Lys
 100 105 110

Asn Val Phe Leu Asn Gln Thr Gln Ile Gln Arg Val Leu Phe Val Asp
 115 120 125

15 Ser Val Gly Leu Pro Ala Pro Pro Ser Ile Ile Lys Ala Met Gly Gly
 130 135 140

Ser Gln Pro Gly Glu Leu Gln Ile Ser Trp Glu Ala Pro Ala Pro Glu
 20 145 150 155 160

Ile Ser Asp Phe Leu Arg Tyr Glu Leu Arg Tyr Gly Pro Lys Asp Leu
 165 170 175

25 Lys Asn Ser Thr Gly Pro Thr Val Ile Gln Leu Ile Ala Thr Glu Thr
 180 185 190

Cys Cys Pro Ala Leu Gln Arg Pro His Ser Ala Ser Ala Leu Asp Gln
 195 200 205

30 Ser Pro Cys Ala Gln Pro Thr Met Pro Trp Gln Asp Gly Pro Lys Gln
 210 215 220

Thr Ser Pro Thr Arg Glu Ala Ser Ala Leu Thr Ala Val Gly Gly Ser
 35 225 230 235 240

Gln Asp Trp Lys Val Leu Glu Pro Pro Leu Gly Ala Arg Gly Gly Thr
 435 440 445

5 Leu Glu Leu Arg Pro Arg Ser Arg Tyr Arg Leu Gln Leu Arg Ala Arg
 450 455 460

Leu Asn Gly Pro Thr Tyr Gln Gly Pro Trp Ser Ser Trp Ser Asp Pro
 465 470 475 480

10 Ala Arg Val Glu Thr Ala Thr Glu Thr Ala Trp Ile Ser Leu Val Thr
 485 490 495

Ala Leu Leu Leu Val Leu Gly Leu Ser Ala Val Leu Gly Leu Leu Leu
 500 505 510

15 Leu Arg Trp Gln Phe Pro Ala His Tyr Arg Arg Leu Arg His Ala Leu
 515 520 525

Trp Pro Ser Leu Pro Asp Leu His Arg Val Leu Gly Gln Tyr Leu Arg
 20 530 535 540

Asp Thr Ala Ala Leu Ser Pro Pro Lys Ala Thr Val Ser Asp Thr Cys
 545 550 555 560

25 Glu Glu Val Glu Pro Ser Leu Leu Glu Ile Leu Pro Lys Ser Ser Glu
 565 570 575

Arg Thr Pro Leu Pro Leu Cys Ser Ser Gln Ser Gln Met Asp Tyr Arg
 580 585 590

30 Arg Leu Gln Pro Ser Cys Leu Gly Thr Met Pro Leu Ser Val Cys Pro
 595 600 605

Pro Met Ala Glu Ser Gly Ser Cys Cys Thr Thr His Ile Ala Asn His
 35 610 615 620

Ser Tyr Leu Pro Leu Ser Tyr Trp Gln Gln Pro
625 630 635

- 5 <210> 166
<211> 24
<212> DNA
<213> Artificial
- 10 <220>
<223> an artificially synthesized sequence
- <400> 166
caggggccag tggatagact gatg 24
- 15
- <210> 167
<211> 23
<212> DNA
20 <213> Artificial
- <220>
<223> an artificially synthesized sequence
- 25 <400> 167
gotcactgga tggtaggaag atg 23
- <210> 168
30 <211> 30
<212> DNA
<213> Artificial
- <220>
35 <223> an artificially synthesized primer sequence

<400> 168

tagaattcca ccatggaatg gcctttgatc

30

5 <210> 169

<211> 56

<212> DNA

<213> Artificial

10 <220>

<223> an artificially synthesized primer sequence

<400> 169

agcctgagtc atcacaatat ccgatccgcc tccacctgca gagacagtga ccagag

56

15

<210> 170

<211> 56

<212> DNA

20 <213> Artificial

<220>

<223> an artificially synthesized primer sequence

25 <400> 170

actctggcca ctgtctctgc aggtggaggc ggatcggata ttgtgatgac tcaggo

56

30 <210> 171

<211> 60

<212> DNA

<213> Artificial

<220>

35 <223> an artificially synthesized primer sequence

<400> 171

attgggccg cttatcactt atcgtcgtca tccttgtagt cttttatttc cagcttggtc 60

5 <210> 172

<211> 8

<212> PRT

<213> Artificial

10 <220>

<223> an artificially synthesized FLAG tag sequence

<400> 172

Asp Tyr Lys Asp Asp Asp Asp Lys

15 1 5

<210> 173

<211> 85

20 <212> DNA

<213> Artificial

<220>

<223> an artificially synthesized primer sequence

25

<400> 173

tagaattcca ccatggaatg gccttgatc tttctcttcc tcctgtcagg aactgcaggt 60

gtccactccc aggttcagct gcagc 85

30

<210> 174

<211> 82

<212> DNA

35 <213> Artificial

<220>

<223> an artificially synthesized primer sequence

<400> 174

5 tggtcactgt ctctgcaggt ggtggtggtt cgggtggtgg tggttcgggt ggtggcggat 60

oggatattgt gatgactcag gc 82

10 <210> 175

<211> 82

<212> DNA

<213> Artificial

15 <220>

<223> an artificially synthesized primer sequence

<400> 175

tgagtcatca caatatcoga tccgccacca cccgaaccac caccaccoga accaccacca 60

20

cctgcagaga cagtgaccag ag 82

<210> 176

25 <211> 25

<212> DNA

<213> Artificial

<220>

30 <223> an artificially synthesized primer sequence

<400> 176

caggttcagc tgcagcagtc tggac 25

35

<210> 177

<211> 81

<212> DNA

<213> Artificial

5 <220>

<223> an artificially synthesized primer sequence

<400> 177

gctgcagctg aacctgcgat ccaccgcctc ccgaaccacc accaccgat ccaccacctc 60

10

ctttatttc cagcttggtc c 81

<210> 178

15 <211> 38

<212> DNA

<213> Artificial

<220>

20 <223> an artificially synthesized primer sequence

<400> 178

gccagccgg ccatggcgga kgtrmagctt caggagtc 38

25

<210> 179

<211> 38

<212> DNA

<213> Artificial

30

<220>

<223> an artificially synthesized primer sequence

<400> 179

35 gccagccgg ccatggcgga ggtbcagctb caggagtc 38

<210> 180

<211> 38

<212> DNA

5 <213> Artificial

<220>

<223> an artificially synthesized primer sequence

10 <400> 180

gccagccgg ccatggcgca ggtgcagctg aagsastc

38

<210> 181

15 <211> 38

<212> DNA

<213> Artificial

<220>

20 <223> an artificially synthesized primer sequence

<400> 181

gccagccgg ccatggcgga ggtccarctg caacartc

38

25

<210> 182

<211> 38

<212> DNA

<213> Artificial

30

<220>

<223> an artificially synthesized primer sequence

<400> 182

35 gccagccgg ccatggcgca ggtycagctb cagcartc

38

<210> 183
<211> 38
<212> DNA
5 <213> Artificial

<220>
<223> an artificially synthesized primer sequence

10 <400> 183
gcccagccgg ccatggcgca ggtcarctg cagcagtc 38

<210> 184
15 <211> 38
<212> DNA
<213> Artificial

<220>
20 <223> an artificially synthesized primer sequence

<400> 184
gcccagccgg ccatggcgca ggtccacgtg aagcagtc 38

25

<210> 185
<211> 38
<212> DNA
<213> Artificial

30

<220>
<223> an artificially synthesized primer sequence

<400> 185
35 gcccagccgg ccatggcgga ggtgaasstg gtggaatc 38

<210> 186
<211> 38
<212> DNA
5 <213> Artificial

<220>
<223> an artificially synthesized primer sequence

10 <400> 186
gcccagccgg ccatggcgga vgtgawgytg gtggagtc 38

<210> 187
15 <211> 38
<212> DNA
<213> Artificial

<220>
20 <223> an artificially synthesized primer sequence

<400> 187
gcccagccgg ccatggcgga ggtgcagskg gtggagtc 38

25
<210> 188
<211> 38
<212> DNA
<213> Artificial

30
<220>
<223> an artificially synthesized primer sequence

<400> 188
35 gcccagccgg ccatggcgga kgtgcamctg gtggagtc 38

<210> 189
<211> 38
<212> DNA
5 <213> Artificial

<220>
<223> an artificially synthesized primer sequence

10 <400> 189
gcccagccgg ccatggcgga ggtgaagctg atggartc 38

<210> 190
15 <211> 38
<212> DNA
<213> Artificial

<220>
20 <223> an artificially synthesized primer sequence

<400> 190
gcccagccgg ccatggcgga ggtgcarctt gttgagtc 38

25 <210> 191
<211> 38
<212> DNA
<213> Artificial

30 <220>
<223> an artificially synthesized primer sequence

<400> 191
35 gcccagccgg ccatggcgga rgtraagctt ctcgagtc 38

<210> 192
<211> 38
<212> DNA
5 <213> Artificial

<220>
<223> an artificially synthesized primer sequence

10 <400> 192
gcccagccgg ccatggcgga agtgaarstt gaggagtc 38

<210> 193
15 <211> 40
<212> DNA
<213> Artificial

<220>
20 <223> an artificially synthesized primer sequence

<400> 193
gcccagccgg ccatggcgca ggttactctr aaagwgtstg 40

25
<210> 194
<211> 38
<212> DNA
<213> Artificial

30
<220>
<223> an artificially synthesized primer sequence

<400> 194
35 gcccagccgg ccatggcgca ggtccaactv cagcarcc 38

<210> 195
<211> 38
<212> DNA
5 <213> Artificial

<220>
<223> an artificially synthesized primer sequence

10 <400> 195
gcccagccgg ccatggcgga tgtgaacttg gaagtgtc 38

<210> 196
15 <211> 38
<212> DNA
<213> Artificial

<220>
20 <223> an artificially synthesized primer sequence

<400> 196
gcccagccgg ccatggcgga ggtgaaggtc atcgagtc 38

25
<210> 197
<211> 36
<212> DNA
<213> Artificial

30
<220>
<223> an artificially synthesized primer sequence

<400> 197
35 ggagccgccg ccgcccgagg aaacggtgac cgtggt 36

<210> 198
<211> 36
<212> DNA
5 <213> Artificial

<220>
<223> an artificially synthesized primer sequence

10 <400> 198
ggagccgccg ccgcccgagg agactgtgag agtggt 36

<210> 199
15 <211> 36
<212> DNA
<213> Artificial

<220>
20 <223> an artificially synthesized primer sequence

<400> 199
ggagccgccg ccgcccgcag agacagtgac cagagt 36

25
<210> 200
<211> 36
<212> DNA
<213> Artificial

30
<220>
<223> an artificially synthesized primer sequence

<400> 200
35 ggagccgccg ccgcccgagg agacggtgac tgaggt 36

<210> 201
<211> 35
<212> DNA
5 <213> Artificial

<220>
<223> an artificially synthesized primer sequence

10 <400> 201
ggcggcggcg gctccgayat ccagctgact cagcc 35

<210> 202
15 <211> 35
<212> DNA
<213> Artificial

<220>
20 <223> an artificially synthesized primer sequence

<400> 202
ggcggcggcg gctccgayat tgttctwcc cagtc 35

25

<210> 203
<211> 35
<212> DNA
<213> Artificial

30

<220>
<223> an artificially synthesized primer sequence

<400> 203
35 ggcggcggcg gctccgayat tgtgmtmact cagtc 35

<210> 204
<211> 35
<212> DNA
5 <213> Artificial

<220>
<223> an artificially synthesized primer sequence

10 <400> 204
ggcggcggcg gctccgayat tgtgytraca cagtc 35

<210> 205
15 <211> 35
<212> DNA
<213> Artificial

<220>
20 <223> an artificially synthesized primer sequence

<400> 205
ggcggcggcg gctccgayat tgtratgacm cagtc 35

25

<210> 206
<211> 35
<212> DNA
<213> Artificial

30

<220>
<223> an artificially synthesized primer sequence

<400> 206
35 ggcggcggcg gctccgayat tmagatramc cagtc 35

<210> 207
<211> 35
<212> DNA
5 <213> Artificial

<220>
<223> an artificially synthesized primer sequence

10 <400> 207
ggcggcggcg gctccgayat tcagatgayd cagtc 35

<210> 208
15 <211> 35
<212> DNA
<213> Artificial

<220>
20 <223> an artificially synthesized primer sequence

<400> 208
ggcggcggcg gctccgayat ycagatgaca cagac 35

25

<210> 209
<211> 35
<212> DNA
<213> Artificial

30

<220>
<223> an artificially synthesized primer sequence

<400> 209
35 ggcggcggcg gctccgayat tgttctcawc cagtc 35

<210> 210
<211> 35
<212> DNA
5 <213> Artificial

<220>
<223> an artificially synthesized primer sequence

10 <400> 210
ggcggcggcg gctccgayat tgggtsacc caatc 35

<210> 211
15 <211> 35
<212> DNA
<213> Artificial

<220>
20 <223> an artificially synthesized primer sequence

<400> 211
ggcggcggcg gctccgayat tstratgacc cartc 35

25

<210> 212
<211> 35
<212> DNA
<213> Artificial

30

<220>
<223> an artificially synthesized primer sequence

<400> 212
35 ggcggcggcg gctccgayrt tktgatgacc carac 35

<210> 213
<211> 35
<212> DNA
5 <213> Artificial

<220>
<223> an artificially synthesized primer sequence

10 <400> 213
ggcggcggcg gctccgayat tgtgatgacb cagkc 35

<210> 214
15 <211> 35
<212> DNA
<213> Artificial

<220>
20 <223> an artificially synthesized primer sequence

<400> 214
ggcggcggcg gctccgayat tgtgataacy cagga 35

25
<210> 215
<211> 35
<212> DNA
<213> Artificial

30
<220>
<223> an artificially synthesized primer sequence

<400> 215
35 ggcggcggcg gctccgayat tgtgatgacc cagwt 35

<210> 216
<211> 35
<212> DNA
5 <213> Artificial

<220>
<223> an artificially synthesized primer sequence

10 <400> 216
ggcggcggcg gctccgayat tgtgatgaca caacc 35

<210> 217
15 <211> 35
<212> DNA
<213> Artificial

<220>
20 <223> an artificially synthesized primer sequence

<400> 217
ggcggcggcg gctccgayat ttgctgact cagtc 35

25

<210> 218
<211> 38
<212> DNA
<213> Artificial

30

<220>
<223> an artificially synthesized primer sequence

<400> 218
35 ggcggcggcg gctccgatgc tgttgact caggaatc 38

<210> 219
<211> 36
<212> DNA
5 <213> Artificial

<220>
<223> an artificially synthesized primer sequence

10 <400> 219
ggaattcggc ccccgaggcc ttgattcca gcttgg 36

<210> 220
15 <211> 36
<212> DNA
<213> Artificial

<220>
20 <223> an artificially synthesized primer sequence

<400> 220
ggaattcggc ccccgaggcc tttattcca gcttgg 36

25

<210> 221
<211> 36
<212> DNA
<213> Artificial

30

<220>
<223> an artificially synthesized primer sequence

<400> 221
35 ggaattcggc ccccgaggcc tttattcca actttg 36

<210> 222
<211> 36
<212> DNA
5 <213> Artificial

<220>
<223> an artificially synthesized primer sequence

10 <400> 222
ggaattcggc ccccgaggcc ttcagctcca gcttgg 36

<210> 223
15 <211> 39
<212> DNA
<213> Artificial

<220>
20 <223> an artificially synthesized primer sequence

<400> 223
ggaattcggc ccccgaggcc cctaggacag tcagtttgg 39

25
<210> 224
<211> 27
<212> DNA
<213> Artificial

30
<220>
<223> an artificially synthesized sequence

<400> 224
35 ttactcggc cccagccggc catggcg 27

<210> 225
<211> 17
<212> DNA
5 <213> Artificial

<220>
<223> an artificially synthesized sequence

10 <400> 225
ggaattcggc ccccgag 17

<210> 226
15 <211> 20
<212> DNA
<213> Artificial

<220>
20 <223> an artificially synthesized sequence

<400> 226
tcacttacag gctcttact 20

25 <210> 227
<211> 20
<212> DNA
<213> Artificial

30 <220>
<223> an artificially synthesized sequence

<400> 227
35 caggtggggt cttcattcc 20

<210> 228

<211> 354

<212> DNA

5 <213> Homo sapiens

<400> 228

caggTgcagc tggTgcagtc tggacctgag gtgaagaagc ctggggcctc agtgaaggtc 60

10 tcttgcaagg cttctggata caccttcacc aactcctgga tgaactgggt gaggcagagg 120

cctggaaagg gtcttgagtg gatgggacgg atttatcctg gagatggaga aactatctac 180

aatgggaaat tcagggtcag agtcacgatt accgcgacg aatccacgag cacagcctac 240

15 atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagaggctat 300

gatgattact cgtttgctta ctggggccag ggaaccacgg tcaccgtctc ttca 354

20

<210> 229

<211> 118

<212> PRT

<213> Homo sapiens

25

<400> 229

Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Ala

1 5 10 15

30 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Ser

20 25 30

Trp Met Asn Trp Val Arg Gln Arg Pro Gly Lys Gly Leu Glu Trp Met

35 40 45

35

Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Ile Tyr Asn Gly Lys Phe

<210> 232
 <211> 14
 5 <212> PRT
 <213> Homo sapiens

<400> 232
 Trp Val Arg Gln Arg Pro Gly Lys Gly Leu Glu Trp Met Gly
 10 1 5 10

<210> 233
 <211> 17
 15 <212> PRT
 <213> Homo sapiens

<400> 233
 Arg Ile Tyr Pro Gly Asp Gly Glu Thr Ile Tyr Asn Gly Lys Phe Arg
 20 1 5 10 15

Val

25

<210> 234
 <211> 32
 <212> PRT
 <213> Homo sapiens

30

<400> 234
 Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu
 1 5 10 15

35 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg
 20 25 30

<210> 235
 <211> 9
 5 <212> PRT
 <213> Homo sapiens

<400> 235
 Gly Tyr Asp Asp Tyr Ser Phe Ala Tyr
 10 1 5

<210> 236
 <211> 11
 15 <212> PRT
 <213> Homo sapiens

<400> 236
 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 20 1 5 10

<210> 237
 <211> 336
 25 <212> DNA
 <213> Homo sapiens

<400> 237
 gatattgtga tgactcagtc tgcactctcc ctgcccgta cccctggaga gccggcctcc 60
 30 atctctgca ggtctagtaa gagtctcctg catagtaatg gcaaacactta cttgtattgg 120
 ttccagcaga agccaggga gtctccacag ctctgatct atcggatgtc caaccttgcc 180
 35 tcagggtcc ctgacaggtt cagtggcagt ggatcaggca cagcttttac actgaaaatc 240

agcagagtgg aggctgagga tgttggggtt tattactgca tgcaacatat agaatacct 300

tttacgttcg gccaaaggac caaactggaa atcaaa 336

5

<210> 238

<211> 112

<212> PRT

<213> Homo sapiens

10

<400> 238

Asp Ile Val Met Thr Gln Ser Ala Leu Ser Leu Pro Val Thr Pro Gly

1 5 10 15

15

Glu Pro Ala Ser Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser

20 25 30

Asn Gly Asn Thr Tyr Leu Tyr Trp Phe Gln Gln Lys Pro Gly Gln Ser

35 40 45

20

Pro Gln Leu Leu Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro

50 55 60

Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Lys Ile

25 65 70 75 80

Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His

85 90 95

30

Ile Glu Tyr Pro Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys

100 105 110

<210> 239

35

<211> 23

<212> PRT

<213> Homo sapiens

<400> 239

Asp Ile Val Met Thr Gln Ser Ala Leu Ser Leu Pro Val Thr Pro Gly

5 1 5 10 15

Glu Pro Ala Ser Ile Ser Cys

20

10

<210> 240

<211> 16

<212> PRT

<213> Homo sapiens

15

<400> 240

Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr

1 5 10 15

20

<210> 241

<211> 15

<212> PRT

<213> Homo sapiens

25

<400> 241

Trp Phe Gln Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr

1 5 10 15

30

<210> 242

<211> 7

<212> PRT

<213> Homo sapiens

35

<400> 242

Arg Met Ser Asn Leu Ala Ser

1 5

5 <210> 243

<211> 32

<212> PRT

<213> Homo sapiens

10 <400> 243

Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr

1 5 10 15

Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys

15 20 25 30

<210> 244

<211> 9

20 <212> PRT

<213> Homo sapiens

<400> 244

Met Gln His Ile Glu Tyr Pro Phe Thr

25 1 5

<210> 245

<211> 10

30 <212> PRT

<213> Homo sapiens

<400> 245

Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys

35 1 5 10

<210> 246

<211> 1924

<212> DNA

5 <213> Homo sapiens

<400> 246

	gaattccacc atgccctcct gggccctctt catggtcacc tctgcctcc tctggcccc	60
10	tcaaaacctg gcccaagtca gcagccaaga tgtctccttg ctggcatcag actcagagcc	120
	cctgaagtgt ttctccgaa catttgagga cctcacttgc ttctgggatg aggaagaggc	180
	aggccccagt gggacatacc agctgctgta tgcctaccgc cgggagaagc cccgtgcttg	240
15	ccccctgagt tcccagagca tgcccactt tggaaccoga tacgtgtgcc agtttccaga	300
	ccaggaggaa gtgcgtctct tctttcogct gcacctctgg gtgaagaatg ttttctaaa	360
20	ccagactcgg actcagcgag tctcttttgt ggacagtgta ggctgcgg ctccccccag	420
	tatcatcaag gccatgggtg ggagccagcc aggggaactt cagatcagct gggaggagcc	480
	agctccagaa atcagtgatt tctgaggta cgaactccgc tatggcccca gagatcccaa	540
25	gaactccact ggtccacgg tcatacagct gattgccaca gaaacctgct gccctgctct	600
	gcagagacct cactcagcct ctgctctgga ccagtctcca tgtgctcagc ccacaatgcc	660
30	ctggcaagat ggaccaaagc agacctcccc aagtagagaa gcttcagctc tgacagcaga	720
	gggtggaagc tgcctcatct caggactcca gcctggcaac tctactggc tgcagctgcg	780
	cagcgaacct gatgggatct ccctcgggtg ctctgggga tcttggccc tcctgtgac	840
35	tgtggacctg cctggagatg cagtggcact tggactgcaa tgctttacct tggacctgaa	900

gaatgttacc tgtcaatggc agcaacagga ccatgctagc tccaaggct tcttctacca 960
 cagcagggca cggctgctgc ccagagacag gtaccccatc tgggagaact gcaagagga 1020
 5 agagaaaaca aatccaggac tacagacccc acagttctct cgctgccact tcaagtcacg 1080
 aatgacagc attattcaca tccttgtgga ggtgaccaca gccccgggta ctgttcacag 1140
 10 ctacctgggc tcccctttct ggatccacca ggctgtgcgc ctccccacc caaacttgca 1200
 ctggagggag atctccagtg ggcatctgga attggagtgg cagcacccat cgtcctgggc 1260
 agcccaagag acctgttata aactccgata cacaggagaa ggccatcagg actggaaggt 1320
 15 gctggagccg cctctcgggg cccgaggagg gaccctggag ctgcgcccgc gatctcgcta 1380
 ccgtttacag ctgcgcgcca ggctcaacgg cccacctac caaggtccct ggagctcgtg 1440
 20 gtcggacca actagggtgg agaccgccac cgagaccgcc tggatctcct tggtgaccgc 1500
 tctgcatcta gtgctgggcc tcagcgccgt cctgggcctg ctgctgctga ggtggcagtt 1560
 tcctgcacac tacaggagac tgaggcatgc cctgtggccc tcacttcag acctgcaccg 1620
 25 ggtcctaggc cagtacctta gggacactgc agccctgagc ccgccaagg ccacagtctc 1680
 agatacctgt gaagaagtgg aaccagcct ccttgaatc ctccccagt cctcagagag 1740
 30 gactccttg ccctgtgtt cctcccaggc ccagatggac taccgaagat tgcagccttc 1800
 ttgctgggg accatgccc tgtctgtgtg cccacccatg gctgagtcag ggtcctgctg 1860
 taccaccac attgccaacc attcctacct accactaagc tattggcagc agccttgagt 1920
 35 cgac 1924

<210> 247
 <211> 1924
 5 <212> DNA
 <213> Homo sapiens

 <220>
 <221> CDS
 10 <222> (11)..(1918)
 <223>

 <400> 247
 gaattccacc atg ccc tcc tgg gcc ctc ttc atg gtc acc tcc tgc ctc 49
 15 Met Pro Ser Trp Ala Leu Phe Met Val Thr Ser Cys Leu
 1 5 10

 ctc ctg gcc cct caa aac ctg gcc caa gtc agc agc caa gat gtc tcc 97
 Leu Leu Ala Pro Gln Asn Leu Ala Gln Val Ser Ser Gln Asp Val Ser
 20 15 20 25

 ttg ctg gca tca gac tca gag ccc ctg aag tgt ttc tcc cga aca ttt 145
 Leu Leu Ala Ser Asp Ser Glu Pro Leu Lys Cys Phe Ser Arg Thr Phe
 30 35 40 45
 25
 gag gac ctc act tgc ttc tgg gat gag gaa gag gca gcg ccc agt ggg 193
 Glu Asp Leu Thr Cys Phe Trp Asp Glu Glu Glu Ala Ala Pro Ser Gly
 50 55 60

 30 aca tac cag ctg ctg tat gcc tac ccg cgg gag aag ccc cgt gct tgc 241
 Thr Tyr Gln Leu Leu Tyr Ala Tyr Pro Arg Glu Lys Pro Arg Ala Cys
 65 70 75

 ccc ctg agt tcc cag agc atg ccc cac ttt gga acc cga tac gtg tgc 289
 35 Pro Leu Ser Ser Gln Ser Met Pro His Phe Gly Thr Arg Tyr Val Cys
 80 85 90

cag ttt cca gac cag gag gaa gtg cct ctc ttc ttt ccg ctg cac ctc 337
 Gln Phe Pro Asp Gln Glu Glu Val Pro Leu Phe Phe Pro Leu His Leu
 95 100 105

5

tgg gtg aag aat gtg ttc cta aac cag act cgg act cag cga gtc ctc 385
 Trp Val Lys Asn Val Phe Leu Asn Gln Thr Arg Thr Gln Arg Val Leu
 110 115 120 125

10

ttt gtg gac agt gta ggc ctg ccg gct ccc ccc agt atc atc aag gcc 433
 Phe Val Asp Ser Val Gly Leu Pro Ala Pro Pro Ser Ile Ile Lys Ala
 130 135 140

15

atg ggt ggg agc cag cca ggg gaa ctt cag atc agc tgg gag gag cca 481
 Met Gly Gly Ser Gln Pro Gly Glu Leu Gln Ile Ser Trp Glu Glu Pro
 145 150 155

20

gct cca gaa atc agt gat ttc ctg agg tac gaa ctc cgc tat ggc ccc 529
 Ala Pro Glu Ile Ser Asp Phe Leu Arg Tyr Glu Leu Arg Tyr Gly Pro
 160 165 170

25

aga gat ccc aag aac tcc act ggt ccc acg gtc ata cag ctg att gcc 577
 Arg Asp Pro Lys Asn Ser Thr Gly Pro Thr Val Ile Gln Leu Ile Ala
 175 180 185

30

aca gaa acc tgc tgc cct gct ctg cag aga cct cac tca gcc tct gct 625
 Thr Glu Thr Cys Cys Pro Ala Leu Gln Arg Pro His Ser Ala Ser Ala
 190 195 200 205

35

ctg gac cag tct cca tgt gct cag ccc aca atg ccc tgg caa gat gga 673
 Leu Asp Gln Ser Pro Cys Ala Gln Pro Thr Met Pro Trp Gln Asp Gly
 210 215 220

35

cca aag cag acc tcc cca agt aga gaa gct tca gct ctg aca gca gag 721
 Pro Lys Gln Thr Ser Pro Ser Arg Glu Ala Ser Ala Leu Thr Ala Glu
 225 230 235

	ggt gga agc tgc ctc atc tca gga ctc cag cct ggc aac tcc tac tgg	769
	Gly Gly Ser Cys Leu Ile Ser Gly Leu Gln Pro Gly Asn Ser Tyr Trp	
	240 245 250	
5	ctg cag ctg cgc agc gaa cct gat ggg atc tcc ctc ggt ggc tcc tgg	817
	Leu Gln Leu Arg Ser Glu Pro Asp Gly Ile Ser Leu Gly Gly Ser Trp	
	255 260 265	
10	gga tcc tgg tcc ctc cct gtg act gtg gac ctg cct gga gat gca gtg	865
	Gly Ser Trp Ser Leu Pro Val Thr Val Asp Leu Pro Gly Asp Ala Val	
	270 275 280 285	
	gca ctt gga ctg caa tgc ttt acc ttg gac ctg aag aat gtt acc tgt	913
15	Ala Leu Gly Leu Gln Cys Phe Thr Leu Asp Leu Lys Asn Val Thr Cys	
	290 295 300	
	caa tgg cag caa cag gac cat gct agc tcc caa ggc ttc ttc tac cac	961
	Gln Trp Gln Gln Gln Asp His Ala Ser Ser Gln Gly Phe Phe Tyr His	
20	305 310 315	
	agc agg gca cgg tgc tgc ccc aga gac agg tac ccc atc tgg gag aac	1009
	Ser Arg Ala Arg Cys Cys Pro Arg Asp Arg Tyr Pro Ile Trp Glu Asn	
	320 325 330	
25	tgc gaa gag gaa gag aaa aca aat cca gga cta cag acc cca cag ttc	1057
	Cys Glu Glu Glu Glu Lys Thr Asn Pro Gly Leu Gln Thr Pro Gln Phe	
	335 340 345	
30	tct cgc tgc cac ttc aag tca cga aat gac agc att att cac atc ctt	1105
	Ser Arg Cys His Phe Lys Ser Arg Asn Asp Ser Ile Ile His Ile Leu	
	350 355 360 365	
	gtg gag gtg acc aca gcc ccg ggt act gtt cac agc tac ctg ggc tcc	1153
35	Val Glu Val Thr Thr Ala Pro Gly Thr Val His Ser Tyr Leu Gly Ser	
	370 375 380	

cct ttc tgg atc cac cag gct gtg cgc ctc ccc acc cca aac ttg cac 1201
 Pro Phe Trp Ile His Gln Ala Val Arg Leu Pro Thr Pro Asn Leu His
 385 390 395

5

tgg agg gag atc tcc agt ggg cat ctg gaa ttg gag tgg cag cac cca 1249
 Trp Arg Glu Ile Ser Ser Gly His Leu Glu Leu Glu Trp Gln His Pro
 400 405 410

10

tcg tcc tgg gca gcc caa gag acc tgt tat caa ctc cga tac aca gga 1297
 Ser Ser Trp Ala Ala Gln Glu Thr Cys Tyr Gln Leu Arg Tyr Thr Gly
 415 420 425

gaa ggc cat cag gac tgg aag gtg ctg gag cgg cct ctc ggg gcc cga 1345
 15 Glu Gly His Gln Asp Trp Lys Val Leu Glu Pro Pro Leu Gly Ala Arg
 430 435 440 445

gga ggg acc ctg gag ctg cgc cgg cga tct cgc tac cgt tta cag ctg 1393
 20 Gly Gly Thr Leu Glu Leu Arg Pro Arg Ser Arg Tyr Arg Leu Gln Leu
 450 455 460

cgc gcc agg ctc aac ggc ccc acc tac caa ggt ccc tgg agc tcg tgg 1441
 Arg Ala Arg Leu Asn Gly Pro Thr Tyr Gln Gly Pro Trp Ser Ser Trp
 465 470 475

25

tcg gac cca act agg gtg gag acc gcc acc gag acc gcc tgg atc tcc 1489
 Ser Asp Pro Thr Arg Val Glu Thr Ala Thr Glu Thr Ala Trp Ile Ser
 480 485 490

30

ttg gtg acc gct ctg cat cta gtg ctg ggc ctc agc gcc gtc ctg ggc 1537
 Leu Val Thr Ala Leu His Leu Val Leu Gly Leu Ser Ala Val Leu Gly
 495 500 505

ctg ctg ctg ctg agg tgg cag ttt cct gca cac tac agg aga ctg agg 1585
 35 Leu Leu Leu Leu Arg Trp Gln Phe Pro Ala His Tyr Arg Arg Leu Arg
 510 515 520 525

	cat gcc ctg tgg ccc tca ctt cca gac ctg cac cgg gtc cta ggc cag	1633
	His Ala Leu Trp Pro Ser Leu Pro Asp Leu His Arg Val Leu Gly Gln	
	530 535 540	
5	tac ctt agg gac act gca gcc ctg agc ccg ccc aag gcc aca gtc tca	1681
	Tyr Leu Arg Asp Thr Ala Ala Leu Ser Pro Pro Lys Ala Thr Val Ser	
	545 550 555	
10	gat acc tgt gaa gaa gtg gaa ccc agc ctc ctt gaa atc ctc ccc aag	1729
	Asp Thr Cys Glu Glu Val Glu Pro Ser Leu Leu Glu Ile Leu Pro Lys	
	560 565 570	
	tcc tca gag agg act cct ttg ccc ctg tgt tcc tcc cag gcc cag atg	1777
15	Ser Ser Glu Arg Thr Pro Leu Pro Leu Cys Ser Ser Gln Ala Gln Met	
	575 580 585	
	gac tac cga aga ttg cag cct tct tgc ctg ggg acc atg ccc ctg tct	1825
	Asp Tyr Arg Arg Leu Gln Pro Ser Cys Leu Gly Thr Met Pro Leu Ser	
20	590 595 600 605	
	gtg tgc cca ccc atg gct gag tca ggg tcc tgc tgt acc acc cac att	1873
	Val Cys Pro Pro Met Ala Glu Ser Gly Ser Cys Cys Thr Thr His Ile	
	610 615 620	
25	gcc aac cat tcc tac cta cca cta agc tat tgg cag cag cct tga	1918
	Ala Asn His Ser Tyr Leu Pro Leu Ser Tyr Trp Gln Gln Pro	
	625 630 635	
30	gtcgac	1924
	<210> 248	
	<211> 635	
35	<212> PRT	
	<213> Homo sapiens	

<400> 248

Met Pro Ser Trp Ala Leu Phe Met Val Thr Ser Cys Leu Leu Leu Ala
 1 5 10 15

5

Pro Gln Asn Leu Ala Gln Val Ser Ser Gln Asp Val Ser Leu Leu Ala
 20 25 30

10

Ser Asp Ser Glu Pro Leu Lys Cys Phe Ser Arg Thr Phe Glu Asp Leu
 35 40 45

Thr Cys Phe Trp Asp Glu Glu Glu Ala Ala Pro Ser Gly Thr Tyr Gln
 50 55 60

15

Leu Leu Tyr Ala Tyr Pro Arg Glu Lys Pro Arg Ala Cys Pro Leu Ser
 65 70 75 80

Ser Gln Ser Met Pro His Phe Gly Thr Arg Tyr Val Cys Gln Phe Pro
 85 90 95

20

Asp Gln Glu Glu Val Pro Leu Phe Phe Pro Leu His Leu Trp Val Lys
 100 105 110

Asn Val Phe Leu Asn Gln Thr Arg Thr Gln Arg Val Leu Phe Val Asp
 25 115 120 125

Ser Val Gly Leu Pro Ala Pro Pro Ser Ile Ile Lys Ala Met Gly Gly
 130 135 140

30

Ser Gln Pro Gly Glu Leu Gln Ile Ser Trp Glu Glu Pro Ala Pro Glu
 145 150 155 160

Ile Ser Asp Phe Leu Arg Tyr Glu Leu Arg Tyr Gly Pro Arg Asp Pro
 165 170 175

35

Lys Asn Ser Thr Gly Pro Thr Val Ile Gln Leu Ile Ala Thr Glu Thr

	180		185		190
	Cys Cys Pro Ala Leu Gln Arg Pro His Ser Ala Ser Ala Leu Asp Gln				
	195		200		205
5	Ser Pro Cys Ala Gln Pro Thr Met Pro Trp Gln Asp Gly Pro Lys Gln				
	210		215		220
	Thr Ser Pro Ser Arg Glu Ala Ser Ala Leu Thr Ala Glu Gly Gly Ser				
10	225		230		235 240
	Cys Leu Ile Ser Gly Leu Gln Pro Gly Asn Ser Tyr Trp Leu Gln Leu				
		245		250	255
15	Arg Ser Glu Pro Asp Gly Ile Ser Leu Gly Gly Ser Trp Gly Ser Trp				
	260		265		270
	Ser Leu Pro Val Thr Val Asp Leu Pro Gly Asp Ala Val Ala Leu Gly				
	275		280		285
20	Leu Gln Cys Phe Thr Leu Asp Leu Lys Asn Val Thr Cys Gln Trp Gln				
	290		295		300
	Gln Gln Asp His Ala Ser Ser Gln Gly Phe Phe Tyr His Ser Arg Ala				
25	305		310		315 320
	Arg Cys Cys Pro Arg Asp Arg Tyr Pro Ile Trp Glu Asn Cys Glu Glu				
		325		330	335
30	Glu Glu Lys Thr Asn Pro Gly Leu Gln Thr Pro Gln Phe Ser Arg Cys				
	340		345		350
	His Phe Lys Ser Arg Asn Asp Ser Ile Ile His Ile Leu Val Glu Val				
	355		360		365
35	Thr Thr Ala Pro Gly Thr Val His Ser Tyr Leu Gly Ser Pro Phe Trp				

	370		375		380	
	Ile His Gln Ala Val Arg Leu Pro Thr Pro Asn Leu His Trp Arg Glu					
	385		390		395	400
5	Ile Ser Ser Gly His Leu Glu Leu Glu Trp Gln His Pro Ser Ser Trp					
		405		410		415
	Ala Ala Gln Glu Thr Cys Tyr Gln Leu Arg Tyr Thr Gly Glu Gly His					
10		420		425		430
	Gln Asp Trp Lys Val Leu Glu Pro Pro Leu Gly Ala Arg Gly Gly Thr					
		435		440		445
15	Leu Glu Leu Arg Pro Arg Ser Arg Tyr Arg Leu Gln Leu Arg Ala Arg					
		450		455		460
	Leu Asn Gly Pro Thr Tyr Gln Gly Pro Trp Ser Ser Trp Ser Asp Pro					
20			470		475	480
	Thr Arg Val Glu Thr Ala Thr Glu Thr Ala Trp Ile Ser Leu Val Thr					
		485		490		495
	Ala Leu His Leu Val Leu Gly Leu Ser Ala Val Leu Gly Leu Leu Leu					
25		500		505		510
	Leu Arg Trp Gln Phe Pro Ala His Tyr Arg Arg Leu Arg His Ala Leu					
		515		520		525
30	Trp Pro Ser Leu Pro Asp Leu His Arg Val Leu Gly Gln Tyr Leu Arg					
		530		535		540
	Asp Thr Ala Ala Leu Ser Pro Pro Lys Ala Thr Val Ser Asp Thr Cys					
35		545		550		555
	Glu Glu Val Glu Pro Ser Leu Leu Glu Ile Leu Pro Lys Ser Ser Glu					

	565	570	575	
	Arg Thr Pro Leu Pro Leu Cys Ser Ser Gln Ala Gln Met Asp Tyr Arg			
	580	585	590	
5	Arg Leu Gln Pro Ser Cys Leu Gly Thr Met Pro Leu Ser Val Cys Pro			
	595	600	605	
10	Pro Met Ala Glu Ser Gly Ser Cys Cys Thr Thr His Ile Ala Asn His			
	610	615	620	
	Ser Tyr Leu Pro Leu Ser Tyr Trp Gln Gln Pro			
	625	630	635	
15	<210> 249			
	<211> 1924			
	<212> DNA			
	<213> Homo sapiens			
20	<220>			
	<221> CDS			
	<222> (11).. (1918)			
	<223>			
25	<400> 249			
	gaattccacc atg ccc tcc tgg gcc ctc ttc atg gtc acc tcc tgc ctc			49
	Met Pro Ser Trp Ala Leu Phe Met Val Thr Ser Cys Leu			
	1 5 10			
30	ctc ctg gcc cct caa aac ctg gcc caa gtc agc agc caa gat gtc tcc			97
	Leu Leu Ala Pro Gln Asn Leu Ala Gln Val Ser Ser Gln Asp Val Ser			
	15 20 25			
35	ttg ctg gca tca gac tca gag ccc ctg aag tgt ttc tcc cga aca ttt			145
	Leu Leu Ala Ser Asp Ser Glu Pro Leu Lys Cys Phe Ser Arg Thr Phe			

	30	35	40	45	
	gag gac ctc act tgc ttc tgg gat gag gaa gag gca gcg ccc agt ggg				193
	Glu Asp Leu Thr Cys Phe Trp Asp Glu Glu Glu Ala Ala Pro Ser Gly				
5		50	55	60	
	aca tac cag ctg ctg tat gcc tac ccg cgg gag aag ccc cgt gct tgc				241
	Thr Tyr Gln Leu Leu Tyr Ala Tyr Pro Arg Glu Lys Pro Arg Ala Cys				
		65	70	75	
10	ccc ctg agt tcc cag agc atg ccc cac ttt gga acc cga tac gtg tgc				289
	Pro Leu Ser Ser Gln Ser Met Pro His Phe Gly Thr Arg Tyr Val Cys				
		80	85	90	
15	cag ttt cca gac cag gag gaa gtg cgt ctc ttc ttt ccg ctg cac ctc				337
	Gln Phe Pro Asp Gln Glu Glu Val Arg Leu Phe Phe Pro Leu His Leu				
		95	100	105	
	tgg gtg aag aat gtg ttc cta aac cag act cgg act cag cga gtc ctc				385
20	Trp Val Lys Asn Val Phe Leu Asn Gln Thr Arg Thr Gln Arg Val Leu				
		110	115	120	125
	ttt gtg gac agt gta ggc ctg ccg gct ccc ccc agt atc atc aag gcc				433
	Phe Val Asp Ser Val Gly Leu Pro Ala Pro Pro Ser Ile Ile Lys Ala				
25		130	135	140	
	atg ggt ggg agc cag cca ggg gaa ctt cag atc agc tgg gag gag cca				481
	Met Gly Gly Ser Gln Pro Gly Glu Leu Gln Ile Ser Trp Glu Glu Pro				
		145	150	155	
30	gct cca gaa atc agt gat ttc ctg agg tac gaa ctc cgc tat ggc ccc				529
	Ala Pro Glu Ile Ser Asp Phe Leu Arg Tyr Glu Leu Arg Tyr Gly Pro				
		160	165	170	
35	aga gat ccc aag aac tcc act ggt ccc acg gtc ata cag ctg att gcc				577
	Arg Asp Pro Lys Asn Ser Thr Gly Pro Thr Val Ile Gln Leu Ile Ala				

	175	180	185	
	aca gaa acc tgc tgc cct gct ctg cag aga cct cac tca gcc tct gct			625
	Thr Glu Thr Cys Cys Pro Ala Leu Gln Arg Pro His Ser Ala Ser Ala			
5	190	195	200	205
	ctg gac cag tct cca tgt gct cag ccc aca atg ccc tgg caa gat gga			673
	Leu Asp Gln Ser Pro Cys Ala Gln Pro Thr Met Pro Trp Gln Asp Gly			
10		210	215	220
	cca aag cag acc tcc cca agt aga gaa gct tca gct ctg aca gca gag			721
	Pro Lys Gln Thr Ser Pro Ser Arg Glu Ala Ser Ala Leu Thr Ala Glu			
		225	230	235
15	ggt gga agc tgc ctc atc tca gga ctc cag cct ggc aac tcc tac tgg			769
	Gly Gly Ser Cys Leu Ile Ser Gly Leu Gln Pro Gly Asn Ser Tyr Trp			
		240	245	250
	ctg cag ctg tgc agc gaa cct gat ggg atc tcc ctc ggt ggc tcc tgg			817
20	Leu Gln Leu Cys Ser Glu Pro Asp Gly Ile Ser Leu Gly Gly Ser Trp			
		255	260	265
	gga tcc tgg tcc ctc cct gtg act gtg gac ctg cct gga gat gca gtg			865
	Gly Ser Trp Ser Leu Pro Val Thr Val Asp Leu Pro Gly Asp Ala Val			
25	270	275	280	285
	gca ctt gga ctg caa tgc ttt acc ttg gac ctg aag aat gtt acc tgt			913
	Ala Leu Gly Leu Gln Cys Phe Thr Leu Asp Leu Lys Asn Val Thr Cys			
		290	295	300
30	caa tgg cag caa cag gac cat gct agc tcc caa ggc ttc ttc tac cac			961
	Gln Trp Gln Gln Gln Asp His Ala Ser Ser Gln Gly Phe Phe Tyr His			
		305	310	315
35	agc agg gca cgg tgc tgc ccc aga gac agg tac ccc atc tgg gag aac			1009
	Ser Arg Ala Arg Cys Cys Pro Arg Asp Arg Tyr Pro Ile Trp Glu Asn			

	320	325	330	
	tgc gaa gag gaa gag aaa aca aat cca gga cta cag acc cca cag ttc			1057
	Cys Glu Glu Glu Glu Lys Thr Asn Pro Gly Leu Gln Thr Pro Gln Phe			
5	335	340	345	
	tct cgc tgc cac ttc aag tca cga aat gac agc att att cac atc ctt			1105
	Ser Arg Cys His Phe Lys Ser Arg Asn Asp Ser Ile Ile His Ile Leu			
	350	355	360	365
10				
	gtg gag gtg acc aca gcc ccg ggt act gtt cac agc tac ctg ggc tcc			1153
	Val Glu Val Thr Thr Ala Pro Gly Thr Val His Ser Tyr Leu Gly Ser			
		370	375	380
15				
	oct ttc tgg atc cac cag gct gtg cgc ctc ccc acc cca aac ttg cac			1201
	Pro Phe Trp Ile His Gln Ala Val Arg Leu Pro Thr Pro Asn Leu His			
		385	390	395
	tgg agg gag atc tcc agt ggg cat ctg gaa ttg gag tgg cag cac cca			1249
20	Trp Arg Glu Ile Ser Ser Gly His Leu Glu Leu Glu Trp Gln His Pro			
		400	405	410
	tcg tcc tgg gca gcc caa gag acc tgt tat caa ctc cga tac aca gga			1297
	Ser Ser Trp Ala Ala Gln Glu Thr Cys Tyr Gln Leu Arg Tyr Thr Gly			
25	415	420	425	
	gaa ggc cat cag gac tgg aag gtg ctg gag ccg cct ctc ggg gcc cga			1345
	Glu Gly His Gln Asp Trp Lys Val Leu Glu Pro Pro Leu Gly Ala Arg			
	430	435	440	445
30				
	gga ggg acc ctg gag ctg cgc ccg cga tct cgc tac cgt tta cag ctg			1393
	Gly Gly Thr Leu Glu Leu Arg Pro Arg Ser Arg Tyr Arg Leu Gln Leu			
		450	455	460
35				
	cgc gcc agg ctc aac ggc ccc acc tac caa ggt ccc tgg agc tcg tgg			1441
	Arg Ala Arg Leu Asn Gly Pro Thr Tyr Gln Gly Pro Trp Ser Ser Trp			

	465	470	475	
	tcg gac cca act agg gtg gag acc gcc acc gag acc gcc tgg atc tcc			1489
	Ser Asp Pro Thr Arg Val Glu Thr Ala Thr Glu Thr Ala Trp Ile Ser			
5	480	485	490	
	ttg gtg acc gct ctg cat cta gtg ctg ggc ctc agc gcc gtc ctg ggc			1537
	Leu Val Thr Ala Leu His Leu Val Leu Gly Leu Ser Ala Val Leu Gly			
	495	500	505	
10				
	ctg ctg ctg ctg agg tgg cag ttt cct gca cac tac agg aga ctg agg			1585
	Leu Leu Leu Leu Arg Trp Gln Phe Pro Ala His Tyr Arg Arg Leu Arg			
	510	515	520	525
15				
	cat gcc ctg tgg ccc tca ctt cca gac ctg cac cgg gtc cta ggc cag			1633
	His Ala Leu Trp Pro Ser Leu Pro Asp Leu His Arg Val Leu Gly Gln			
	530	535	540	
20				
	tac ctt agg gac act gca gcc ctg agc ccg ccc aag gcc aca gtc tca			1681
	Tyr Leu Arg Asp Thr Ala Ala Leu Ser Pro Pro Lys Ala Thr Val Ser			
	545	550	555	
25				
	gat acc tgt gaa gaa gtg gaa ccc agc ctc ctt gaa atc ctc ccc aag			1729
	Asp Thr Cys Glu Glu Val Glu Pro Ser Leu Leu Glu Ile Leu Pro Lys			
	560	565	570	
30				
	tcc tca gag agg act cct ttg ccc ctg tgt tcc tcc cag gcc cag atg			1777
	Ser Ser Glu Arg Thr Pro Leu Pro Leu Cys Ser Ser Gln Ala Gln Met			
	575	580	585	
35				
	gac tac cga aga ttg cag cct tct tgc ctg ggg acc atg ccc ctg tct			1825
	Asp Tyr Arg Arg Leu Gln Pro Ser Cys Leu Gly Thr Met Pro Leu Ser			
	590	595	600	605
35				
	gtg tgc cca ccc atg gct gag tca ggg tcc tgc tgt acc acc cac att			1873
	Val Cys Pro Pro Met Ala Glu Ser Gly Ser Cys Cys Thr Thr His Ile			

	610	615	620	
	gcc aac cat tcc tac cta cca cta agc tat tgg cag cag cct tga			1918
	Ala Asn His Ser Tyr Leu Pro Leu Ser Tyr Trp Gln Gln Pro			
5	625	630	635	
	gtcgcac			1924
10	<210> 250			
	<211> 635			
	<212> PRT			
	<213> Homo sapiens			
15	<400> 250			
	Met Pro Ser Trp Ala Leu Phe Met Val Thr Ser Cys Leu Leu Leu Ala			
	1	5	10	15
	Pro Gln Asn Leu Ala Gln Val Ser Ser Gln Asp Val Ser Leu Leu Ala			
20	20	25	30	
	Ser Asp Ser Glu Pro Leu Lys Cys Phe Ser Arg Thr Phe Glu Asp Leu			
	35	40	45	
25	Thr Cys Phe Trp Asp Glu Glu Glu Ala Ala Pro Ser Gly Thr Tyr Gln			
	50	55	60	
	Leu Leu Tyr Ala Tyr Pro Arg Glu Lys Pro Arg Ala Cys Pro Leu Ser			
	65	70	75	80
30	Ser Gln Ser Met Pro His Phe Gly Thr Arg Tyr Val Cys Gln Phe Pro			
	85	90	95	
	Asp Gln Glu Glu Val Arg Leu Phe Phe Pro Leu His Leu Trp Val Lys			
35	100	105	110	

Asn Val Phe Leu Asn Gln Thr Arg Thr Gln Arg Val Leu Phe Val Asp
 115 120 125

Ser Val Gly Leu Pro Ala Pro Pro Ser Ile Ile Lys Ala Met Gly Gly
 5 130 135 140

Ser Gln Pro Gly Glu Leu Gln Ile Ser Trp Glu Glu Pro Ala Pro Glu
 145 150 155 160

10 Ile Ser Asp Phe Leu Arg Tyr Glu Leu Arg Tyr Gly Pro Arg Asp Pro
 165 170 175

Lys Asn Ser Thr Gly Pro Thr Val Ile Gln Leu Ile Ala Thr Glu Thr
 180 185 190

15 Cys Cys Pro Ala Leu Gln Arg Pro His Ser Ala Ser Ala Leu Asp Gln
 195 200 205

Ser Pro Cys Ala Gln Pro Thr Met Pro Trp Gln Asp Gly Pro Lys Gln
 20 210 215 220

Thr Ser Pro Ser Arg Glu Ala Ser Ala Leu Thr Ala Glu Gly Gly Ser
 225 230 235 240

25 Cys Leu Ile Ser Gly Leu Gln Pro Gly Asn Ser Tyr Trp Leu Gln Leu
 245 250 255

Cys Ser Glu Pro Asp Gly Ile Ser Leu Gly Gly Ser Trp Gly Ser Trp
 260 265 270

30 Ser Leu Pro Val Thr Val Asp Leu Pro Gly Asp Ala Val Ala Leu Gly
 275 280 285

Leu Gln Cys Phe Thr Leu Asp Leu Lys Asn Val Thr Cys Gln Trp Gln
 35 290 295 300

Ala Leu His Leu Val Leu Gly Leu Ser Ala Val Leu Gly Leu Leu Leu
500 505 510

Leu Arg Trp Gln Phe Pro Ala His Tyr Arg Arg Leu Arg His Ala Leu
5 515 520 525

Trp Pro Ser Leu Pro Asp Leu His Arg Val Leu Gly Gln Tyr Leu Arg
530 535 540

10 Asp Thr Ala Ala Leu Ser Pro Pro Lys Ala Thr Val Ser Asp Thr Cys
545 550 555 560

Glu Glu Val Glu Pro Ser Leu Leu Glu Ile Leu Pro Lys Ser Ser Glu
565 570 575

15 Arg Thr Pro Leu Pro Leu Cys Ser Ser Gln Ala Gln Met Asp Tyr Arg
580 585 590

Arg Leu Gln Pro Ser Cys Leu Gly Thr Met Pro Leu Ser Val Cys Pro
20 595 600 605

Pro Met Ala Glu Ser Gly Ser Cys Cys Thr Thr His Ile Ala Asn His
610 615 620

25 Ser Tyr Leu Pro Leu Ser Tyr Trp Gln Gln Pro
625 630 635

<210> 251
30 <211> 1924
<212> DNA
<213> Homo sapiens

<220>
35 <221> CDS
<222> (1)..(1918)

<223>

<400> 251

	gaattccacc atg ccc tcc tgg gcc ctc ttc atg gtc acc tcc tgc ctc	49
5	Met Pro Ser Trp Ala Leu Phe Met Val Thr Ser Cys Leu	
	1 5 10	
	ctc ctg gcc cct caa aac ctg gcc caa gtc agc agc caa gat gtc tcc	97
10	Leu Leu Ala Pro Gln Asn Leu Ala Gln Val Ser Ser Gln Asp Val Ser	
	15 20 25	
	ttg ctg gca tca gac tca gag ccc ctg aag tgt ttc tcc cga aca ttt	145
15	Leu Leu Ala Ser Asp Ser Glu Pro Leu Lys Cys Phe Ser Arg Thr Phe	
	30 35 40 45	
	gag gac ctc act tgc ttc tgg gat gag gaa gag gca gcg ccc agt ggg	193
20	Glu Asp Leu Thr Cys Phe Trp Asp Glu Glu Glu Ala Ala Pro Ser Gly	
	50 55 60	
	aca tac cag ctg ctg tat gcc tac ccg cgg gag aag ccc cgt gct tgc	241
25	Thr Tyr Gln Leu Leu Tyr Ala Tyr Pro Arg Glu Lys Pro Arg Ala Cys	
	65 70 75	
	ccc ctg agt tcc cag agc atg ccc cac ttt gga acc cga tac gtg tgc	289
30	Pro Leu Ser Ser Gln Ser Met Pro His Phe Gly Thr Arg Tyr Val Cys	
	80 85 90	
	cag ttt cca gac cag gag gaa gtg cgt ctc ttc ttt ccg ctg cac ctc	337
35	Gln Phe Pro Asp Gln Glu Glu Val Arg Leu Phe Phe Pro Leu His Leu	
	95 100 105	
	tgg gtg aag aat gtg ttc cta aac cag act cgg act cag cga gtc ctc	385
35	Trp Val Lys Asn Val Phe Leu Asn Gln Thr Arg Thr Gln Arg Val Leu	
	110 115 120 125	
	ttt gtg gac agt gta ggc ctg ccg gct ccc ccc agt atc atc aag gcc	433

	Phe Val Asp Ser Val Gly Leu Pro Ala Pro Pro Ser Ile Ile Lys Ala	
	130 135 140	
	atg ggt ggg agc cag cca ggg gaa ctt cag atc agc tgg gag gag cca	481
5	Met Gly Gly Ser Gln Pro Gly Glu Leu Gln Ile Ser Trp Glu Glu Pro	
	145 150 155	
	gct cca gaa atc agt gat ttc ctg agg tac gaa ctc cgc tat ggc ccc	529
10	Ala Pro Glu Ile Ser Asp Phe Leu Arg Tyr Glu Leu Arg Tyr Gly Pro	
	160 165 170	
	aga gat ccc aag aac tcc act ggt ccc acg gtc ata cag ctg att gcc	577
15	Arg Asp Pro Lys Asn Ser Thr Gly Pro Thr Val Ile Gln Leu Ile Ala	
	175 180 185	
	aca gaa acc tgc tgc cct gct ctg cag aga cct cac tca gcc tct gct	625
	Thr Glu Thr Cys Cys Pro Ala Leu Gln Arg Pro His Ser Ala Ser Ala	
	190 195 200 205	
20	ctg gac cag tct cca tgt gct cag ccc aca atg ccc tgg caa gat gga	673
	Leu Asp Gln Ser Pro Cys Ala Gln Pro Thr Met Pro Trp Gln Asp Gly	
	210 215 220	
	cca aag cag acc tcc cca agt aga gaa gct tca gct ctg aca gca gag	721
25	Pro Lys Gln Thr Ser Pro Ser Arg Glu Ala Ser Ala Leu Thr Ala Glu	
	225 230 235	
	ggt gga agc tgc ctc atc tca gga ctc cag cct ggc aac tcc tac tgg	769
30	Gly Gly Ser Cys Leu Ile Ser Gly Leu Gln Pro Gly Asn Ser Tyr Trp	
	240 245 250	
	ctg cag ctg cgc agc gaa cct gat ggg atc tcc ctc ggt ggc tcc tgg	817
35	Leu Gln Leu Arg Ser Glu Pro Asp Gly Ile Ser Leu Gly Gly Ser Trp	
	255 260 265	
	gga tcc tgg tcc ctc act gtg act gtg gac ctg cct gga gat gca gtg	865

	Gly Ser Trp Ser Leu Thr Val Thr Val Asp Leu Pro Gly Asp Ala Val				
	270	275	280	285	
	gca ctt gga ctg caa tgc ttt acc ttg gac ctg aag aat gtt acc tgt			913	
5	Ala Leu Gly Leu Gln Cys Phe Thr Leu Asp Leu Lys Asn Val Thr Cys	290	295	300	
	caa tgg cag caa cag gac cat gct agc tcc caa ggc ttc ttc tac cac			961	
10	Gln Trp Gln Gln Gln Asp His Ala Ser Ser Gln Gly Phe Phe Tyr His	305	310	315	
	agc agg gca cgg tgc tgc ccc aga gac agg tac ccc atc tgg gag aac			1009	
15	Ser Arg Ala Arg Cys Cys Pro Arg Asp Arg Tyr Pro Ile Trp Glu Asn	320	325	330	
	tgc gaa gag gaa gag aaa aca aat cca gga cta cag acc cca cag ttc			1057	
	Cys Glu Glu Glu Glu Lys Thr Asn Pro Gly Leu Gln Thr Pro Gln Phe	335	340	345	
20	tct cgc tgc cac ttc aag tca cga aat gac agc att att cac atc ctt			1105	
	Ser Arg Cys His Phe Lys Ser Arg Asn Asp Ser Ile Ile His Ile Leu	350	355	360	365
	gtg gag gtg acc aca gcc ccg ggt act gtt cac agc tac ctg ggc tcc			1153	
25	Val Glu Val Thr Thr Ala Pro Gly Thr Val His Ser Tyr Leu Gly Ser	370	375	380	
	cct ttc tgg atc cac cag gct gtg cgc ctc ccc acc cca aac ttg cac			1201	
30	Pro Phe Trp Ile His Gln Ala Val Arg Leu Pro Thr Pro Asn Leu His	385	390	395	
	tgg agg gag atc tcc agt ggg cat ctg gaa ttg gag tgg cag cac cca			1249	
35	Trp Arg Glu Ile Ser Ser Gly His Leu Glu Leu Glu Trp Gln His Pro	400	405	410	
	tcg tcc tgg gca gcc caa gag acc tgt tat caa ctc cga tac aca gga			1297	

	Ser Ser Trp Ala Ala Gln Glu Thr Cys Tyr Gln Leu Arg Tyr Thr Gly	
	415	420
		425
	gaa ggc cat cag gac tgg aag gtg ctg gag ccg cct ctc ggg gcc cga	1345
5	Glu Gly His Gln Asp Trp Lys Val Leu Glu Pro Pro Leu Gly Ala Arg	
	430	435
		440
		445
	gga ggg acc ctg gag ctg cgc ccg cga tct cgc tac cgt tta cag ctg	1393
10	Gly Gly Thr Leu Glu Leu Arg Pro Arg Ser Arg Tyr Arg Leu Gln Leu	
	450	455
		460
	cgc gcc agg ctc aac ggc ccc acc tac caa ggt ccc tgg agc tcg tgg	1441
15	Arg Ala Arg Leu Asn Gly Pro Thr Tyr Gln Gly Pro Trp Ser Ser Trp	
	465	470
		475
	tcg gac cca act agg gtg gag acc gcc acc gag acc gcc tgg atc tcc	1489
	Ser Asp Pro Thr Arg Val Glu Thr Ala Thr Glu Thr Ala Trp Ile Ser	
	480	485
		490
20	ttg gtg acc gct ctg cat cta gtg ctg ggc ctc agc gcc gtc ctg ggc	1537
	Leu Val Thr Ala Leu His Leu Val Leu Gly Leu Ser Ala Val Leu Gly	
	495	500
		505
	ctg ctg ctg ctg agg tgg cag ttt cct gca cac tac agg aga ctg agg	1585
25	Leu Leu Leu Leu Arg Trp Gln Phe Pro Ala His Tyr Arg Arg Leu Arg	
	510	515
		520
		525
	cat gcc ctg tgg ccc tca ctt cca gac ctg cac cgg gtc cta ggc cag	1633
30	His Ala Leu Trp Pro Ser Leu Pro Asp Leu His Arg Val Leu Gly Gln	
	530	535
		540
	tac ctt agg gac act gca gcc ctg agc ccg ccc aag gcc aca gtc tca	1681
	Tyr Leu Arg Asp Thr Ala Ala Leu Ser Pro Pro Lys Ala Thr Val Ser	
	545	550
		555
35	gat acc tgt gaa gaa gtg gaa ccc agc ctc ctt gaa atc ctc ccc aag	1729

	Asp Thr Cys Glu Glu Val Glu Pro Ser Leu Leu Glu Ile Leu Pro Lys	
	560	570
	tcc tca gag agg act cct ttg ccc ctg tgt tcc tcc cag gcc cag atg	1777
5	Ser Ser Glu Arg Thr Pro Leu Pro Leu Cys Ser Ser Gln Ala Gln Met	
	575	585
	gac tac cga aga ttg cag cct tct tgc ctg ggg acc atg ccc ctg tct	1825
10	Asp Tyr Arg Arg Leu Gln Pro Ser Cys Leu Gly Thr Met Pro Leu Ser	
	590	605
	gtg tgc cca ccc atg gct gag tca ggg tcc tgc tgt acc acc cac att	1873
15	Val Cys Pro Pro Met Ala Glu Ser Gly Ser Cys Cys Thr Thr His Ile	
	610	620
	gcc aac cat tcc tac cta cca cta agc tat tgg cag cag cct tga	1918
	Ala Asn His Ser Tyr Leu Pro Leu Ser Tyr Trp Gln Gln Pro	
	625	635
20	gtcgac	1924
	<210> 252	
	<211> 635	
25	<212> PRT	
	<213> Homo sapiens	
	<400> 252	
30	Met Pro Ser Trp Ala Leu Phe Met Val Thr Ser Cys Leu Leu Leu Ala	
	1	5
		10
		15
	Pro Gln Asn Leu Ala Gln Val Ser Ser Gln Asp Val Ser Leu Leu Ala	
	20	25
		30
35	Ser Asp Ser Glu Pro Leu Lys Cys Phe Ser Arg Thr Phe Glu Asp Leu	
	35	40
		45

Thr Cys Phe Trp Asp Glu Glu Glu Ala Ala Pro Ser Gly Thr Tyr Gln
 50 55 60

5 Leu Leu Tyr Ala Tyr Pro Arg Glu Lys Pro Arg Ala Cys Pro Leu Ser
 65 70 75 80

Ser Gln Ser Met Pro His Phe Gly Thr Arg Tyr Val Cys Gln Phe Pro
 85 90 95

10 Asp Gln Glu Glu Val Arg Leu Phe Phe Pro Leu His Leu Trp Val Lys
 100 105 110

Asn Val Phe Leu Asn Gln Thr Arg Thr Gln Arg Val Leu Phe Val Asp
 15 115 120 125

Ser Val Gly Leu Pro Ala Pro Pro Ser Ile Ile Lys Ala Met Gly Gly
 130 135 140

20 Ser Gln Pro Gly Glu Leu Gln Ile Ser Trp Glu Glu Pro Ala Pro Glu
 145 150 155 160

Ile Ser Asp Phe Leu Arg Tyr Glu Leu Arg Tyr Gly Pro Arg Asp Pro
 165 170 175

25 Lys Asn Ser Thr Gly Pro Thr Val Ile Gln Leu Ile Ala Thr Glu Thr
 180 185 190

Cys Cys Pro Ala Leu Gln Arg Pro His Ser Ala Ser Ala Leu Asp Gln
 30 195 200 205

Ser Pro Cys Ala Gln Pro Thr Met Pro Trp Gln Asp Gly Pro Lys Gln
 210 215 220

35 Thr Ser Pro Ser Arg Glu Ala Ser Ala Leu Thr Ala Glu Gly Gly Ser
 225 230 235 240

Gln Asp Trp Lys Val Leu Glu Pro Pro Leu Gly Ala Arg Gly Gly Thr
 435 440 445

5 Leu Glu Leu Arg Pro Arg Ser Arg Tyr Arg Leu Gln Leu Arg Ala Arg
 450 455 460

Leu Asn Gly Pro Thr Tyr Gln Gly Pro Trp Ser Ser Trp Ser Asp Pro
 465 470 475 480

10 Thr Arg Val Glu Thr Ala Thr Glu Thr Ala Trp Ile Ser Leu Val Thr
 485 490 495

Ala Leu His Leu Val Leu Gly Leu Ser Ala Val Leu Gly Leu Leu Leu
 15 500 505 510

Leu Arg Trp Gln Phe Pro Ala His Tyr Arg Arg Leu Arg His Ala Leu
 515 520 525

20 Trp Pro Ser Leu Pro Asp Leu His Arg Val Leu Gly Gln Tyr Leu Arg
 530 535 540

Asp Thr Ala Ala Leu Ser Pro Pro Lys Ala Thr Val Ser Asp Thr Cys
 545 550 555 560

25 Glu Glu Val Glu Pro Ser Leu Leu Glu Ile Leu Pro Lys Ser Ser Glu
 565 570 575

Arg Thr Pro Leu Pro Leu Cys Ser Ser Gln Ala Gln Met Asp Tyr Arg
 30 580 585 590

Arg Leu Gln Pro Ser Cys Leu Gly Thr Met Pro Leu Ser Val Cys Pro
 595 600 605

35 Pro Met Ala Glu Ser Gly Ser Cys Cys Thr Thr His Ile Ala Asn His
 610 615 620

ctggaaatca aaggaggtgg tggatcgggt ggtggtggtt cgggaggcgg tggatcgag 840
 gtgcagctgg tgcagtctgg acctgaggtg aagaagcctg gggcctcagt gaaggtctcc 900
 5 tgaaggctt ctggatacac cttaccaac tcctggatga actgggtgag gcagaggcct 960
 ggaaagggtc ttgagtgggt tggacggatt tctcctggag atggagaaac tatctacaat 1020
 10 ggaaattca ggtcagagt cacgattacc gcggacgaat ccacgagcac agcctacatg 1080
 gagctgagca gcctgagatc tggagacacg gccgtgtatt actgtgagag aggctatgat 1140
 gattactcgt ttgcttactg gggccagggg accacggtca ccgtctcttc aggtggtggt 1200
 15 ggatccggag gtggtggatc ggggtggtgga ggatcggata ttgtgatgac tcagtctgca 1260
 ctctccctgc ccgtcacccc tggagagcog gcctccatct cctgcaggtc tagtaagagt 1320
 20 ctctgcata gtaatggcaa cacttacttg tattggtacc tgcagaagcc agggcagtct 1380
 ccacagctcc tgatctatcg gatgtccaac cttgcctcag ggtccctga caggttcagt 1440
 ggacgtggat caggcacagc tttacactg aaaatcagca gactggaggc tgaggatggt 1500
 25 ggggtttatt actgcatgca acatatagaa tctcctttta cgttcggcca agggacccaa 1560
 ctggaaatca aa 1572
 30
 <210> 254
 <211> 524
 <212> PRT
 <213> Homo sapiens
 35
 <400> 254

Met Asp Trp Thr Trp Arg Phe Leu Phe Val Val Ala Ala Ala Thr Gly
 1 5 10 15

Val Gln Ser Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys
 5 20 25 30

Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe
 35 40 45

10 Thr Asn Ser Trp Met Asn Trp Val Arg Gln Arg Pro Gly Lys Gly Leu
 50 55 60

Glu Trp Val Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Ile Tyr Asn
 65 70 75 80

15 Gly Lys Phe Arg Val Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser
 85 90 95

20 Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val
 100 105 110

Tyr Tyr Cys Ala Arg Gly Tyr Asp Asp Tyr Ser Phe Ala Tyr Trp Gly
 115 120 125

25 Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
 130 135 140

Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Ala
 145 150 155 160

30 Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg
 165 170 175

35 Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr Trp
 180 185 190

Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Arg Met
 195 200 205

Ser Asn Leu Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser
 5 210 215 220

Gly Thr Ala Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val
 225 230 235 240

10 Gly Val Tyr Tyr Cys Met Gln His Ile Glu Tyr Pro Phe Thr Phe Gly
 245 250 255

Gln Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly
 260 265 270

15 Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Pro
 275 280 285

Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
 20 290 295 300

Gly Tyr Thr Phe Thr Asn Ser Trp Met Asn Trp Val Arg Gln Arg Pro
 305 310 315 320

25 Gly Lys Gly Leu Glu Trp Val Gly Arg Ile Tyr Pro Gly Asp Gly Glu
 325 330 335

Thr Ile Tyr Asn Gly Lys Phe Arg Val Arg Val Thr Ile Thr Ala Asp
 340 345 350

30 Glu Ser Thr Ser Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu
 355 360 365

Asp Thr Ala Val Tyr Tyr Cys Ala Arg Gly Tyr Asp Asp Tyr Ser Phe
 35 370 375 380

Ala Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly
 385 390 395 400

Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met
 5 405 410 415

Thr Gln Ser Ala Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser
 420 425 430

10 Ile Ser Cys Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr
 435 440 445

Tyr Leu Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu
 450 455 460

15 Ile Tyr Arg Met Ser Asn Leu Ala Ser Gly Val Pro Asp Arg Phe Ser
 465 470 475 480

Gly Ser Gly Ser Gly Thr Ala Phe Thr Leu Lys Ile Ser Arg Val Glu
 20 485 490 495

Ala Glu Asp Val Gly Val Tyr Tyr Cys Met Gln His Ile Glu Tyr Pro
 500 505 510

25 Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
 515 520

<210> 255
 30 <211> 354
 <212> DNA
 <213> Homo sapiens

<400> 255
 35 caggtgcagc tgggtcagtc tggacctgag gtgaagaagc ctggggcctc agtgaaggtc 60

tctgcaagg cttctggata caccttcacc aactcctgga tgaactgggt gaggcagagg 120

cctggaaagg gtcttgagtg ggttggacgg atttatcctg gagatggaga aactatctac 180

5 aatgggaaat tcagggtcag agtcacgatt accgcggacg aatccacgag cacagcctac 240

atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagaggctat 300

gatgattact ogtttgctta ctggggccag ggaaccacgg tcaccgtctc ttca 354

10

<210> 256

<211> 118

<212> PRT

15 <213> Homo sapiens

<400> 256

Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Ala
1 5 10 15

20

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Ser
20 25 30

25

Trp Met Asn Trp Val Arg Gln Arg Pro Gly Lys Gly Leu Glu Trp Val
35 40 45

Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Ile Tyr Asn Gly Lys Phe
50 55 60

30

Arg Val Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr
65 70 75 80

Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys
85 90 95

35

Ala Arg Gly Tyr Asp Asp Tyr Ser Phe Ala Tyr Trp Gly Gln Gly Thr

ggatccggag gtggtggatc ggggtggtgga ggatcggata ttgtgatgac tcagtctgca 480

ctctccctgc ccgtcacccc tggagagccg gcctccatct cctgcaggtc tagtaagagt 540

5 ctctgcata gtaatggcaa cacttacttg tattggtacc tgcagaagcc agggcagtct 600

ccacagctcc tgatctatcg gatgtccaac cttgcctcag gggtcctga caggttcagt 660

10 ggacagtgat caggcacagc ttttacctg aaaatcagca gactggaggc tgaggatggt 720

ggggtttatt actgcatgca acatatagaa taccctttta cgttcggcca agggaccaaa 780

ctggaaatca aaggaggtgg tggatcgggt ggtggtggtt cgggaggcgg tggatcgag 840

15 gtgcagctgg tgcagtctgg acctgaggtg aagaagcctg gggcctcagt gaaggtctcc 900

tgcaaggctt ctggatacac cttaccaaac tcttgatga actggatcag gcagaggcct 960

20 ggaaagggtc ttgagtgat tggacggatt taccctggag atggagaaac tatctacaat 1020

gggaaattca ggtcagagt cacgattacc gcggacgaat ccacgagcac agcctacatg 1080

gagctgagca gcctgagatc tgaggacagc gccgtgtatt actgtgcgag aggctatgat 1140

25 gattactcgt ttgcttactg gggccagga accctggtca ccgtctcttc aggtggtggt 1200

ggatccggag gtggtggatc ggggtggtgga ggatcggata ttgtgatgac tcagtctgca 1260

30 ctctccctgc ccgtcacccc tggagagccg gcctccatct cctgcaggtc tagtaagagt 1320

ctctgcata gtaatggcaa cacttacttg tattggtacc tgcagaagcc agggcagtct 1380

ccacagctcc tgatctatcg gatgtccaac cttgcctcag gggtcctga caggttcagt 1440

35 ggacagtgat caggcacagc ttttacctg aaaatcagca gactggaggc tgaggatggt 1500

ggggtttatt actgcatgca acatatagaa tatkctttta cgttcggcca agggaccaa 1560

ctggaaatca aa 1572

5

<210> 260

<211> 524

<212> PRT

10 <213> Homo sapiens

<400> 260

Met Asp Trp Thr Trp Arg Phe Leu Phe Val Val Ala Ala Ala Thr Gly

1 5 10 15

15

Val Gln Ser Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys

20 25 30

Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe

20 35 40 45

Thr Asn Ser Trp Met Asn Trp Ile Arg Gln Arg Pro Gly Lys Gly Leu

50 55 60

25 Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Ile Tyr Asn

65 70 75 80

Gly Lys Phe Arg Val Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser

85 90 95

30

Thr Ala Tyr Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val

100 105 110

Tyr Tyr Cys Ala Arg Gly Tyr Asp Asp Tyr Ser Phe Ala Tyr Trp Gly

35 115 120 125

Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly
 130 135 140

Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ser Ala
 5 145 150 155 160

Leu Ser Leu Pro Val Thr Pro Gly Glu Pro Ala Ser Ile Ser Cys Arg
 165 170 175

10 Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr Trp
 180 185 190

Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Arg Met
 195 200 205

15 Ser Asn Leu Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser
 210 215 220

Gly Thr Ala Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val
 20 225 230 235 240

Gly Val Tyr Tyr Cys Met Gln His Ile Glu Tyr Pro Phe Thr Phe Gly
 245 250 255

25 Gln Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly
 260 265 270

Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Val Gln Ser Gly Pro
 275 280 285

30 Glu Val Lys Lys Pro Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser
 290 295 300

Gly Tyr Thr Phe Thr Asn Ser Trp Met Asn Trp Ile Arg Gln Arg Pro
 35 305 310 315 320

Phe Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys
 515 520

5 <210> 261
 <211> 354
 <212> DNA
 <213> Homo sapiens

10 <400> 261
 caggtgcagc tggcgcagtc tggacctgag gtgaagaagc ctggggcctc agtgaaggtc 60
 tcctgcaagg cttctggata caccttcacc aactcctgga tgaactggat caggcagagg 120

15 cctggaaagg gtcttgagtg gattggacgg atttatcctg gagatggaga aactatctac 180
 aatgggaaat tcagggtcag agtcacgatt accgcggaag aatccacgag cacagcctac 240
 atggagctga gcagcctgag atctgaggac acggccgtgt attactgtgc gagaggctat 300

20 gatgattact cgtttgotta ctggggccag ggaaccctgg tcaccgtctc ttca 354

<210> 262
 25 <211> 118
 <212> PRT
 <213> Homo sapiens

<400> 262
 30 Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Asn Ser
 20 25 30

35 Trp Met Asn Trp Ile Arg Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile

	35		40		45	
	Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Ile Tyr Asn Gly Lys Phe					
	50		55		60	
5	Arg Val Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr					
	65		70		75	80
	Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys					
10		85		90		95
	Ala Arg Gly Tyr Asp Asp Tyr Ser Phe Ala Tyr Trp Gly Gln Gly Thr					
		100		105		110
15	Leu Val Thr Val Ser Ser					
	115					
	<210> 263					
20	<211> 1572					
	<212> DNA					
	<213> Mus musculus					
	<400> 263					
25	atggaatggc ctttgatott tctcttcctc ctgtcaggaa ctgcaggtgt ccaactcccag				60	
	gttcagctgc agcagtctgg acctgagctg gtgaagcctg gggcctcagt gaagatttcc				120	
	tgcaaggott ctggctatgc attcactaac tcttggatga actgggtgaa gcagaggcct				180	
30	ggaaagggtc ttgagtggat tggacggatt tatcctggag atggagaaac tatctacaat				240	
	gggaaattca gggtaaggc cacactgact gcagacaaat cctccagcac agcctacatg				300	
35	gatatcagca gcctgacatc tggaggactct gcggtctact tctgtgcaag aggctatgat				360	

gattactcgt ttgcttactg gggccaaggg actctgggtca ctgtctctgc aggtggtggt 420

ggttcgggtg gtggtggttc ggggtggtggc ggatcggata ttgtgatgac tcaggctgca 480

5 ccctctatac ctgtcactcc tggagagtca gtatccatct cctgtaggtc tagtaagagt 540

ctcctgcata gtaatggcaa cacttacttg tattggttcc tgcagaggcc aggccagtct 600

cctcaactcc tgatatatcg gatgtccaac cttgcctcag gagtcccaga taggttcagt 660

10 ggcagtgggt caggaactgc tttcacactg agaatcagta gaggggaggc tgaggatgtg 720

gggttttatt actgtatgca acatatagaa taccctttta cgttcggatc ggggaccaag 780

15 ctggaataaa aaggaggtgg tggatcgggt ggtggtggtt cgggaggcgg tggatcgcag 840

gttcagctgc agcagtctgg acctgagctg gtgaagcctg gggcctcagt gaagatttcc 900

tgcaaggctt ctggctatgc attcactaac tcctggatga actgggtgaa gcagaggcct 960

20 ggaaagggtc ttgagtggat tggacggatt taccctggag atggagaaac tatctacaat 1020

gggaaattca gggtaaggc cacttgact gcagacaaat cctccagcac agcctacatg 1080

25 gatatcagca gcctgacatc tgaggactct gcggtctact tctgtgcaag aggctatgat 1140

gattactcgt ttgcttactg gggccaaggg actctgggtca ctgtctctgc aggtggtggt 1200

ggttcgggtg gtggtggttc ggggtggtggc ggatcggata ttgtgatgac tcaggctgca 1260

30 ccctctatac ctgtcactcc tggagagtca gtatccatct cctgtaggtc tagtaagagt 1320

ctcctgcata gtaatggcaa cacttacttg tattggttcc tgcagaggcc aggccagtct 1380

35 cctcaactcc tgatatatcg gatgtccaac cttgcctcag gagtcccaga taggttcagt 1440

ggcagtgggt caggaactgc tttcacactg agaatcagta gaggaggagc tgaggatgtg 1500

ggtgtttatt actgtatgca acatatagaa tatcctttta cgttcggatc ggggaccaag 1560

5 ctggaataa aa 1572

<210> 264

<211> 524

10 <212> PRT

<213> Mus musculus

<400> 264

15 Met Glu Trp Pro Leu Ile Phe Leu Phe Leu Leu Ser Gly Thr Ala Gly
1 5 10 15

Val His Ser Gln Val Gln Leu Gln Gln Ser Gly Pro Glu Leu Val Lys
20 25 30

20 Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser Gly Tyr Ala Phe
35 40 45

Thr Asn Ser Trp Met Asn Trp Val Lys Gln Arg Pro Gly Lys Gly Leu
50 55 60

25 Glu Trp Ile Gly Arg Ile Tyr Pro Gly Asp Gly Glu Thr Ile Tyr Asn
65 70 75 80

30 Gly Lys Phe Arg Val Lys Ala Thr Leu Thr Ala Asp Lys Ser Ser Ser
85 90 95

Thr Ala Tyr Met Asp Ile Ser Ser Leu Thr Ser Glu Asp Ser Ala Val
100 105 110

35 Tyr Phe Cys Ala Arg Gly Tyr Asp Asp Tyr Ser Phe Ala Tyr Trp Gly
115 120 125

Gln Gly Thr Leu Val Thr Val Ser Ala Gly Gly Gly Gly Ser Gly Gly
 130 135 140

5 Gly Gly Ser Gly Gly Gly Gly Ser Asp Ile Val Met Thr Gln Ala Ala
 145 150 155 160

Pro Ser Ile Pro Val Thr Pro Gly Glu Ser Val Ser Ile Ser Cys Arg
 165 170 175

10 Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr Trp
 180 185 190

Phe Leu Gln Arg Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr Arg Met
 15 195 200 205

Ser Asn Leu Ala Ser Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser
 210 215 220

20 Gly Thr Ala Phe Thr Leu Arg Ile Ser Arg Val Glu Ala Glu Asp Val
 225 230 235 240

Gly Val Tyr Tyr Cys Met Gln His Ile Glu Tyr Pro Phe Thr Phe Gly
 245 250 255

25 Ser Gly Thr Lys Leu Glu Ile Lys Gly Gly Gly Gly Ser Gly Gly Gly
 260 265 270

Gly Ser Gly Gly Gly Gly Ser Gln Val Gln Leu Gln Gln Ser Gly Pro
 30 275 280 285

Glu Leu Val Lys Pro Gly Ala Ser Val Lys Ile Ser Cys Lys Ala Ser
 290 295 300

35 Gly Tyr Ala Phe Thr Asn Ser Trp Met Asn Trp Val Lys Gln Arg Pro
 305 310 315 320

Phe Thr Phe Gly Ser Gly Thr Lys Leu Glu Ile Lys
 515 520

5

<210> 265
 <211> 30
 <212> PRT
 <213> Homo sapiens

10

<400> 265
 Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Ala
 1 5 10 15

15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
 20 25 30

20

<210> 266
 <211> 5
 <212> PRT
 <213> Homo sapiens

25

<400> 266
 Asn Ser Trp Met Asn
 1 5

30

<210> 267
 <211> 14
 <212> PRT
 <213> Homo sapiens

35

<400> 267
 Trp Val Arg Gln Arg Pro Gly Lys Gly Leu Glu Trp Val Gly
 1 5 10

<210> 268

<211> 17

5 <212> PRT

<213> Homo sapiens

<400> 268

Arg Ile Tyr Pro Gly Asp Gly Glu Thr Ile Tyr Asn Gly Lys Phe Arg

10 1 5 10 15

Val

15

<210> 269

<211> 32

<212> PRT

<213> Homo sapiens

20

<400> 269

Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu

1 5 10 15

25 Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg

20 25 30

<210> 270

30 <211> 9

<212> PRT

<213> Homo sapiens

<400> 270

35 Gly Tyr Asp Asp Tyr Ser Phe Ala Tyr

1 5

<210> 271
 <211> 11
 5 <212> PRT
 <213> Homo sapiens

<400> 271
 Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser
 10 1 5 10

<210> 272
 <211> 23
 15 <212> PRT
 <213> Homo sapiens

<400> 272
 Asp Ile Val Met Thr Gln Ser Ala Leu Ser Leu Pro Val Thr Pro Gly
 20 1 5 10 15

Glu Pro Ala Ser Ile Ser Cys
 20

25

<210> 273
 <211> 16
 <212> PRT
 <213> Homo sapiens

30

<400> 273
 Arg Ser Ser Lys Ser Leu Leu His Ser Asn Gly Asn Thr Tyr Leu Tyr
 1 5 10 15

35

<210> 274

<211> 15
 <212> PRT
 <213> Homo sapiens

5 <400> 274
 Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr
 1 5 10 15

10 <210> 275
 <211> 7
 <212> PRT
 <213> Homo sapiens

15 <400> 275
 Arg Met Ser Asn Leu Ala Ser
 1 5

20 <210> 276
 <211> 32
 <212> PRT
 <213> Homo sapiens

25 <400> 276
 Gly Val Pro Asp Arg Phe Ser Gly Ser Gly Ser Gly Thr Ala Phe Thr
 1 5 10 15

30 Leu Lys Ile Ser Arg Val Glu Ala Glu Asp Val Gly Val Tyr Tyr Cys
 20 25 30

<210> 277
 <211> 9
 35 <212> PRT
 <213> Homo sapiens

<400> 277

Met Gln His Ile Glu Tyr Pro Phe Thr

1 5

5

<210> 278

<211> 10

<212> PRT

10 <213> Homo sapiens

<400> 278

Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys

1 5 10

15

<210> 279

<211> 30

<212> PRT

20 <213> Homo sapiens

<400> 279

Gln Val Gln Leu Val Gln Ser Gly Pro Glu Val Lys Lys Pro Gly Ala

1 5 10 15

25

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr

 20 25 30

30 <210> 280

<211> 5

<212> PRT

<213> Homo sapiens

35 <400> 280

Asn Ser Trp Met Asn

1 5

<210> 281

5 <211> 14

<212> PRT

<213> Homo sapiens

<400> 281

10 Trp Ile Arg Gln Arg Pro Gly Lys Gly Leu Glu Trp Ile Gly

1 5 10

<210> 282

15 <211> 17

<212> PRT

<213> Homo sapiens

<400> 282

20 Arg Ile Tyr Pro Gly Asp Gly Glu Thr Ile Tyr Asn Gly Lys Phe Arg

1 5 10 15

Val

25

<210> 283

<211> 32

<212> PRT

30 <213> Homo sapiens

<400> 283

Arg Val Thr Ile Thr Ala Asp Glu Ser Thr Ser Thr Ala Tyr Met Glu

1 5 10 15

35

Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys Ala Arg

20

25

30

<210> 284

5 <211> 9

<212> PRT

<213> Homo sapiens

<400> 284

10 Gly Tyr Asp Asp Tyr Ser Phe Ala Tyr

1 5

<210> 285

15 <211> 11

<212> PRT

<213> Homo sapiens


<400> 285

20 Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser


1 5 10

[Document Name] Drawings


[Fig. 1]




[Fig. 2]




[Fig. 3]



[Fig.4]



[Fig. 5]




[Fig. 6]

		CDR1		CDR2
VA7	DIVMTQAAPSIPTVTPGESVSI	RSSKSLLSHNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VA130	DIVMTQAAPSVPTVTPGESVSI	RSSKSLLSHNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VA259	DIVMTQAAPSVPTVTPGESVSI	RSSKSLLSHNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB17B	DIVMTQAAPSVPTVTPGESVSI	RSSKSLLSHNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB12B	DIVMTQAAPSVPTVTPGESVSI	RSSKSLLSHNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB140	DIVMTQAAPSVPTVTPGESVSI	RSSKSLLSHNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB33	DIVMTQAAPSVPTVTPGESVSI	RSSKSLLSHNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB45B	DIVMTQAAPSVPTVTPGESVSI	RSSKSLLSHNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB8B	DIVMTQAAPSVPTVTPGESVSI	RSSKSLLSHNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB115	DIVMTQAAPSVPTVTPGESVSI	RSSKSLLSHNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB14B	DIVMTQAAPSVPTVTPGESVSI	RSSKSLLSHNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB22B	DIVMTQAAPSIPTVTPGESVSI	RSSKSLLSHNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB16	DIVMTQAAPSVPTVTPGESVSI	RSSKSLLSHNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB157	DIVMTQAAPSVPTVTPGESVSI	RSSKSLLSHNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB4B	DIVMTQAAPSVPTVTPGESVSI	RSSKSLLSHNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB51	DIVMTQAAPSLPTVTPGESVSI	RSSKSLLSHNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
		CDR3		
VA7	GVPDRFSGSGGTAFTLRISRVEAEDVGIYYC	MQHLEYPT	FGTGTKLEIK	
VA130	GVPDRFSGSGGTAFTLRISRVEAEDVGVYYC	MQHLEYPT	FGSGTKLEIK	
VA259	GAPDRFSGSGGTAFTLRISRVEDVGVYYC	MQHLEYPT	FGSGTKLEIK	
VB17B	GVPDRFSGSGGTAFTLRISRVEAEDVGVYYC	MQHLEYPT	FGSGTKLEIK	
VB12B	GVPDRFSGSGGTAFTLRISRVEAEDVGVYYC	MQHLEYPT	FGSGTKLEIK	
VB140	GVPDRFSGSGGTAFTLRISRVEAEDVGVYYC	MQHLEYPT	FGSGTKLEIK	
VB33	GVPDRFSGSGGTAFTLRISRVEAEDVGVYYC	MQHLEYPT	FGSGTKLEIK	
VB45B	GVPDRFSGSGGTAFTLRISRVEAEDVGVYYC	MQHLEYPT	FGSGTKLEIK	
VB8B	GVPDRFSGSGGTAFTLRISRVEAEDVGVYYC	MQHVEYPT	FGSGTKLEIK	
VB115	GVPDRFSGSGGTAFTLRISRVEAEDVGVYYC	MQHLEYPT	FGSGTKLEIK	
VB14B	GVPDRFSGSGGTAFTLRISRVEAEDVGVYYC	MQHLEYPT	FGSGTKLEIK	
VB22B	GVPDRFSGSGGTAFTLRISRVEAEDVGVYYC	MQHIEYPT	FGSGTKLEIK	
VB16	GVPDRFSGSGGTAFTLTISSVEAEDVGVYYC	MQHLEYPT	FGSGTKLEIK	
VB157	GVPDRFSGSGGTAFTLKRISRVEAEDVGVYYC	MQHLEYPT	FGSGTKLEIK	
VB4B	GVPDRFSGSGGTAFTLRISRVEAEDVGVYYC	MQHIEYPT	FGSGTKLEIK	
VB51	GVPDRFSGSGGTAFTLRISRVEAEDVGVYYC	MQHLEYPT	FGSGTKLEIK	


[Fig. 7]

		CDR1		CDR2
VA7	DIVMTQAAPSI PVTPGESVSISC	RSSKSLHLSNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VA130	DIVMTQAAPSV PVTPGESVSISC	RSSKSLHLSNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VA259	DIVMTQAAPSV PVTPGESVSISC	RSSKSLHLSNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB17B	DIVMTQAAPSV PVTPGESVSISC	RSSKSLHLSNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB12B	DIVMTQAAPSV PVTPGESVSISC	RSSKSLHLSNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB140	DIVMTQAAPSV PVTPGESVSISC	RSSKSLHLSNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB33	DIVMTQAAPSV PVTPGESVSISC	RSSKSLLYSNGNIYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB45B	DIVMTQAAPSV PVTPGESVSISC	RSSKSLHLSNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB8B	DIVMTQAAPSV PVTPGESVSISC	RSSKSLHLSNGNTYLY	WFMQRPQGSPQLLIY	RMSNLAS
VB115	DIVMTQAAPSV PVTPGESVSISC	RSSKSLHLSNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB14B	DIVMTQAAPSV PVTPGESVSISC	RSSKSLHLSNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB22B	DIVMTQAAPSI PVTPGESVSISC	RSSKSLHLSNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB16	DIVMTQAAPSV PVTPGESVSISC	RSSKSLLYSNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB157	DIVMTQAAPSV SVTPGESVSISC	RSSKSLLYSNGNIYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB4B	DIVMTQAAPSV PVTPGESVSISC	RSSKSLHLSNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
VB51	DIVMTQAAPSL PVTPGESVSISC	RSSKSLHLSNGNTYLY	WFLQRPQGSPQLLIY	RMSNLAS
		CDR3		
VA7	GVPDRFSGSGSGTAFTLRI SRVEAEDVGIYYC	MQHLEYPFT	FGTGTKLEIK	
VA130	GVPDRFSGSGSGTAFTLRI SRVEAEDVGVIYYC	MQHLEYPYT	FGSGTKLEIK	
VA259	GAPDRFSGSGSGTAFTLRI SRVETEDVGVIYYC	MQHLEYPYT	FGSGTKLEIK	
VB17B	GVPDRFSGSGSGTAFTLRI SRVEAEDVGVIYYC	MQHLEYPYT	FGSGTKLEIK	
VB12B	GVPDRFSGSGSGTAFTLRI SRVEAEDVGVIYYC	MQHLEYPYT	FGSGTKLEIK	
VB140	GVPDRFSGSGSGAAFTLRI SRVEAEDVGVIYYC	MQHLEYPYT	FGSGTKLEIK	
VB33	GVPDRFSGSGSGTAFTLRI SRVEAEDVGVIYYC	MQHLEYPYT	FGSGTKLEIK	
VB45B	GVPDRFSGSGSGAAFTLRI SRVEAEDVGVIYYC	MQHLEYPYT	FGSGTKLEIK	
VB8B	GVPDRFSGSGSGTAFTLRI SRVEAEDVGVIYYC	MQHVEYPYT	FGSGTKLEIK	
VB115	GVPDRFSGSGSGTAFTLRI SRVEAEDVGVIYYC	MQHLEYPYT	FGSGTKLEIK	
VB14B	GVPDRFSGSGSGTAFTLRI SRVEAEDVGVIYYC	MQHLEYPYT	FGSGTKLEIK	
VB22B	GVPDRFSGSGSGTAFTLRI SRVEAEDVGVIYYC	MQHIEYPFT	FGSGTKLEIK	
VB16	GVPDRFSGSGSGTAFTLTI SSVEAEDVGVIYYC	MQHLEYPYT	FGSGTKLEIK	
VB157	GVPDRFSGSGSGTAFTLKI SRVEAEDVGVIYYC	MQHLEYPYT	FGSGTKLEIK	
VB4B	GVPDRFSGSGSGTAFTLRI SRVEAEDVGVIYYC	MQHIEYPFT	FGSGTKLEIK	
VB51	GVPDRFSGSGSGTAFTLRI SRVEAEDVGVIYYC	MQHLEYPYT	FGSGTKLEIK	


[Fig. 8]




[Fig. 9]




[Fig. 10]




[Fig. 11]




[Fig. 12]




[Fig. 13]




[Fig. 14]




[Fig. 15]



[Fig. 16]



[Fig. 17]




[Fig. 18]

HUMANIZED HEAVY CHAIN
 QVQLVQSGPEVKKPKGASVKVSKASKGYTFINSMNINWVYRQRPCKGLEWMCRIYPGDGETIYNGKFRIVRTITADESTAYMELSSLRSEDYAVYYCARIGYDDYSFAIWGGGTTVTVSS
 FR1 CDR1 FR2 CDR2 FR3 CDR3 FR4

HUMANIZED LIGHT CHAIN
 DIVMTQSALSIPVTPGEPASISCRSSKSLLSHNGNTYLYWFFQKPKGSPQLLIYRMSNLASGVPRFSGSGTAFTLKI SRVEAEDVGVYYCMQHIETPFIFGGGKLEIK
 FR1 CDR1 FR2 CDR2 FR3 CDR3 FR4

[Fig. 19]



[Document Name] Abstract

[Abstract]

5 [Problems to be Solved] An objective of the present invention is to provide novel anti-Mpl antibodies having TPO-agonistic activity.

[Means for Solving the Problems] Anti-human Mpl antibodies were isolated and purified, and then anti-human Mpl diabodies and anti-human Mpl sv(Fv)₂ were purified using genetic engineering techniques. Furthermore, the present inventors succeeded in humanizing anti-human Mpl sc(Fv)₂.

10 The diabodies and sc(Fv)₂ were assayed for TPO-like agonistic activity, and were found to have activities higher than those of anti-human Mpl antibodies, or activities equivalent to or higher than those of naturally-occurring human TPO ligand.

[Selected Drawings] None